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Background: Since the discovery of Hepatitis C there have been studies of the
natural history of the infection. The outcome is dependent on whether the research is
performed in the community or in hospital and where the patients are drawn from.
Scotland is a country with a low prevalence of Hepatitis C infection but Edinburgh
has a large intravenous drug using population in whom the prevalence is high. The
Royal Infirmary of Edinburgh is the main tertiary centre for the assessment and
treatment of these patients.
Aim: Describe the characteristics of those patients that have ongoing Hepatitis C
infection that have been referred and assessed. Describe the progression of the
disease to cirrhosis and its complications. Identify the independent factors that
influence this progression. Describe the outcome of treatment with interferon
monotherapy, combination standard interferon and ribavirin and combination
pegylated interferon and ribavirin, and identify the predictors of response.
Methods: All patients that have been referred to the Royal Infirmary of Edinburgh
and assessed between 1990 and 2004 with Hepatitis C infection. Retrospective
analysis of the patient's case notes, laboratory, pathology and endoscopy records was
performed. There was entry of data into a specially constructed Microsoft Access
relational database. Kaplan-Meier analysis was used to describe progression. Cox
regression analysis was used to identify independent predictors of progression. A
sustained viral response was the primary end-point of the treatment studies, with
binary logistical regression to identify predictors of this outcome. Documentation of
adverse events for each treatment was made.
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Results: Six hundred and ninety-four patients were identified that have ongoing
infection. This cohort was made up of a significant proportion of middle-aged men
who have acquired the infection less than 20 years ago, principally through
intravenous drug use, who have a significant history of alcohol abuse. At least 22%
of patients have had cirrhosis diagnosed clinically, although only about half of these
have had it confirmed by biopsy or laparoscopy. In 12% of patients at least one
complication of cirrhosis has been recorded. Grade 2 oesophageal varices have been
found in about 7% of patients overall, but only half of these have bled. A major
complication of cirrhosis has occurred in 10.5% and Hepatocellular carcinoma
(HCC) in 3.3%. So far only 13 patients have been transplanted. Eleven percent of the
cohort has died and in those in whom the cause is known, liver-related death is twice
as common as non-liver-related death. It has not been possible to establish a median
time from infection to cirrhosis or its complications but it appears to be in excess of
35 years. The age of the patient and previous alcohol intake of greater than 50 units
per week for more than five years independently influences progression. A steady
improvement in the efficacy of treatment with the introduction of each new treatment
regime has been confirmed. In interferon nai've patients, treated with pegylated
interferon and ribavirin, the sustained viral response rate was 29.0% and 59.3% for
genotype 1 and genotype 2 or 3 infections respectively. Significant side effects
occurred with treatment that necessitated both dose reduction and sometimes its
termination. About 45% of all patients referred and assessed each year were deemed
suitable for treatment and listed.
Conclusion: Chronic Hepatitis C infection is a significant health problem in
Edinburgh with large numbers being referred for assessment, treatment and
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management of the complications of cirrhosis. The natural history of the infection
and how it is influenced by therapy is becoming clearer, in particular the influence of
alcohol and the age of the patient. Treatments are effective, although do have
significant side effects that affect compliance.
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Aims and structure
This thesis aims to describe the characteristics and outcomes of those patients that
have ongoing Hepatitis C infection that have been referred and assessed to the Royal
Infirmary of Edinburgh. It aims to give insights into the natural and therapy-
influenced history of similar cohorts of patients with Hepatitis C infection and to
compare the results with the current medical literature in this field of study.
The first part of this thesis (Chapter 1; Introduction) provides a general
background of the virology and molecular biology of the Hepatitis C virus. The
immunological response of the host is described in detail, as well as the pathological
consequences of infection. The epidemiology in the United Kingdom and worldwide
is also discussed. The current literature on the natural history of the infection is
analysed to highlight the factors that are thought to influence progression to cirrhosis
and its complications. The final section describes treatment of Hepatitis C infection
with interferon-based treatments and includes a synopsis of the major randomised
controlled trials in this area.
The second part of the thesis is based on the retrospective and prospective analysis of
all patients that have been referred to the Royal Infirmary of Edinburgh for
assessment of their Hepatitis C infection from the Edinburgh 'EH' postcode area.
There is a description of data collection on this cohort and the typical management of
these patients (Chapter 2; Methods). There is a description of data collection on a
second cohort of patients that have had combination standard interferon and ribavirin
in other liver units around the United Kingdom.
The basic characteristics, demographics and outcomes of all Hepatitis C Ribonucleic
acid polymerase chain reaction positive patients in the Edinburgh cohort are
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documented (Chapter 3). Correlation between various features of the cohort, such as
previous alcohol intake and gender, are explored. The factors that influence the time
of presentation are also described.
The progression of infection to uncomplicated cirrhosis either clinically diagnosed or
biopsy proven is described (Chapter 4). The factors that influence this progression
are explored. There is also a discussion concerning the most appropriate method of
statistical analysis and its limitations.
The progression to the complications cirrhosis from infection or from uncomplicated
cirrhosis (either clinically diagnosed or biopsy proven) is described (Chapter 5).
Identification of the independent factors that influence this progression is also
attempted.
The final analytical work covers the outcome and side effects of treatment with
interferon monotherapy, combination standard interferon and ribavirin and
combination pegylated interferon and ribavirin (Chapter 6). The outcome of
treatment with combination standard interferon and ribavirin in other United
Kingdom liver units and is compared and contrasted with the Edinburgh cohort.
Identification of the predictors of response and side effects is attempted.
A detailed critical discussion of the work is included at the end of each chapter.
There is also a final overall discussion highlighting the main results and insights
made by the thesis (Chapter 7; Discussion).
Finally a description is given of the Hepatitis C management database that was
constructed to facilitate data collection for the thesis (Appendix). This application is
a major positive outcome of the thesis, as it is currently being used as an audit tool in
all the major liver units in Scotland.
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Abbreviations
The abbreviations frequently used and / or novel to this thesis are listed below.
ALT Alanine aminotransferase
CSAGS Confidentiality and Security Advisory Group for Scotland
DNA Deoxyriboneucleic acid
ECM Extracellular matrix
HBcAb Hepatitis B core antibody
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HCC Hepatocellular carcinoma
HCV Hepatitis C virus
HIV Human Immunodeficiency virus
HSC Hepatic stellate cells
IDU Intravenous drug use
IFN Interferon
IRF Interferon regulatory factor
ISG Interferon stimulated gene
MHC Major Histocompatibility Complex
NANB Non A Non B
NFkB Nuclear factor kB
PAMP Pathogen-associated molecular pattern
PBMC Peripheral blood mononuclear cells
PCR Polymerase chain reaction
PCT Porphyria Cutanea Tarda
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PEG-IFN Pegylated interferon
PNALT Persistently Normal Alanine aminotransferase
RCT Randomised controlled trial
RNA Ribonucleic acid
RT-PCR Reverse Transcription Polymerase Chain Reaction
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1.1 Discovery of Hepatitis C virus
For many years prior to the discovery of Hepatitis C virus (HCV) its existence had
been assumed. It was known that patients undergoing blood transfusion could
develop a hepatitis that was negative on serological testing for Hepatitis A virus and
Hepatitis B virus (HBV). This was therefore termed Non A Non B (NANB) hepatitis.
In 1989 the genome of this virus was cloned and sequenced and soon after an ELISA
test for its viral proteins was produced (Choo et al. 1989). The virus was then
officially given the name Hepatitis C virus.
1.2 Virology of Hepatitis C Virus
1.2.1 Classification
HCV is a member of the Flaviviridae family. Other members of this family include
the Yellow fever virus and Dengue virus. HCV is the only member of the
Hepacivirus genus of this family. It is a small, enveloped, positive-sense, single
stranded Ribonucleic Acid (RNA) virus.
1.2.2 Molecular biology of Hepatitis C virus
1.2.2.1 The genome and its products
The HCV genome consists of approximately 9600 nucleotides. It has a single open
reading frame about 9000 nucleotides in length. This is flanked at each terminus by
untranslated regions including control elements required for translation and
replication (Kong & Sarnow 2002). Translation of this produces a polyprotein of
3010 or 3011 amino acids that is cleaved into 10 structural and non-structural
proteins by a combination of host and viral proteases (Kato et al. 1990).
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1.2.2.1.1 Untranslated regions
The 5' untranslated region is highly conserved (Bukh et al. 1992) and has been of
great importance in the development of diagnostic assays for the detection of HCV
viraemia. It contains an internal ribosome entry site that controls translation and has
sequences that can directly interact with the 3' end of the viral genome or indirectly
with RNA-protein as replication signals (Zhang et al. 1999).
In the 3' untranslated region, there is a non essential short variable region, a
polypyrimidine stretch that must be more than 26 nucleotides long and finally a
highly conserved sequence of 98 nucleotides (X domain), which constitutes the 3'
terminus of the HCV genome (Okamoto et al. 1991),(Chayama et al. 1994) . The
latter two regions are required for genomic replication.
1.2.2.1.2 Structural protein region
The amino-terminal one third of the polyprotein encodes the virion structural
proteins.
The Core protein is highly basic and is associated with the viral genomic RNA to
form the nucleocapsid (Takeuchi et al. 1990). It is a highly conserved protein,
contains several B-cell epitopes and has been very important in the development of
serological tests for HCV (Akatsuka et al. 1993).
A lipid-containing envelope derived from the host membrane surrounds the
nucleocapsid. There are two structural N-glycosylated proteins (El and E2) in the
envelope. They have a hydrophobic portion that anchors them to the membrane and
they function as heterodimers that are stabilized by noncovalent interactions. There is
a high degree of heterogeneity in the part of the genome that encodes these proteins.
In particular, the N-terminus of the E2 protein, and this has been designated the
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"hypervariable region 1". In genotype lb isolates a "hypervariable region 2" has also
been described downstream of the first on the E2 protein (Chayama et al. 1994).
After the structural proteins, comes the small integral membrane protein, p7, which
appears to function as an ion channel (Pavlovic et al. 2003). The structural proteins
mature by signal peptidase cleavages.
1.2.2.1.3 Non-structural protein region
The rest of the polyprotein is processed into six non-structural (NS) proteins that
coordinate the intracellular processes of the virus life cycle.
The C-terminal two-thirds of NS2 protein contains the catalytic triad of a cysteine
protease. Cleavage of the NS2/3 junction requires these residues as well as the
downstream expression of the NS3 serine protease domain. Cleavage of N2/3 is
partially dependent on the presence of microsomal membranes, implying a cellular
cofactor is required for processing. It is enhanced by Zn2+, which has a structural role
in stabilising the NS3 fold (Stempniak et al. 1997).
The NS3 serine-protease activity cleaves NS3/4A, 4A/4B, 4B/5A, and 5A/5B
junctions of the polyprotein (Hahm et al. 1995). It forms a stable complex with
NS4A protein. The C-terminal of the NS3 protein contains an NTPase and an RNA-
helicase. The latter unwinds the duplex RNA during replication; hydrolysis by the
NTPase supplies the energy for this process (Zhang et al. 2005).
NS4A is a small protein that anchors NS3 to cellular membranes to allow its serine
protease to function (Bartenschlager et al. 1995).
The integral membrane protein NS4B induces ultrastructural vesicular structures,
termed 'membranous webs' to form within the endoplasmic reticulum and these been
proposed to serve as a scaffold for replication complex assembly (Egger et al. 2002).
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NS5A can be phosphorylated on multiple serine residues by cellular kinases (Reed et
al. 1997), but the role of remains unknown. Hyperphosphorylation appears to reduce
replication levels (Appel et al. 2005). NS5A associates with membranes through an
N-terminal alpha helix. The structure suggests it may have a role in binding RNA
(Tellinghuisen et al. 2005). A region on NS5A has been labelled the interferon-
sensitive determining region, after some research that suggested that mutations in
this region appeared to correlate with the sensitivity of HCV genotype lb isolates to
interferon (IFN) treatment (Sato & Enomoto 1996). NS5A has been found to interact
with the interferon-induced cellular protein kinase PKR (Gale, Jr. et al. 1998)
providing a possible mechanism for this observation. These findings however were
not replicated in European (Khorsi et al. 1997) or North American (Hofgartner et al.
1997) patients.
NS5B protein is an RNA-dependent RNA polymerase (Lin et al. 1994). NS5B has a
typical 'right hand' polymerase structure, with catalytic sites in the base of the palm
domain, surrounded by thumb and finger domains (Penin et al. 2004). NS5B is
anchored to the membrane by a C-terminal peptide region (Schmidt-Mende et al.
2001).
1.2.2.1.4 Genomic variations
HCV is characterised by extensive genetic heterogeneity. HCV isolates have been
classified into 6 major genotypes and over 100 subtypes (Simmonds et al. 1994).
There is up to 35% variation in the genome between the most different isolates. In an
infected individual, HCV circulates as quasispecies, which is a mixture of closely
related but distinct genomes, differing by up to 2% (Enomoto et al. 1994). These
arise as a result of error prone replication by the viral polymerase that lacks a
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proofreading function. They can accumulate over time during the infection or can
occur from the onset of the infection due to simultaneous transmission of multiple
viral species (Laskus et al. 2004). They can also occur early in the treatment of the
infection (Abbate et al. 2004). The heterogeneity of quasispecies can be found
throughout the genome but certain regions are hypervariable, such as the N-terminus
of the E2 protein.
1.2.2.2 Life cycle
After entry into the bloodstream, by the methods described in the epidemiology
section, the virus enters cells to begin replication of the virus. There is ongoing
controversy as to which cells are susceptible to infection.
1.2.2.2.1 Cell tropism
1.2.2.2.1.1 Hepatocytes
Although the primary site of replication is definitely the liver, it has been very
difficult to demonstrate the presence and the precise location of the RNA
transcription and the translated viral proteins. The traditional methods of
immunohistochemistry for viral proteins (Sansonno & Dammacco 1993) and in situ
hybridization and digital image analysis of liver biopsies (Gosalvez et al. 1998) have
produced mixed results.
1.2.2.2.1.2 Extrahepatic
Extrahepatic replication has been proposed to occur at low levels in a number of
other tissues. During replication of the virus, a negative strand of RNA is produced
from the positive strand. Therefore the traditional method used to investigate the sites
of HCV replication has been to detect this negative strand. However some caution in
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interpretation of these studies should be observed, as extensive artifactual detection
of negative strand RNA, due to self-priming and mispriming events can occur. Both
artifacts can be dramatically reduced (mispriming) or eliminated (self-priming) using
CAP-based Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay,
which uses a primer located in the nucleocapsid part of viral genome outside the
highly structured 5' untranslated region (Lerat et al. 1996) or Thermus thermophilics
(Tth)-based RT PCR (Radkowski et al. 2002).
Using the CAP-based RT-PCR assay, 8% of Peripheral Blood Mononuclear Cells
(PBMC) were observed to have the negative strands while in sera and fresh bone
marrow cells none were detected (Lerat et al. 1996). Occult HCV infection,
characterised by the presence of HCV-RNA in the liver, in the absence of anti-HCV
and serum HCV-RNA, is also documented. In these patients negative strands of
HCV RNA have been found in 3% of PBMC (Castillo et al. 2005;0tsuka et al.
2005). Thus, they could be potentially infectious.
The brain is another postulated site of replication due to the observed
neuropsychological changes seen patients infected with HCV (Forton et al. 2002).
One study has documented the presence negative strands RNA in three out of six
post mortem patients have using Tth-based RT PCR (Radkowski et al. 2002). In two
of these patients, the viral genomic sequence was different from RNA isolated from
the same patient's serum. In one of these patients the same sequence negative strand
was also found in a lymph node. The authors suggest that HCV can replicate in the
central nervous system, probably in cells of the macrophage/monocyte lineage.
Overall extrahepatic HCV replication remains controversial.
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1.2.2.2.2 Cell entry
The mechanism by which HCV enters cells is not known, but it is likely that El and
E2 are involved. The cell surface molecule CD81 has been identified as a possible
binding receptor for E2 (Pileri et al. 1998). It is expressed on a variety of cell types
including hepatocytes. It has also been suggested that HCV can form complexes with
very low density lipoproteins or low density lipoproteins and enter via the low
density lipoprotein receptor (Agnello et al. 1999). Other candidate HCV receptors
have also been identified including scavenger receptor class-B type-1 (Bartosch et al.
2005), L-SIGN and DC-SIGN (Cormier et al. 2004).
The bound virus is probably then internalised and fusion of the viral and cellular
membranes occurs, presumably triggered by the low pH of the endocytic
compartment. This leads to the release of a single-stranded, positive-sense RNA
genome into the cytoplasm.
1.2.2.2.3 RNA translation
The positive-sense RNA genome initially serves as a messenger RNA for translation
of the viral polyprotein. The HCV internal ribosome site within the 5' untranslated
region binds 40S ribosomal subunits directly, bypassing the requirement for pre-
initiation factors. This complex recruits eukaryotic initiation factor 3 and the ternary
complex of Met-tRNA-eIF2-GTP to eventually become the translationally active 80S
complex (Ji et al. 2004). This produces the polyprotein that is then proteolytically
cleaved to produce the 10 viral proteins described above.
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1.2.2.2.4 RNA replication
As for all positive-strand RNA viruses, HCV RNA replication occurs in association
with altered cytoplasmic membranes. As mentioned, NS4B can induce this
membranous web formation. The lipid composition of these membranes affects the
efficiency of replication suggesting membrane fluidity is important (Kapadia &
Chisari 2005). Little is known about the process of RNA synthesis but if it is similar
to related viruses it is likely to be semiconservative and asymmetric with the
positive-strand serving as a template to make a negative-strand intermediate. The
negative strand then serves as a template to produce multiple genomes. This
replication probably involves de novo initiation by a multiprotein complex
(replicase) including the NS5B coded RNA polymerase. As mentioned above both
the 3' and 5' untranslated regions are involved in efficient RNA replication, as are
NS3 and NS5A. Adaptive mutations in these and NS4B and NS5B have been shown
to enhance replication in 'subgenomic' replicons in cell culture by up to 10,000-fold
(Blight et al. 2000).
1.2.2.2.5 Virion assembly and release
The process of virion assembly and release has been hampered by the lack of a cell
culture system that can mimic this process in vitro. Although adaptive mutations of
the genome can produce replication of replicons in cell culture, they appear to
prevent virion release. However recently an isolate from a patient in Japan (JFH-1)
has been shown to produce infectious particles in cell culture (Wakita et al. 2005)
and undoubtedly this will lead to further insights to this process. Core protein is
localised to the cytoplasmic surface of the endoplasmic reticulum and lipid droplets
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(Yasui et al. 1998). Its central hydrophobic domain allows membrane association and
the N-terminal region interacts with the RNA genome. The envelope glycoproteins
El and E2 require complex folding that involves a number of endoplasmic reticulum
resident chaparones. Virions presumably form by budding into the endoplasmic
reticulum and leave the cell through the secretory pathway. Despite the difficulty in
demonstrating the presence and the location of the HCV replication, it does appear
that HCV virions turn over rapidly (with a half-life of about three hours) and up to
12about 10 viruses are produced every day in an infected person (Neumann et al.
1998).
1.3 Immunology of Hepatitis C
Following inoculation, HCV triggers both innate and adaptive immune responses.
Despite this the virus is able to persist and cause chronic infection in approximately
50 to 80 percent of patients (Wiese et al. 2005), (Niederau et al. 1998). These
immune responses are now starting to be characterised and the strategies by which
the virus evades them, are being better understood.
1.3.1 Innate immune response
When HCV infection occurs within the liver a series of intracellular events are
triggered that protect the infected cells and the surrounding tissues. This response is
initiated when a pathogen-associated molecular pattern (PAMP) presented by the
infecting virus (such as single strand RNA or polyuridine signatures), is recognised
and engaged by specific PAMP receptor factors (Toll-like receptor 3 and Retinoic-
acid-inducible gene 1) expressed in the host cell, triggering signals via a number of
Interferon regulatory factors (IRF) and Nuclear factor kB (NFkB) that induce the
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expression of antiviral effector genes (IFN-a / IFN-P and cytokines/chemokines
respectively) (Iwasaki & Medzhitov 2004). IFN-a and IFN-p released then binds its
common receptor and activates a number of Interferon stimulated genes (ISG) via the
Jak-STAT pathway (Sarcar et al. 2004). These ISG products impart regulatory
functions that limit HCV replication through processes that include disruption of
viral RNA translation and inhibition of antigenomic strand RNA synthesis (Wang et
al. 2003).
HCV proteins can interfere with these pathways. The NS3/4A protease can inhibit
the IRF (Foy et al. 2005) and the NFkB (Li et al. 2005) pathways triggered by PAMP
receptor activation. HCV Core protein induces Suppressor of Cytokine Signalling
proteins that inhibit the Jak-STAT pathway (Bode et al. 2003). HCV protein leads to
expression of high levels of protein phosphatase 2A which may also inhibit this
pathway (Duong et al. 2004). NS5A and E2 proteins bind protein kinase R, and
inhibit its catalytic activity, which may allow HCV to evade in part the translational-
suppressive actions of IFN and protein kinase R dependent signalling processes that
amplify the host response to infection (Taylor et al. 1999). NS5A can also induce
Interleukin 8 expression through transactivation of the interleukin 8 promoter
(Polyak et al. 2001). The process by which Interleukin 8 antagonises the action of
IFN is not known. RNase L is an ISG product that should be able to cleave HCV
genomic RNA at specific dinucleotide sites into non-functioning nucleolytic
products. Genotype 1 RNA sequences, in general, have fewer of these cleavage sites
compared with genotype 2 or 3 and may explain some of the resistance of this
genotype to IFN based treatment (Han et al. 2004).
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In acutely infected chimpanzees HCV triggers a strong IFN-a and IFN-p release
within the liver, however the strength of this response is no different between those
animals that clear the infection acutely and those that do not (Bigger et al. 2004).
This might suggest either no role in determining outcome of the acute infection or
the determinant having its effect downstream of the IFN receptor by the methods
described above. In chronic human infection, there is evidence for a clear absence or
only low level of IFN-a and IFN-P expression (Mihm et al. 2004). This suggests that
at this stage in the disease, there maybe suppression of the IRF pathways by the
method described above. However, despite this, some of these patients still have
abundant ISG expression. It has been suggested that the explanation for this, is that
cellular stress from fibrosis and / or cirrhosis maybe sufficient to stimulate ISG
expression (Smith et al. 2003). Secretion of IFN-y by hepatic effector T cells and
Natural Killer cells also contribute to the level of ISG expression (Frese et al. 2002).
Overtime, the host's innate immune system pressure may also drive the outgrowth or
selection of quasispecies with variations in the proteins discussed above, that are
better able to resist the actions of IFN and thereby maintain persistence (Farci et al.
2000).
1.3.2 Adaptive immune response
1.3.2.1 Humoral immunity
Virus-specific antibodies can be detectable 7-8 weeks after HCV infection
(Pawlotsky 1999). There is evidence that antibodies can neutralise HCV infectivity
in vitro prior to inoculation into chimpanzees (Farci et al. 1994). The outcome of
acute infection in humans has been predicted by the occurrence of sequence changes
in the hypervariable region 1 of glycoprotein E2, which is the major target of the
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antibody response, and this occurred simultaneously with antibody seroconversion,
presumably reflecting immune selective pressure (Farci et al. 2000). However in both
chimpanzees and humans, clearance of acute infection can occur without antibody
production (Post et al. 2004) and the presence of antibodies do not prevent
reinfection (Farci et al. 1992). Therefore their role remains unclear.
Antibodies to HCV proteins wane over time in those that have cleared the infection.
In the German Anti-D single source cohort, HCV antibodies were undetectable in
21% patients after 25 years of infection (Wiese et al. 2005), although T-cell memory




HCV RNA genomes appear in the serum within a few days of inoculation, and peak
at 6 to 10 weeks irrespective of outcome (Abe et al. 1992). In successful clearance of
the virus in acute infection, CD8+ cytotoxic T-cell responses are vigorous and
generally target multiple major histocompatibility complex (MHC) class I-restricted
epitopes in structural and non-structural HCV proteins (Lechner et al. 2000).
Expansion of these cells coincides with the rise in the serum transaminases
suggesting the damage to the liver is immunopathological. At the same time strong,
sustained CD4+ T helper proliferation to multiple MHC class II-restricted epitopes on
the structural and non-structural viral proteins is required for clearance (Cramp et al.
1999). Work in chimpanzees suggest a further complexity in that the response
initially focuses on a limited number of dominant epitopes and then spreads to
additional targets only after viraemia is mostly controlled (Shoukry et al. 2004).
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With control in viraemia there is a contraction in the CD4+ and CD8+ T-cell
responses almost certainly by programmed cell death. If no rebound viraemia occurs
durable T-cell memory populations occur within the liver (Takaki et al. 2000).
Although chimpanzees that have resolved acute infection are susceptible to
reinfection there is a marked reduction in the duration and the peak of viraemia
(Bassett et al. 2001) and this coincides with massive CD4+ and CD8+ T-cell recall
responses (Shoukry et al. 2003). Pre-treatment with anti-CD4+ (Grakoui et al. 2003)
and anti-CD8+ (Shoukry et al. 2003) antibodies prolonged viraemia on reinfection
and led to persistence of the virus. In injecting drug users, previous clearance of the
infection also provided immunity on re-exposure unless co-infected with Human
Immunodeficiency Virus (HIV) (Mehta et al. 2002).
1.3.2.2.2 Chronic infection
If the immune response does not conform to the description above, there is a higher
chance that the viraemia either does not fully come under control or relapses after a
period of control (Abe et al. 1992). This will usually lead to viral persistence and
chronic infection, where the level of the viraemia may vary from person to person
■j n
(typically 10 to 10 genomes per ml of serum) but remains remarkably constant over
time in an individual. It is not clear whether in chronic infection CD8+ cytotoxic T-
cells contribute to the control of replication, due to conflicting evidence on
correlations with viral load (Freeman et al. 2003b), (Nelson et al. 1997b). The
activity of CD8+ cytotoxic T-cells in liver biopsies correlates with both Alanine
aminotransferase (ALT) serum levels and Histologic Activity Index and tend to be
found in areas of lobular and piecemeal necrosis (Leroy et al. 2003). Intrahepatic
pro-inflammatory cytokine (such as IFN-y) messenger RNA levels have been
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correlated with severity of portal inflammation and liver fibrosis (Napoli et al. 1996).
It is unclear if T-cells are the major source of these cytokines or whether it is from
the other inflammatory cell types, such as macrophages, recruited to the liver and the
degree that these cells mediate tissue injury (McGuinness et al. 2000).
1.3.2.3 Evasion of the adaptive immune response
The outcome of acute infection therefore seems to be decided in the first six months.
It may be that the mechanism of evasion needs only to act for a time during this
critical period to be sufficient to alter the timing or vigour of T-cell immunity and
favour persistence. However there will need to be mechanisms that can explain the
antigen-specific defect in adaptive immunity that lasts for decades and appears to be
exclusive to HCV that occurs in chronic infection.
1.3.2.3.1 Viral determinants
Mutational escape of HCV epitopes: The virus's ability to generate genomic
diversity has been one of the theories put forward to explain how the virus evades the
control exerted by the adaptive immune system. CD8+ T-cell mediated selection
pressure against HCV has been demonstrated in the chimpanzee model (Weiner et al.
1995). In human infections from a single source there is also evidence of escape
mutations in targeted MHC class I.-restricted epitopes (Tester et al. 2005). It is
possible that CD8+ T-cells that achieve viral clearance target a set of protective
epitopes functionally constrained from mutation, although the evidence so far is
against this (Lauer et al. 2002). It is unlikely that this method of evasion is the only
mechanism at work, as some individuals who develop persistent infection have
multi-specific CD8+cytotoxic T-cell responses and many T-cell epitopes are intact in
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persistently replicating genomes and do not mutate despite and intense focal response
(Urbani et al. 2005).
Deletion or anergy: Recent studies of HCV-specific CD8+ T-cells have indicated
that these cells may be functionally impaired, or anergic in chronic infection
(Wedemeyer et al. 2002). However, CD8+ T-cell function has also been shown to be
impaired in patients that have cleared the infection (Gruener et al. 2001). Virus
specific CD4+ T-cell responses are generally weak or absent when assessed using
functional methods of identification (Rosen et al. 2002). But it is unclear whether
they are present but functionally impaired or have been lost from the immune
response.
Regulatory T-cell populations: Certain HCV specific CD8+ T-cells found in the
liver in chronically infected patients produce the cytokine interleukin 10 which
downregulates T-cell responses (Koziel et al. 1995). In the peripheral circulation of
these individuals the proportion of CD4+CD25+ regulatory T-cells is elevated
compared with recovered or uninfected individuals (Cabrera et al. 2004). These cells
can suppress HCV specific CD8+ T-cells activity in vitro (Boettler et al. 2005).
Impaired antigen presentation: Dendritic cells are the main presenters of antigen in
the liver. Natural Killer cells are potent regulators of dendritic cell function, and
there is evidence of inhibition of these cells by HCV E2 protein (Tseng & Klimpel
2002). It has also been suggested that viral proteins may directly inhibit dendritic cell
maturation and function but these findings have been inconsistent and permanent
global defects in chronic infection are not seen (Larsson et al. 2004).
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Impaired T-cell recruitment: An inability of effector T-cells to move into the
infected liver has been proposed with limited experimental evidence (Thimme et al.
2002).
1.3.2.3.2 Host determinants
Major Histocompatibility Complex: An individual's MHC alleles do appear to
affect the likelihood of viral clearance, in particular the DRB1*01 allele in an Irish
anti-D cohort (Barrett et al. 1999). There are other MHC allele associations with
clearance but none are universal (Cramp et al. 1999).
Co-infection: Acute HCV infection in patients infected with HBV that are Hepatitis
B surface antigen (HBsAg) positive and have active HBV replication, usually have
transient HCV viraemia with poor antibody responses to HCV (Chu et al. 2002).
Immunosuppressive medication: In a renal transplant recipient, who acquired HCV
post transplant and who had their immunosuppression medication stopped after
failure of the graft, spontaneously cleared the infection (Somsouk et al. 2003).
1.4 Pathology of Hepatitis C
1.4.1 Histopathology of the liver in chronic infection
The classic histological presentation of HCV infection is portal lymphocyte
infiltration leading to lymphoid follicles or aggregates in approximately 50% of cases
(Scheuer et al. 1992). Bile duct damage is generally lymphocytic and non-destructive
and is seen in 30% (Lefkowitch & Apfelbaum 1989). There also can be varying
degrees of lobular lymphocyte infiltration, with both lobular and piecemeal necrosis
(Dhillon & Dusheiko 1995). The later two features are the main determinants of the
grading of the severity of the necroinflammatory component of the hepatitis, used in
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scoring systems mentioned below. Steatosis is seen in approximately 60% of cases
and is usually macrovesicular, mild and non-zonal (Hourigan et al. 1999).
The fibrosis tends to develop from the portal tracts with portal spurring, progressing
to portal-portal bridging and then cirrhosis once nodular regeneration of the
hepatocytes occurs (Gerber et al. 1992). This pattern of fibrosis progression is
recognised in the various scoring systems that have developed to stage the disease.
The three commonly used ones have been the Histological Activity Index (Knodell et
al. 1981), the Ishak system (modified histological activity index) (Ishak et al. 1995)
and the METAVIR system (French METAVIR Cooperative Study Group 1994).
1.4.2 Pathophysiology of liver disease during chronic infection
The mechanisms responsible for the onset and progression of hepatic lesions during
chronic HCV infection are not fully understood. As previously stated HCV is not
thought generally to be cytopathic, largely due to the lack of correlation of viral load
to severity and prognosis of liver disease (Fanning et al. 1999). The only lesion that
has been attributed to a direct pathogenic effect of the virus is steatosis in HCV
genotype 3 infections (Kumar et al. 2002), whilst in the other genotypes steatosis is
seen less frequently and is usually associated with the insulin resistance of the
metabolic syndrome (Fartoux et al. 2005b). In transgenic mice models that either
overexpress HCV Core or NS5A protein, accumulation of intracytoplasmic lipid
droplets occurs (Moriya et al. 1997). The core protein has been shown to inhibit the
function of microsomal triglyceride transfer protein, a major regulator of hepatic
assembly of Very Low Density Lipoproteins (Perlemuter et al. 2002). HCV Core
protein has also been observed to induce mitochondrial injury resulting oxidative
stress which then perturbs lipid peroxidation (Okuda et al. 2002). HCV genotype 3 in
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particular has also been shown to induce transcription of a number of genes involved
in lipid metabolism, including Stearoyl coenzyme A desaturase 4, a rate limiting
enzyme in the synthesis of monounsaturated fats (Bigger et al. 2001). The situation
in the immunocomprimised patient pre- or post-transplant is poorly understood as
higher levels of virus replication are seen and these are associated with severer liver
lesions and a poorer outcome (Tolan et al. 2001). This has been stated as evidence of
a direct cytopathic effect of the virus.
As previously stated in the immunology section, the activity of CD8+ cytotoxic T-
cells is important in removal of virus-infected cells but also bystander cells, and is
therefore the mediator of damage in the liver in chronic infection. This is through
TNF-a-,ybs- and perforin-mediated mechanisms (Ando et al. 1997).
Fibrosis is the main complication of F1CV in the liver and is a wound healing
response to injury. It results from a dynamic mechanism of gene transcription and
synthesis of extracellular matrix (ECM) components (collagen, laminin, fibronectin
and proteoglycans) that are deposited within the liver parenchyma (Rockey 2000).
Flepatic Stellate cells (FISC) are the main ECM producing cells and reside in the
space of Disse. Following chronic injury, HSCs activate or transdifferentiate into
myofibroblast-like cells, acquiring contractile, proinflammatory and fibrogenic
properties (Marra 1999). When activated they migrate to the sites of tissue repair.
Platelet Derived Growth Factor produced by Kuppfer cells is the main mitogen for
activated HSCs (Lau et al. 2005). Myofibroblasts derived from small portal blood
vessels also have fibrogenic potential when liver injury occurs periportally (Knittel et
al. 1999).
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Damaged hepatocytes and activated Kuppfer cells release reactive oxygen species
and fibrogenic mediators such as Transforming Growth Factor pi and Tumour
Necrosis Factor a that activate HSCs in HCV infection (Nelson et al. 1997a).
Apoptosis of damaged hepatocytes stimulates the fibrogenic actions of liver
myofibroblasts (Canbay et al. 2004). There is also some very preliminary evidence of
a direct effect of HCV on HSCs. When adenoviruses encoding core and nonstructural
proteins (NS3-NS5) were used to express HCV proteins in HSCs, it induced
proinflammatory actions, such as increased the secretion of bioactive Transforming
Growth Factor pi and the expression of procollagen al and intercellular cell
adhesion molecule type 1 (Bataller et al. 2004).
Activated HSCs secrete inflammatory chemokines, express cell adhesion molecules,
and modulate the activation of lymphocytes (Vinas et al. 2003) which amplifies and
perpetuates the process. As well as the fibrogenic factors such as Transforming
Growth Factor pi, vasoactive substances (angiotensin II, norepinephrine) (Bataller et
al. 2003) and adipokines (leptin and adiponectin) (Ikejima et al. 2002) are required
for the development of fibrosis.
Finally, removal of excess collagen can occur by various matrix metalloproteinases
and is regulated by Tissue inhibitor of metalloproteinase type 1 and Transforming
Growth Factor pi (Yoshiji et al. 2002). These pathways may be involved in the
reduction of fibrosis that has been observed following successful clearance of HCV
post treatment (Poynard et al. 2002b).
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1.4.3 Development of Hepatocellular carcinoma
Epidemiologic, clinical, and virologic data have shown a close association between
chronic infection with HCV and the development of HCC (Bruix et al. 1989). In
many countries of the developed world, HCV infection accounts for more than half
of the cases of HCC (Hasan et al. 1990). HCC usually arises after 2-4 decades of
infection, typically in the context of underlying cirrhosis (Kiyosawa et al. 1990).
Viral hepatitis greatly influences the incidence of somatic and genetic events in
hepatocytes, by increasing cell turnover. A direct role for viral proteins has been the
suggested as the mechanism for carcinogenesis but this still remains controversial.
Core protein has been shown in vitro to modulate the expression of the p21WAF1
gene, which is a major target of the tumour suppressor protein p53. It causes
proliferation or apoptosis of the hepatocyte depending on whether the Core protein is
in the cytoplasm or the nucleus (Kwun & Jang 2003). HCC has also been shown to
occur in transgenic mice expressing the Core protein or the full-length HCV
polyprotein (Lerat et al. 2002). NS3 can form a complex with p53 and modulate its
activity and repress p21WAFI gene expression (Kwun et al. 2001). NS5A appears to
interact with cellular signalling apparatus and cell cycle-regulatory kinases including
p53 and p21WAF1 (Majumder et al. 2001). These block the apoptotic cellular response
to persistent HCV infection suggesting a potential role in the pathogenesis of HCC.
However the influence of overexpression of these proteins that occurs these models
is unknown, when compared with human infection.
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1.5 Epidemiology of Hepatitis C
1.5.1 Prevalence and incidence
The prevalence varies widely from country to country depending on the prevalence
of the risk factors for infection.
1.5.1.1 United Kingdom
A recent study on sera from residual specimens from adult patients submitted to
laboratories in England and Wales, estimated the prevalence in England and Wales to
be 1.07% and not changing significantly from 1986 to 1996 (Balogun et al. 2002).
The prevalence rate in health blood donors in the West Midlands ranges from 0.01 to
0.02% (Mutimer et al. 1994). In a study on 224,000 consecutive blood donors from
the North-West of England, it was found to be 0.04% (McLindon et al. 1995). If an
overall estimated prevalence rate of 0.5% were taken, then there would be
approximately 250,000 HCV antibody positive people in England and Wales. Up to
the end of 2004 only 49,527 positive blood samples had been reported, with 8,084
reported in 2004 (Health Protection Agency 2005). This figure is rising year on year.
In Scotland the overall prevalence rate has been estimated to be 1% (Drug Misuse
Information Strategy Team 2005), giving approximately 50,000 patients being HCV
antibody positive. Up to the end of 2003, 18,109 positive blood samples had been
reported, with 1,779 reported in 2003 (Scottish Centre for Infection and
Environmental Health 2004). This figure is now falling year on year. In Lothian up
to the end of 2003, 2,461 positive blood samples had been reported, with 103
reported in 2003 (Scottish Centre for Infection and Environmental Health 2004).
A study in the United Kingdom (UK) estimated the rate of seroconversion rate in
repeat blood donors in England found it to be 0.26 per 100 000 person years (95%
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confidence interval 0.15 to 0.43) (Soldan et al. 1998). There is, of course,
predonation screening of blood donators to exclude people with high-risk behaviours.
This will therefore lead to an underestimation of the true incidence. Despite this 5 of
the 14 people who seroconverted had these high-risk behaviours.
1.5.1.2 Worldwide
Similar prevalence rates as the UK are seen in Northern Europe (Trepo & Pradat
1999). In Southern Europe it is estimated to be between 1-2.4% (Kondili et al. 2002).
In Italy, the adult incidence of HCV is reported to be between 14 to 50 cases/100 000
person years (Kondili et al. 2002), (Mazzeo et al. 2003). The rate rises in Equatorial
Africa to 6% with the highest recorded in adults over 50 years old in Egypt at 41%
(bdel-Wahab et al. 1994).
A study in the United States obtained serum samples from 21,241 persons six years
old or older who participated in the third National Elealth and Nutrition Examination
Survey, conducted during 1988 through to 1994 (Alter et al. 1999). The overall
prevalence of anti-HCV was 1.8%, corresponding to an estimated 3.9 million persons
nationwide (95% CI, 3.1 million to 4.8 million) with HCV infection. Sixty-five
percent of the persons with HCV infection were 30 to 49 years old. Seventy-four
percent were positive for HCV RNA, indicating that an estimated 2.7 million persons
in the United States (95% CI, 2.4 million to 3.0 million) were chronically infected.
1.5.2 Genotype distribution
Phylogenetic analysis of the Non-Structural-5 region of the genome allows
classification of HCV into six major genotypes and a series of subtypes (Simmonds
et al. 1994). Using this method, the prevalence of each of these genotypes can be
determined around the world (Smith et al. 1995).
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1.5.2.1 United Kingdom
In a study on 567 patients across England and Wales, the majority of HCV infections
were types la (32%), lb (15%), or 3a (37%). The genotype distribution in individual
risk groups was similar to the overall genotype distribution except for haemophilia
patients, in whom the frequencies were la (39%), lb (23%), and 3a (21%) (Harris et
al. 2000). In a report on 104 patients referred to a teaching hospital in the North-East
of England there was a higher proportion that were Genotype 1 (69%) (Watson et al.
1996).
1.5.2.2 Worldwide
There are clear differences in the distribution of the genotypes around the world.
Genotypes la, lb, 2a, 2b, 2c and 3a account for about 90% of the HCV infections in
North and South America, Europe, Russia, China, Japan and Australia / New
Zealand (Smith et al. 1995). In the United States, HCV genotypes la and lb are the
predominant genotypes in patients with chronic hepatitis C and account for greater
than 40% of isolates (Zein et al. 1996). Genotype lb accounts for the majority of
infections in Southern and Eastern Europe, China and Japan. Genotype 3a is
common throughout America and Europe. Genotype 4a accounts for most of the
infections in Egypt. The subtypes of Genotype 4 make up the majority of infections
in Central Africa. About 50% of infections in South Africa are Genotype 5a.
Genotype 6 isolates are found mainly in South-East Asia (Simmonds et al. 1996).
The risk group and age of the patient may also determine the genotype prevalence. In
particular Genotype 3a is commoner in isolates from younger people in western
countries, especially amongst intravenous drugs users (Simmonds & Smith 1997).
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1.5.3 Transmission
The modes of transmission reflect HCV being a blood borne virus.
1.5.3.1 Intravenous drug abuse
The high prevalence (20 to 90%) of the HCV infection in populations using
intravenous drugs clearly establishes this as a route of transmission (Roy et al. 2002).
In 773 drug users who had hepatitis serology performed between January 1992 and
April 1996 in Liverpool, 67% were HCV antibody positive (Lamden et al. 1998).
Undoubtedly there have been changes in the incidence of HCV infection over time.
In the pre-HIV era (1975-1985) sharing of needles and equipment was widespread in
the Intravenous drug use (IDU) populations. Acquisition of HCV infection was rapid
with seroprevalence rates of 54%, 78%, 83% and 94% among users of less than a
year, 1 year, 5 years and more than 10 years respectively (Thomas et al. 1995a).
Between 1986 and 1995 harm reduction schemes were introduced and there has been
some evidence that incidence and prevalence rates fell. In a study to ascertain the
HCV antibody prevalence among injectors from Glasgow between 1990 and 1995,
sera from injectors who had undergone HIV antibody testing were tested
anonymously for HCV antibody (Goldberg et al. 1998). The prevalence of HCV
antibody in Glasgow fell significantly among IDUs of all ages (90% to 77%), IDUs
aged 15 to 19 years (92% to 29%), and IDUs aged 20 to 24 years (91% to 65%).
Since 1995, there is evidence that the incidence and prevalence may have plateaued
or started to increase again. The above study was repeated in Glasgow, Lothian,
Tayside and Grampian, in the late 1990s. There were no significant changes in
prevalence in each of the four regions among those aged less than 25 years (Glasgow
1997-00: 43% to 41%; Lothian 1997-9: 13% to 17%; Tayside 1997-9: 45% to 35%;
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Grampian 1996-9: 28% to 29%). Among those aged greater than 25 years, significant
decreases in prevalence were only observed in Glasgow (1997-00: 79% to 72%, p =
0.03) and Lothian (1997-9: 54% to 45%, p = 0.05) (Hutchinson et al. 2002). In San
Francisco between 1997 and 1999, IDUs aged less than 30 years old had an
estimated incidence rate of 25.1 per 100 person-years (95% CI, 18.7-32.9 per 100
person-years) (Hahn et al. 2002). The incidence of HCV infection among new
injecting drug users in London (aged below 30 years or had been injecting for six
years or fewer) has recently been estimated to be 41.8 cases per 100 person-years
(Judd et al. 2005), with a baseline prevalence of 44%.
1.5.3.2 Blood products
NANB post transfusion hepatitis had been recognised for many years prior to the
discovery of HCV. In the United States prior to 1985 the incidence of was 8-10 per
100 persons transfused (Alter 1994). Once the serological test for HCV became
available it become clear that HCV was the main aetiological agent (Alter et al.
1989). Transmission by this route has been extremely rare since the introduction of
screening of donors using the antibody test in late 1991. With the HCV antibody test
there is still a potential 10-week window from infection to antibody production when
infection may be missed (Soldan et al. 1998). HCV RNA testing of donations
reduces this window down to 17 days (Flanagan & Snape 1998). In the UK, the
frequency of HCV infectious donations was 1 in 520,000 during 1993-98 and fell to
1 in 30 million during 1999-2001 when all donations were tested for HCV RNA
(Soldan et al. 2003).
Patients that have received transfusion with pooled blood products, such as Factor
VIII concentrates and Anti-D prior to 1985, unfortunately have high prevalence rates
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for HCV (70 to 90%) (Jacyna et al. 1990). A single infected donation could
contaminate numerous recipients of the pooled product. In 1985/86 a heat
inactivation step was introduced and was shown to reduce the risk of NANB hepatitis
to less than 1% of transfusions (Study Group of the UK Haemophilia Centre
Directors on Surveillance of Virus Transmission by Concentrates 1988). Since then
donor and pool product screening for antibody and HCV RNA has eliminated these
products as a source (Makris et al. 1993).
1.5.3.3 Body tattooing and piercing
There is clearly a theoretical risk of transmitting the virus using unsterilised
equipment. However despite one report that claimed it explained 41% of all cases
(Haley & Fischer 2001), case-control studies in the United States have found no
association with tattooing, acupuncture, or ear piercing (Alter 1999).
1.5.3.4 Sexual
HCV can be transmitted sexually however the route is not efficient. In long-term
studies of heterosexual couples in relationships of 15-20 years duration, the
prevalence among sexual partners of HCV infected persons was 0 to 2.5% with the
majority of couple not using condoms (Bresters et al. 1993), (Neumayr et al. 1999).
In a survey of from genitourinary clinics in the UK, 17,586 specimens from 1995,
showed an adjusted prevalence of HCV antibody in of 1.03% (95% CI: 0.89 to 1.16)
overall and 0.65% (95% CI: 0.51 to 0.78) among those who did not report injecting
drug use. One study has suggested that transmission from an infected male to an
uninfected female partner maybe more efficient that the other way round (Thomas et
al. 1995b). The prevalence of the infection in homosexual / bisexual men is usually
reported as higher than the general population at 4% in the United States and Europe
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(Tedder et al. 1991). In a recent study of Scottish genitourinary clinics, the non-
injecting prevalence rates for homosexual / bisexual males was 0.6%, for
heterosexual males 0.8%, for heterosexual females 0.3% (Goldberg et al. 2001).
1.5.3.5 Vertical
The risk of transmission from mother to child in those that are HCV RNA PCR
positive is about 5% (Conte et al. 2000). The risk increases if the mother is known to
have injected drugs (9%) (Resti et al. 2002) or if she is co infected with HIV (16%)
(Papaevangelou et al. 1998). If there is intrapartum infantile exposure to maternal
blood or a higher level of HCV viraemia, the risk is also increased (Steininger et al.
2003). A study of HCV prevalence among Scottish childbearing women found a rate
of 0.29-0.40% (Hutchinson et al. 2004). Based on reported rates of mother to child
transmission, 8-11 paediatric infections are expected per annum. Only 24% and 46%
of mothers were estimated to have been diagnosed prior to pregnancy and birth,
respectively (Hutchinson et al. 2004). Breast-feeding is not thought to confer a risk
of transmission (Spencer et al. 1997).
1.5.3.6 Household contacts
Anecdotal reports of transmission by exposure of broken skin or mucous membranes
to someone else's blood such by sharing shaving equipment have been made but are
very rare (Tumminelli et al. 1995). Being a sibling or a non-sexual household contact
does increase a person's risk of HCV infection, but it is always difficult to be certain
of absence of other shared known risk factors (Ackerman et al. 2000).
1.5.3.7 Occupational
Within a health care setting, a percutaneous injury with a sharp implement that has
previously been used on a known HCV infected patient can transmit infection. The
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incidence of seroconversion following these needlestick injuries is on average 1.8%
(0% to 7%) (Centers for Disease Control and Prevention 1998). The prevalence of
antibodies to HCV was 0.28% in healthcare workers in the West of Scotland
(Thorburn et al. 2001). The rate did not vary according to the degree of patient
exposure or to duration of potential exposure. In dental surgeons in the same area,
prevalence of HCV antibodies was 0.1% (Roy et al. 2003). These rates are not
significantly greater than the estimated prevalence of HCV infection in the local
population.
1.5.3.8 Iatrogenic
In countries and previous eras, where adequate sterilisation of medical equipment
that is used for invasive procedures is or was not practised, the risk of transmission is
high (Frank et al. 2000). Even in countries where this is not the case occasional
transition can occur due to breakdown in usual practise (Esteban et al. 1996).
Dialysis units are the commonest setting for patient-to-patient nosocomial infection.
A surveillance study in the United States dialysis units found a seroprevalence rate of
10%, with an annual incidence of 3% (none of these had received a transfusion or
used injection drugs) (Niu et al. 1993). The mechanisms of transmission in this
setting is believed to be breaches in routine dialysis unit procedures and precautions
(Kellerman & Alter 1999). Other documented nosocomial routes of transmission that
have been documented are endoscopes and multidose vials.
1.5.3.9 Sporadic
The proportion of patients in whom it is not possible to identify a route of
transmission has fallen over the years to less than 10% of cases in the United States
(Alter 1999). Most people in this category are associated with low socioeconomic
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level and may report high-risk behaviour such as imprisonment, multiple sexual
partners and use of non-injection illicit drugs. Therefore they may be secondary to
occult or undisclosed percutaneous exposure.
1.6 Natural History of Hepatitis C
1.6.1 Methods of study
Characterising the natural history of any infection requires establishing accurately
the onset of infection, identifying and evaluating the full spectrum of the acute
disease, tracking the process to resolution or development of complications,
evaluating outcome without treatment and comparison with a properly matched
control group without the infection. Unfortunately there are a number of inherent
difficulties in studying the outcome of HCV infection: the onset is not recognised in
the majority, it is generally asymptomatic, the progression is slow and many patients
have undergone various treatments as they became available.
1.6.2 Acute Infection
In the early years after discovery of the virus most researchers felt that following a
mild acute infection in which a minority are symptomatic (Koretz et al. 1993), a
majority (80 to 90%) then go on to develop chronic infection (Niederau et al. 1998).
These studies were particularly susceptible to referral bias, loose definitions of acute
infection and lack of a control group. Recent studies have challenged this view. In
the past there have been a number of occasions when a large group of individuals
have been exposed to the virus at one time. Studying such a cohort decreases the
influence of referral bias, and gives much more accurate figures on those that go on
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to clear the virus. One study of this type concerns mothers given contaminated anti-D
injections in Ireland between 1977 and 1978 (Kenny-Walsh 1999). A screening
program of the 94% of those mothers potentially involved was performed. Seven
hundred and four people were found to have HCV antibodies. Of these, only 390
(55%) were HCV PCR positive. A history of icteric hepatitis was reported in 20.6%
of PCR negative and 3.4% of PCR positive women after inoculation (Barrett et al.
2001).
In Germany there is a similar cohort of 2867 women exposed to HCV through
contaminated anti-D injections between 1978 and 1979 (Wiese et al. 2005). Cases
were initially identified using repeated Alanine transferase (ALT) screening. It has
been possible to re-examine 1980 women (70% of the original cohort) 25 years after
the initial exposure. An acute hepatitis was seen in 93%. Of those that had an acute
hepatitis, 25% were icteric and 35% were asymptomatic. At 25 years of the 1833
people that had the hepatitis, 86% remained positive for antibody and 48% had
become HCV RNA PCR negative spontaneously and 6 % with IFN treatment.
In another study 14 patients with acute hepatitis C were identified among 29 healthy
volunteers participating in 2 consecutive pharmacokinetics studies (Larghi et al.
2002). At presentation, all 14 patients tested HCV PCR positive. Infection resolved
spontaneously in 8 patients, HCV RNA becoming undetectable by 4 to 5 months
after the presumed time of infection in 5 of them and by 8, 13, and 24 months in the
remaining 3. Six patients developed chronic infection. Liver biopsies performed in 9
subjects who were HCV PCR positive 6 months after diagnosis revealed that the
prevalent histological finding was lobular inflammation.
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In a further study of 60 patients in hospital practise, diagnosed with acute HCV
infection (on the basis of being HCV antibody negative but HCV PCR positive on a
first sample and subsequently becoming HCV antibody positive), 85% were
symptomatic at presentation (Gerlach et al. 2003). Spontaneous clearance was
observed in 52%, usually within 12 weeks after the onset of symptoms, whereas all
asymptomatic patients developed chronic hepatitis C.
1.6.3 Chronic Hepatitis C
The vast majority of cases of patients diagnosed with HCV infection have chronic
infection at presentation and the acute infection has gone unrecognised.
1.6.3.1 Rate of progression to cirrhosis
One of the most important questions regarding chronic infection is whether it will
eventually progress to cirrhosis in all cases.
1.6.3.1.1 Retrospective / cross-sectional studies in liver clinics
Numerous retrospective / cross-sectional studies have been performed recruiting
patients with established chronic liver disease due to HCV from liver clinics in
tertiary hospitals. Unfortunately few have been controlled. The first large series
analysed the biopsies of 1157 French patients with chronic hepatitis C who had a
probable date of infection (Poynard et al. 1997). As with most studies of this kind,
the investigators took the first year of active intravenous drug use or the time of
exposure of a known risk factor such as blood transfusion. The median time from
infection to biopsy in the French cohort was 12.4 years. The median time to
histologically confirmed cirrhosis was 30 years estimated by Kaplan-Meier analysis,
with 17.9% of the cohort being cirrhotic. Without treatment 33% had a median time
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to cirrhosis of less than 20 years, 31% greater than 50 years. Cox regression analysis
identified the age at infection of greater than 40 years, male sex and a daily alcohol
intake of greater than 50g predicted early cirrhosis development. The researchers
constructed a model to predict the median time to biopsy proven cirrhosis based on
the independent variables identified. This is 12 years in men infected after the age of
40 who drink greater than 50 grams of alcohol per day compared with 42 years in
women infected before the age of 40 who do not drink. They were able to stage the
fibrosis in all these patients using the METAVIR scoring system (0=no fibrosis to
4=cirrhosis) and then calculate a median rate of fibrosis. They validated this method
by analysing a subset of patients who had repeat biopsies. The figure they produced
was 0.133 METAVIR fibrosis units per year for the cohort as a whole. This cohort of
patients has subsequently been expanded to include 2313 liver biopsies but drew
similar conclusions (Poynard et al. 2001).
1.6.3.1.2 Prospective studies in the community
Analysis of the Irish Anti-D cohort provides a method of minimising the influence of
referral bias, as the patients are recruited from the community. Therefore we know
accurately who was at risk, the number infected and when they were infected. Three
hundred and seventy-six of 390 HCV RNA PCR positive patients have been
followed up for a median 17 years (Kenny-Walsh 1999). Currently only 2% have
been found to be cirrhotic and there have been no liver related deaths or development
of HCC. The explanation for this low progression rate lies in this cohort's known risk
factors for progression. Only 5% of this cohort drank more than 14 units of alcohol
weekly, the mean age at infection was 28 years and obviously all were female. The
French study would estimate the median time to a biopsy of cirrhosis to be 42 years
50
(Poynard et al. 1997). Therefore at 17 years it is unlikely that a significant number
would have progressed to cirrhosis. However 51% had evidence of fibrosis on their
biopsies and the mean progression per year of the cohort based on the numbers given
for each stage of fibrosis was 0.048 METAVIR units per year, which is
approximately half that predicted by the French group. There is therefore still
discrepancy between the two studies. In the German Anti-D cohort at 25 years after
infection only 1.5% had developed precirrhotic stages, 0.5% had overt cirrhosis
(Wiese et al. 2005).
There have been two other studies that are more representative of the typical HCV
infected population in most industrialised countries (young, intravenous drug using
and coexisting alcohol abuse) and have also been community based and prospective.
The first, based in the United States, enrolled between 1988-1989, 1667 persons aged
17 years or older with a history of injection drug use and an HCV antibody-positive
test result during follow-up (Thomas et al. 2000). Of these 722 remained persistently
HCV RNA PCR positive. The mean duration of infection was 23 years and 6.5% of
this group were cirrhotic at the end of follow-up. A second cohort from Australia,
were drawn from patients admitted to hospital with acute viral hepatitis from 1971
through 1975. Stored sera availability from this time enabled testing to identify 238
persons who were anti-HCV-positive on admission. Systematic approaches were
used to locate 95 patients in this the cohort. Of these 51 (54%) remained HCV RNA
PCR positive at follow-up. At a mean duration of infection of 23 years 7.5% were
cirrhotic (Rodger et al. 2000). Clearly in this study it is not possible to be sure that all
these patients did have acute HCV due to the difficulty of making this diagnosis,
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however this would mean the numbers progressing to cirrhosis would be an
overestimate.
1.6.3.1.3 Paired biopsy studies
Another way to assess progression of fibrosis is to follow a cohort of patients after an
initial biopsy and then repeat it in all patients after a specified time interval. This was
performed in a cohort of 123 patients with chronic HCV that underwent 2 liver
biopsies 4-212 months (mean, 44 months) apart without intervening treatment
(Ghany et al. 2003). Liver histology was graded using the Ishak modified Histology
Activity Index (score, 0-18) and fibrosis staged using a scoring system of 0 (no
fibrosis) to 6 (cirrhosis). 48 (39%) showed progression in fibrosis scores, 46 (37%)
showed no change, and 29 (24%) showed improvement. Of those with worsening
fibrosis, 75% had a 1-point increase and 25% a 2-point or greater increase in scores,
and 9% showed progression to cirrhosis. The overall rate of progression was 0.12
fibrosis units per year, a rate that predicts progression to cirrhosis in 50 years if
progression was linear. The rate of fibrosis progression was variable, and it was
higher among older patients, those with higher serum alanine and aspartate
aminotransferase levels, and those with the most extensive periportal necrosis on
initial liver biopsy. A similar study was performed on 180 patients with a mean time
interval between biopsies of 3.67+/-2.69 years. This showed overall no significant
progression (Zarski et al. 2003). The Trent HCV study group in England performed a
similar paired biopsy study to look at the rate of progression of fibrosis (Ryder et al.
2004). The median time interval between biopsies was 30 months. Two hundred and
fourteen patients with predominantly mild liver disease and who had not had
treatment were included. There was worsening of the fibrosis in 33% by at least one
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point in the Ishak score and 10.7% progressed by more than two points. The major
criticisms of this type of study is whether it is possible to detect and quantify small
changes in the stage of fibrosis accurately enough over this short time interval, with
the discrete and bounded nature of the fibrosis score? Use of a single pathologist
helps to decrease interobserver variability but there were no measures of
intraobserver variability in these studies. This is important if the median change is
small. Another major concern is whether selection was involved in choosing those
that underwent the initial biopsy and did all those that had a first biopsy have a
second or were they again selected? This could introduce significant bias. In those
studies where there is a considerable variation in the time between biopsies suggests
the influence of clinical decisions rather than a true prospective study.
1.6.3.2 Variations in the rate of progression over time
Does fibrosis progress in a linear, exponential or episodic manner? The French group
plotted mean fibrosis score against patients grouped by duration of infection and
produced a linear plot (Poynard et al. 1997). However their subsequent analysis with
the larger cohort and a different statistical method, suggested four distinct phases of
linear fibrosis (Poynard et al. 2001). During the first 10 years from infection there
was little if any progression (except in those infected after the age of 50 years old).
The second period lasted approximately 15 years with a slow regular progression of
fibrosis. The third period lasted approximately 10 years, with an intermediate rate of
progression. The final period was the last five years, which was associated with the
most rapid progression. This finding would certainly be in keeping with an older age
at infection hastening fibrosis progression. The authors themselves however do
recommend caution in their analysis of the data, as those that have had the infection
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for between 20 and 40 years make up a small proportion of the total cohort.
Interpretation also depends on the fibrosis staging score itself being a linear scale,
but as yet it is unclear how much collagen has to be laid down to progress from one
stage to another. We will only get answers to this question when a technique is
developed which can quantify this accurately.
1.6.3.3 Established major predictors of progression to cirrhosis
1.6.3.3.1 Alcohol
As alcohol can cause cirrhosis alone it has been important to establish if its effect in
patients with HCV is purely additive or synergistic. An Italian study established the
interaction between Lifetime daily alcohol intake (LDAI) and HCV showed an
additive structure for LDAI below 50g/day and a multiplicative structure for
consumption greater than 125g/day (Corrao & Arico 1998). A more recent study
based on 800 patients that had detailed LDAI recorded and had had liver biopsies for
assessment of HCV infection report conflicting results. On univariate analysis heavy
alcohol intake (>50g/day) was associated with an increase in mean fibrosis but was
not seen in light or moderate alcohol use (Monto et al. 2004). For each category of
alcohol intake, a spectrum of fibrosis was observed, suggesting that other factors are
also influencing fibrosis. In this study there was no correlation between alcohol
intake and inflammation or ALT. Alcohol did not display an independent association
with fibrosis in multivariate models in this study, although the statistical model
chosen to perform the analysis could be criticised for being inappropriate. Another
study demonstrated that both activity and fibrosis gradually increase according to the
amount of alcohol ingested, and that even moderate alcohol consumption, as low as
31-50g/day in men and 21-50g/day in women, may aggravate histological lesions in
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patients with chronic hepatitis C (Hezode et al. 2003). This was also seen in a paired
biopsy study looking at fibrosis progression with moderate alcohol intake (less than
40g/day) (Westin et al. 2002), however it was not seen to have an effect in other
similar studies (Wright et al. 2003), (Ryder et al. 2004).
1.6.3.3.2 Older age at infection
An older age at infection does appear to lead to a faster fibrosis progression (Poynard
et al. 1997). In paired biopsy studies this has also been seen (Wright et al. 2003), or
instead the age at first biopsy appears to have more influence (Ryder et al. 2004).
This may be due to the age of the liver rather than the age of the patient, as it appears
that HCV progresses faster in a transplanted liver from an older donor (Berenguer et
al. 2002).
1.6.3.3.3 Co-infection with Human Immunodeficiency Virus
HIV co-infection with HCV is not unusual. HCV related cirrhosis is now becoming
the major cause of mortality in HIV cohorts (Jaggy et al. 2003), (Salmon-Ceron et al.
2005). Although a study in a US urban cohort contradicts this (Sulkowski et al.
2002). In a retrospective cross-sectional study the median time from infection to
cirrhosis was 6.9 years and 23.2 years, in HIV antibody positive and negative
patients (Pol et al. 1998). There is a meta-analysis to quantify the effect of HIV
coinfection on progressive liver disease in persons with HCV. Eight studies were
identified that included outcomes of histological cirrhosis and they had a pooled
relative risk of 2.07 (95% CI, 1.40-3.07) (Graham et al. 2001). The Trent group in
another paired biopsy study has found that HIV infection accelerates the rate of
fibrosis progression by 1.4 fold, and the development of advanced fibrosis threefold
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(Mohsen et al. 2003). A low CD4 cell count was independently associated with
advanced disease and correlated with higher histological index, which suggests that
early antiretroviral therapy may be of benefit in slowing HCV progression in co-
infected patients. In another single-centred, cross-sectional study the length of time
on HAART was inversely related to the stage of fibrosis (Tural et al. 2003).
Reassuringly protease inhibitor therapy does not appear to accelerate progression to
HCV-related cirrhosis (Benhamou et al. 2001).
1.6.3.3.4 Hepatic steatosis
As mentioned in the pathology section steatosis of the liver is common in HCV
infection. Naturally researchers have tried to discover whether its presence affects
progression of the disease. Fibrosis on biopsy was found to correlate significantly
with body mass index and steatosis (Hourigan et al. 1999). In a paired biopsy study,
worsening of steatosis was observed in 34% of patients, stability in 50%, and
improvement in 16%. Worsening of steatosis but not worsening histological activity,
was significantly associated with hepatic fibrosis progression in patients with or
without steatosis at diagnosis (Castera et al. 2003). In a similar study progression of
fibrosis occurred in 16% of patients after a median delay of 65 months. Cumulative
probabilities of the progression of fibrosis at 4 and 6 years were 5.2% and 19.8%,
respectively. In multivariate analysis, steatosis was the only independent factor
predictive of progression of fibrosis (Relative Risk, 4.8; CI, 1.3-18.3). Probability of
progression of fibrosis was significantly related to the percentage of hepatocytes with
steatosis. This observation was independent of alcohol intake, genotype and insulin
resistence (Fartoux et al. 2005a). Other studies have found an association between
insulin resistence and fibrosis (Hui et al. 2003b).
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1.6.3.4 Postulated / minor predictors of progression to cirrhosis
1.6.3.4.1 Co-infection with Hepatitis B virus
Continuing or past HBV co-infection is common in HCV infected patients. There is
an increased risk of cirrhosis in co-infected patients that are HBsAg positive and
HBV Deoxyribonucleic acid (DNA) positive compared with HBsAg negative HCV
patients (Zarski et al. 1998). In HBsAg positive co-infected patients those with HBV
DNA detectable in the serum have higher inflammation and fibrosis scores on biopsy
compared with those that do not, despite having a lower level of HCV viraemia.
Another study confirmed the lower levels of both HCV RNA and the HBV DNA in
co-infection compared with single infections (Jardi et al. 2001). In Hepatitis B core
antibody (HBcAb) positive but HBsAg negative patients, in 46% of patients HBV
DNA was present in the liver and this correlated with increased risk of cirrhosis
compared with those in whom it was not detected (Cacciola et al. 1999). This occult
co-infection also been observed in haemodialysis patients and the DNA found
represents a YMDD mutant in 50% of cases (Besisik et al. 2003). However there
appears to be no difference in progression to advanced fibrosis between Anti-HBc
antibody positive and negative patients (Myers et al. 2003).
1.6.3.4.2 Sex of patient
Retrospective studies have reported that men infected with HCV are more likely to
progress to advanced fibrosis than women (Poynard et al. 1997). While in the paired
biopsy studies it has been demonstrated in some (Wright et al. 2003), but not others
(Zarski et al. 2003), (Ryder et al. 2004).
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1.6.3.4.3 Activity of hepatitis on biopsy
The large retrospective studies have not established a relationship with the
necroinflammatory score (Poynard et al. 2001), although smaller ones have
suggested a link (Monto et al. 2004), (Asselah et al. 2003). The paired biopsy studies
are similarly divided between those that have shown a relationship (Ryder et al.
2004), and those that have not (Zarski et al. 2003).
1.6.3.4.4 Iatrogenic immunosuppression
In view of the findings in HIV coinfected patients it has been suggested that
iatrogenic immunosuppression may hasten progression. However in a paired biopsy
study (37 months apart) comparing renal transplant recipients and with a matched
group of controls without renal disease, fibrosis progression was slower and the final
stage was lower in the transplant group (Alric et al. 2002).
1.6.3.4.5 Major Histocompatibility Complex alleles
The individual's MHC alleles do affect the outcome of the infection, although as
with viral clearance, the positive predictive value of the presence or absence of a
particular allele in predicting progression is very low (Cramp et al. 1998),
(McKiernan et al. 2000).
1.6.3.4.6 Haemochromatosis mutations
The role of coexisting Haemochromatosis (HFE) mutations remains controversial. In
one study the presence of HFE mutations was independently associated with iron
loading (in serum and liver) and advanced fibrosis in patients with compensated liver
disease from chronic hepatitis C, especially after controlling for duration of disease
(Tung et al. 2003). They suggest that HFE mutations accelerate hepatic fibrosis in
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hepatitis C but may not be responsible for progression to end-stage liver disease.
Another study has shown increased liver fibrosis and cirrhosis in heterozygotes for
the common mutations compared with those that do not have the mutations (Erhardt
et al. 2003). However a study performed in Glasgow concluded that although
patients with chronic HCV infection frequently have elevated serum iron markers,
elevated liver iron concentrations are uncommon in their cohort (Thorburn et al.
2002). They felt the mutations do not have a role in the accumulation of iron or the
progression of liver disease in HCV infection.
1.6.3.4.7 Factor V Leiden polymorphism:
In a single study possession of the factor V Leiden polymorphism significantly
increased the risk of rapid disease progression in HCV (Wright et al. 2003), but this
has yet to be confirmed by other groups.
1.6.3.4.8 Smoking
Smoking has been correlated with increased histological activity but not stage of
fibrosis and appears to be independent of the effect of alcohol (Hezode et al. 2003),
(Pessione et al. 2001).
1.6.3.4.9 Patients with persistently normal ALTs
Some patients with HCV antibody have a persistently normal ALTs (PNALT). If
followed-up, 21% of the patients had a slight increase in serum ALT levels, but
histological lesions remained stable (Martinot-Peignoux et al. 2001). The presence of
a PNALT however does not exclude the presence of significant liver disease (Puoti et
al. 2002). In a paired biopsy study those with a PNALT with an initial fibrosis of F0
or F1 were less likely to develop progression of fibrosis than those with an elevated
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ALT, although patients with PNALT may have histologically and clinically
progressive disease (Hui et al. 2003a). These patients are also at risk of ALT flares,
which can lead to progressive liver disease (Rumi et al. 2002). Hence, extended
surveillance of HCV antibody positive patients with consistently normal or
minimally elevated ALT values is warranted.
1.6.3.5 Factors that have not been shown to influence progression
In the large cross-sectional studies the genotype of the virus and the absolute level of
the viraemia were not shown to be independent predictors of progression in Western
populations. Only one paired biopsy study has suggested that a non-1 genotype, may
hasten the rate of fibrosis (Wright et al. 2003).
1.6.4 The rate of progression to the complications of cirrhosis
The previous studies concentrate on the length of time it takes to progress to
cirrhosis, however arguably the most important end-points are liver decompensation,
development of HCC, liver failure and death or transplantation. There have been a
number of studies describing the natural history of a large cohort of compensated
cirrhotics with HCV. One followed 112 patients for a median of 4.5 years but
included 49 patients who were treated with IFN. The cumulative probabilities for
decompensation and development of HCC were 22.2% and 10.1% in five years, with
an estimated yearly incidence of 4.4% and 2.0% respectively (Hu & Tong 1999). The
cumulative survival probability was 82.8% from entry and 51.1% from
decompensation in five years. Independent variables predicting decompensation were
albumin level and older age at infection. As albumin is a known marker for the
severity of cirrhosis, its influence may simply have been due to this (those with lower
albumins had more advanced cirrhosis at recruitment for the study and required less
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progression to get reach decompensation). The second study followed 103 patients
for a median of 3.4 years (Serfaty et al. 1998). Fifty-nine patients were treated with
IFN. The cumulative probabilities for decompensation and development of HCC
were 20% and 11.5% (with an annual incidence of 3.3%) respectively at four years.
Absence of treatment with IFN was the only independent variable predictive of
progression to these two end-points. As there would have been selection criteria for
those that received IFN, this study is deeply flawed. In another study 255 biopsy-
proven cirrhotics, with no complications of cirrhosis and no other potential causes of
chronic liver disease were followed for a median period of 7 years (Fattovich et al.
2001). Genotype lb was present in 69%. Kaplan-Meier 5-year risk of HCC was 6%
and 4% for patients infected by type lb and non-lb, respectively (P=0.8); for
decompensation 18% and 7% (P=0.0009) and for event-free survival 79% and 89%
(P=0.09), respectively. Finally in an Italian study of 254 uncomplicated compensated
cirrhotic patients (biopsy-proven and clinically determined) that were followed-up
for a median of 91 months, 30.7% developed at least one complication of cirrhosis.
HCC developed in 20.5% and was the commonest first complication. Ascites
developed in 17.7% and 4.7% had a variceal bleed. Progression of Child's stage was
seen in 18.1% and 16.3% died a liver-related death (Benvegnu et al. 2004). During
follow-up 45.3% received IFN based therapy and a lower rate of complications was
seen in this group (25.2% versus 35.9%).
The longest running and largest retrospective-prospective study looking at mortality
has been performed by the National Heart, Lung and Blood Institute (Seeff et al.
1992). Five hundred and sixty-eight patients who received a transfusion at time of
cardiac surgery and subsequently developed a post-transfusion hepatitis were
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recruited between 1968 and 1980. Two hundred and eight patients had samples
available that retrospectively confirmed them to be HCV antibody positive. These
were compared with a control group of 379 patients who also underwent cardiac
surgery and received a transfusion but did not develop hepatitis and were HCV
antibody negative. At a mean of 18 years from the time of transfusion all-cause
mortality in the HCV group was 49% while 54% in the matched controls. This
difference was not significant. At approximately 25 years of follow-up, the All-cause
mortality was 67% among the hepatitis C-related cases and 65% among the controls
(P=Non-significant) (Seeff et al. 2001). Liver-related mortality was 4.1% and 1.3%,
respectively (P=0.05). Follow-up of the 90 alive HCV cases revealed viraemia with
chronic hepatitis in 38%, viraemia without chronic hepatitis in 39%, anti-HCV
without viraemia in 17%, and no residual HCV markers in 7%. Clinically evident
liver disease was observed in 86% with cirrhosis, but in only 23% with chronic
hepatitis alone. A major criticism of the study is the high mortality in both groups,
due the medical problems and age of the cohort, and that this may mask small
differences in early mortality due to HCV. However due to the age of the cohort it
would have been expected there would have been faster progression.
In the UK there is an ongoing study organized at the Public Health Laboratory
Service in England looking at 924 transfusion recipients infected with the HCV
traced during the HCV lookback programme (Harris et al. 2002). These have been
matched to 475 transfusion recipients who tested negative for antibodies to HCV
(controls). After 10 years of infection the All cause mortality was not significantly
different between patients and controls. Patients were more likely to be certified
with a death related to liver disease than were controls, but although the risk of death
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directly from liver disease was higher in patients than controls this difference was not
significant. Forty per cent of the patients who died directly from liver disease were
known to have consumed excess alcohol. Clinical follow up of 826 patients showed
that liver function was abnormal in 307 (37.2%), and 115 (13.9%) reported physical
signs or symptoms of liver disease.
In the Irish Anti-D cohort study no patient had developed liver decompensation or
HCC at 17 years (Kenny-Walsh 1999). In the German Anti-D cohort study only
0.35% had developed liver decompensation and had died of this and one HCC had
been diagnosed at 25 years (Wiese et al. 2005). In the American community based
study at mean duration of 23 years, 2.4% had developed a complication of cirrhosis
but no HCC had been diagnosed. In a multivariate model, the risk of a complication
of cirrhosis was higher for persons aged 38 years or older at enrollment (adjusted
relative incidence, 3.67; 95% CI, 1.96-6.88) and those that reported ingestion of
more than 260 g of alcohol per week (adjusted relative incidence, 3.60; 95% CI,
1.73-7.52) (Thomas et al. 2000). In the Australian acute hepatitis study at a mean
duration of infection of 23 years, 6% had a complication of cirrhosis but again no
HCC had been diagnosed (Rodger et al. 2000).
1.6.4.1 Predictors of progression to the complications of cirrhosis
As can be seen from the studies above, the variables that predict progression to
complications of cirrhosis are not as clearly defined as those that predict the
progression to cirrhosis. It is likely, however that there will be common factors.
In a case controlled study in the US, a synergistic rather than an additive interaction
were observed between heavy alcohol consumption and chronic hepatitis virus
infection and diabetes mellitus in those that developed HCC (Hassan et al. 2002).
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Obesity does not appear to be an additional risk factor for HCC in HCV (Nair et al.
2002). Porphyria Cutanea Tarda (PCT) may increase the risk of a patient developing
an HCC (Fracanzani et al. 2001).
1.6.4.2 Symptoms of chronic HCV infection
The symptoms related to chronic HCV infection are very non-specific. In a study of
these symptoms at presentation of 1614 patients with HCV infection, fatigue was
present in 53% of patients (Poynard et al. 2002a). In 17% of patients fatigue was
severe and impairing activity. Five other symptoms had a prevalence above 10%
including, in decreasing order: arthralgia, paresthesia, myalgia, pruritus, and sicca
syndrome. The presence of fatigue, was associated with female gender, age over 50
years, cirrhosis, depression and purpura. The prevalence of fibromyalgia (as defined
by the association of fatigue with arthralgia or myalgia) was 19%. There was no
significant association between fatigue and the following characteristics: viral load or
genotype, alcohol consumption, abnormal thyroid function, and type and level of
cryoglobulinemia. One study found that fatigue was associated with high circulating
leptin levels even after correction for fat mass (Piche et al. 2002).
Patients with HCV infection have been shown to have slight but significant
neurocognitive impairment even before the onset of cirrhosis (Kramer et al. 2002),
(Hilsabeck et al. 2002). Using proton magnetic-resonance spectroscopy, elevations in
basal ganglia and white matter choline/creatine ratios can be demonstrated in patients
with histologically-mild hepatitis C, compared with healthy volunteers and patients
with hepatitis B. This elevation is unrelated to hepatic encephalopathy or a history of
intravenous drug abuse or by depression, or fatigue (Forton et al. 2001), (Forton et al.
2002).
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It has been shown clearly that chronic HCV infection with or without cirrhosis
causes a reduction in the usual measures of quality of life (Foster et al. 1998),
(McHutchison et al. 2001b). This reduction can occur in the absence of major
cognitive impairment (Cordoba et al. 2003).
In early cirrhosis the only symptoms experienced can be the ones mentioned above.
However with the onset of portal hypertension and liver failure new symptoms can
occur such as abdominal distension with ascites, peripheral oedema with low serum
albumin, vomiting blood with oesophageal varices or portal hypertensive
gastropathy, excessive drowsiness and day-night reversal with encephalopathy or
right upper quadrant pain with HCC.
1.6.4.3 Extra hepatic manifestations
As well as the neuropsychiatric complications that may lead to the non-specific
symptoms mentioned above, there are also some specific extra hepatic disease
associations with chronic HCV infection. In a study of male veterans in the US,
significant associations were found between HCV infection and PCT, lichen planus,
vitiligo, cryoglobulinemia, membranoproliferative glomerulonephritis, and Non-
Hodgkin's Lymphoma (El Serag et al. 2002).
Approximately 40% of patients with chronic HCV infection develop detectable
serum cryoglobulins or cryoprecipitates, although most do not show clinical or
physical signs of syndromic cryoglobulinemia. These are commoner in cirrhotic
patients but causality is unknown (Kayali et al. 2002).
1.7 Treatment of Hepatitis C
In the last 10 years considerable progress has been made in the management of
chronic HCV infection. The objectives of treatment are (a) prevention of the
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occurrence of cirrhosis and its complications (b) reduce the extrahepatic
manifestations (c) prevent transmission of virus to other people. The history of
treatment started before discovery of the virus with the use of IFN monotherapy to
treat Non-A, Non-B hepatitis (Hoofnagle et al. 1986). This was continued with the
discovery of the virus but markedly improved with the introduction of ribavirin to the
regime. The most recent advance is the change to Pegylated interferon (PEG-IFN)
with ribavirin and this is now the established treatment of choice in the UK (Booth et
al. 2001), (National Institute for Clinical Excellence 2004) and worldwide (National
Institutes of Health 2002).
1.7.1 Interferon monotherapy
Interferon monotherapy was the first treatment tried and although the initial trials
demonstrated promising efficacy, ultimately this was not borne out in clinical
practice. Over 50 randomised controlled trials (RCTs) were performed comparing it
with placebo but usually with small numbers of participants. However there are two
good meta-analysis' that have been performed (Thevenot et al. 2001), (Myers et al.
2002).
1.7.1.1 Pharmacology
IFNs are naturally occurring proteins secreted by many mammalian cells (Isaacs &
Lindenmann 1957). Alpha IFN, a type 1 IFN actually represents a family of more
than 20 subspecies of proteins and glycoproteins. The two main forms that have been
thoroughly assessed are IFN alpha-2b and IFN alpha-2a. Both are produced by
recombinant DNA techniques using a strain of Escherichia coli bearing a genetically
engineered plasmid containing an IFN alpha-2b or IFN alpha-2a gene from human
leucocytes. They differ from each other by a single amino acid in the peptide
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sequence (Emanuel & Pestka 1993). It is usually administered by subcutaneous
injection. Maximum serum levels occur 3 to 12 hours after injection and serum levels
are usually below the limit of detection by 16 hours (Wills 1990). The elimination
half-life of IFN is 2 to 3 hours and clearance is largely by renal catabolism.
1.7.1.2 Mode of action
As previously described IFN alpha binds a common receptor and activates over a
hundred Interferon stimulated genes (ISG) via the Jak-STAT pathway (Sarcar et al.
2004). These ISG products impart regulatory functions that limit HCV replication
through processes that include disruption of viral RNA translation and inhibition of
antigenomic strand RNA synthesis via 2',5'-oligoadenylate synthetase (Wang et al.
2003). Other ISGs are involved in lipid metabolism, apoptosis, protein degradation
and inflammatory cell responses (DE Veer et al. 2001). Type 1 IFNs promote
memory T-cell proliferation, prevent T-cell apoptosis and stimulate natural -killer
cell activation and dendritic-cell maturation (Tilg 1997). IFN also upregulates the
production of MHC class-I and class-II peptides and might promote a T-helper-1
over a T-helper-2 phenotype (Lechner et al. 2000). The methods by which the virus
evades these actions have been previously described in the immunology section.
1.7.1.3 Efficacy
1.7.1.3.1 Duration of treatment
In the Cochrane review on IFN naive patients, the meta-analysis revealed a
significant difference in Sustained viral response (SVR) between those treated thrice
weekly dosage of 3 MU for 12 or more months compared with 6 months (14% (95%
CI 11 to 19%) and 7% (95% CI 5 to 11%) (Myers et al. 2002).
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1.7.1.3.2 Dose
In the Cochrane review SVR for thrice weekly 6 MU versus 3 MU for at least 12
months was 43% (95% CI 32 to 55%) and 25% (95% CI 17 to 37%) respectively
(Myers et al. 2002).
1.7.1.3.3 Genotype
Analysis of the IFN monotherapy trials reveals a significant difference between the
SVR for genotype 1 infection (18.1%) and the non-genotype 1 infections (54.9%)
(Davis & Lau 1997).
1.7.1.3.4 Cirrhotic patients
SVR were seen in 17% of treated patients with varying regimes (Myers et al. 2002).
1.7.1.3.5 HIV co-infection
There were no large RCTs in patients with co-infection with HIV, however smaller
studies suggested similar efficacy as long as the CD4 count remained preserved
(Mauss et al. 1998).
1.7.1.3.6 Other predictors of response
A younger age at infection and a lower viral load were also found to be predictive of
a SVR (Chemello et al. 1995).
1.7.1.4 Assessment of response
Retrospective analysis of monotherapy trials suggested that non-response to IFN
monotherapy could be predicted at 12 weeks of treatment by the ongoing presence on
HCV RNA on PCR testing (McHutchison et al. 1998a). Treatment could be
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discontinued in these patients. However the variability in the sensitivity of the PCR
assay at the time of these studies made interpretation of these data difficult.
1.7.1.5 Long-term outcome
The long-term outcome of patients who are sustained responders to IFN
monotherapy has been documented. The proportion that remains HCV RNA PCR
negative has ranged from 96% at a mean follow-up of 4 years to 92% (Marcellin et
al. 1997) at a mean of 5.4 years (Reichard et al. 1999).
There is evidence that treatment with IFN monotherapy irrespective of whether a
SVR is achieved reduces the risk of decompensation and HCC. In a study of a total
of 286 sustained virological responders, the rate of decompensation after five years
of follow up was 1.0% (95% CI 0.0-2.3) and none developed HCC. Survival was
comparable with the general population, matched for age and sex, the standard
mortality ratio being 1.4 (95% CI 0.3-2.5) (Veldt et al. 2004). A meta-analysis of all
the IFN monotherapy trials in cirrhotic patients suggests a slight preventative effect
on HCC development but the magnitude is probably low and may be spurious due to
confounding influences (Camma et al. 2001). There is also a large retrospective
cohort study of 2889 patients with histological-proven chronic HCV (2430 patients
received IFN therapy, and 459 patients were untreated). It demonstrated that the risk
of death was reduced, compared with untreated patients, among IFN-treated patients
(risk ratio for overall death: 0.37; CI: 0.24-0.60; for liver-related death: 0.28; CI:
0.16-0.49) and among sustained responders (risk ratios for overall death: 0.15; CI:
0.06-0.34 and for liver-related death 0.05; CI: 0.01-0.22). The risk of liver-unrelated
deaths remained unchanged (Yoshida et al. 2002).
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1.7.1.6 Adverse events
A wide array of side effects has been described with IFN treatment. The prevalences
quoted are for 3 MU three times a week for six months and based on a meta-analysis
of the monotherapy trials (Poynard et al. 1996). The early flu-like side effects are
common (41%) and predictable. These include fever, fatigue, headache, myalgias
and arthralgia. Although problematic they do not usually necessitate dose
modification. Neuropsychiatric side effects such as depression (7%) and irritability
can also occur. Dermatological adverse events include alopecia (16%) and worsening
of psoriasis. The common laboratory abnormalities are due to the myelosuppressive
actions of IFN. These include neutropenia (9%), thrombocytopenia (8%) and
anaemia. They are usually mild and well tolerated but may necessitate dose
reductions or discontinuation. IFN can precipitate autoimmune phenomenon such as
thyroiditis (2%) leading to hypo- or hyperthyroidism. Severe and even life-
threatening idiosyncratic side effects occur in 0.1% to 1% of patients; these include
hepatic decompensation, retinopathy, acute renal failure, suicidal ideation and dilated
cardiomyopathy and pulmonary interstitial fibrosis. These may be irreversible.
Overall the rate of dose reductions is 9% and discontinuation is 4% for 3 MU three
times a week. Higher doses of IFN cause higher rates of adverse events than standard
doses (Poynard et al. 1996). The contraindications of therapy are based on the known
side effects and are relative.
1.7.2 Combination standard interferon and ribavirin
Two large randomised controlled trials established that combination IFN and
ribavirin was an effective treatment for chronic HCV infection in IFN-naive patients
(McHutchison et al. 1998b), (Poynard et al. 1998). The standard regime was IFN
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alpha 3MU three times a week and ribavirin in divided doses of 800 to l,200mg/day
depending on the weight of the patient.
1.7.2.1 Pharmacology of ribavirin
Ribavirin is a water-soluble nucleoside analogue of guanosine with activity against
DNA and RNA viruses (Sidwell et al. 1972). It is well absorbed orally and cleared by
the kidney.
1.7.2.2 Mode of action of ribavirin
Ribavirin monotherapy was associated with improvements in serum ALT but viral
RNA levels long term did not change (Dusheiko et al. 1996). The addition to IFN
alpha treatment however led to an improvement in the SVR rates by reducing the
relapse rate at the end of treatment (McHutchison et al. 1998b). When combination is
compared with IFN alpha monotherapy, there appears to be no effect on the first and
second phases of viral kinetics but it does reduce the rebound in viral levels seen
before the second dose of IFN and this was dependent on the concentration of
ribavirin (Pawlotsky et al. 2004).
Ribavirin is phosphorylated intracellularly to form a triphosphate. If this is
misincorporated by the HCV RNA polymerase, it can lead to early chain termination
and inhibition of replication. However, this appears to only occur at very high
concentrations (Maag et al. 2001). Ribavirin monophosphate is also a competitive
inhibitor of inosine monophosphate dehydrogenase, which leads to depletion of the
GTP necessary for viral RNA synthesis (Lau et al. 2002). Mutagenesis and error
catastrophe has been suggested as another mechanism of action. There is some
evidence of that as it increases the mutation rate and thereby decreases replicative
fitness of the virus, making it more susceptible to the actions of IFN alpha (Dixit et
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al. 2004). However this is disputed by some researchers (Pawlotsky et al. 2004).
Several studies have suggested that ribavirin can alter the T-helper-1 / T-helper-2
balance, favouring the former and therefore increasing the chance of viral clearance
(Cramp et al. 2000). The mechanism by which this occurs is not known.
1.7.2.3 Efficacy
1.7.2.3.1 Duration of treatment and genotype
Treatment of genotype 1 patients for 24 weeks and for 48 weeks produces a SVR of
between 16-18% and 28-31% respectively. For genotype 2 or 3 patients it is 64-69%
and 64-66% respectively (McHutchison et al. 1998b), (Poynard et al. 1998).
Therefore patients infected a genotype 2 or 3 virus require only six months of
treatment, while those with a genotype 1 virus that have a negative serum HCV RNA
PCR test at six months do benefit from a further six months of treatment
(McHutchison et al. 1998b), (Poynard et al. 1998). These SVRs are significantly
better than those achieved by standard IFN monotherapy.
1.7.2.3.2 Cirrhotic patients
Due to the small number of cirrhotics in the RCTs comparing standard IFN and
ribavirin with IFN monotherapy, little can be concluded except that a higher stage of
fibrosis did reduce SVR and SVR was better in those patients treated with
combination treatment (McHutchison et al. 1998b), (Poynard et al. 1998). In the
RCTs comparing it with PEG-IFN and ribavirin, the SVR with standard IFN and
ribavirin in cirrhotics was 33%.
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1.7.2.3.3 HIV coinfection
The overall SVR for standard IFN alpha-2a and ribavirin for 48 weeks in co-infected
patients is 8% for genotype 1 and 27% for genotype 2 or 3 (Torriani et al. 2004).
1.7.2.3.4 Other predictors of response
In both the 6 month and 12 month treatment subgroup binary logistical regression
identified that genotype 3 infection, a low degree of fibrosis at baseline, female sex,
baseline viral load of 2x106 copies per millilitre or less as independently predictive of
a SVR (McHutchison et al. 1998b), (Poynard et al. 1998). The European randomised
controlled trial also identified young age as an independent predictor of response
(Poynard et al. 1998).
1.7.2.4 Assessment of response
Subsequent analysis of the main RCTs has shown that a negative serum HCV PCR
test at 6 months of treatment, is the earliest time response can be assessed to ensure
that no eventual sustained responders are discontinued too early (McHutchison et al.
2001a).
1.7.2.5 Adverse events
Flu-like side effects predominate with fatigue occurring in 70% but are no more
frequent than in IFN monotherapy. Ribavirin is known to concentrated in red blood
cells, causing haemolysis and a mean drop of 3g/dl in haemoglobin in the first 4
weeks of treatment (Poynard et al. 1998). The addition of ribavirin increases the
prevalence of itch and rashes compared with IFN monotherapy (20% versus 9%)
(McHutchison et al. 1998b), (Poynard et al. 1998). Dose reduction occurred in 13%-
17% of patients, with anaemia triggering this in 7-9% of patients. Overall
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discontinuation of therapy due to a severe adverse event occurred in 8% for 24 weeks
of treatment and 19-21% for 48 weeks of treatment was seen in the trials with
depression being the commonest cause (McHutchison et al. 1998b), (Poynard et al.
1998).
As ribavirin is teratogenic in animal studies, pregnancy is an absolute
contraindication to treatment. Due to the risk of anaemia with the treatment end-stage
renal failure, severe anaemia and haemoglobinopathies should only be treated with
PEG-IFN monotherapy. For the same reason a history of ischaemic heart disease and
cerebrovascular disease is a relative contraindication.
1.7.2.6 Long-term outcome
It has been assumed that the persistence of the SVR following combination treatment
will be equivalent to that of IFN monotherapy. The only data so far reported,
followed up 25 sustained responders of which 94% remained HCV RNA PCR
negative at a mean of 9.4 months (Barnes et al. 1999).
1.7.3 Pegylated Interferon monotherapy
1.7.3.1 Pharmacology
Standard IFN can be modified by the addition of a polyethylene glycol moiety. This
pegylation achieves a slower rate of clearance and a longer half-life and therefore
more stable levels in the blood and a weekly dosing regime. There are currently two
PEG-IFNs, PEG-IFN alpha 2a (covalently bonded to a branched 40KD molecule)
and PEG-IFN alpha 2b (non-convalently bonded to a straight 12KD molecule). They
have distinct pharmacokinetics and pharmacodynamics (Wang et al. 2000). The
PEG-IFN alpha 2a has a smaller volume of distribution and a longer half-life but is
less bioavailable. For PEG-IFN alpha 2b the maximum serum levels occur 48 to 72
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hours after injection. The elimination half-life of IFN is approximately 40 hours and
clearance is only 30% by renal catabolism. The remaining clearance may be affected
by binding to IFN receptors and non-specific hepatic metabolism (Glue et al. 2000).
The recommended dosing regimes differ in that PEG-IFN alpha 2a is a fixed dose of
180pg once a week and PEG-IFN alpha 2b is 1.0 pg/kg once a week.
1.7.3.2 Efficacy
1.7.3.2.1 Duration of treatment and genotype
The main RCTs comparing PEG-IFN alpha 2a monotherapy (180pg) with standard
IFN monotherapy for 48 weeks demonstrated SVRs rates of 39-44% versus 8-19%
respectively (Zeuzem et al. 2000), (Heathcote et al. 2000).
In the main study that compared PEG-IFN alpha-2b (0.5, 1.0, or 1.5 pg /kg) with
standard IFN alpha-2b for 48 weeks demonstrated the SVR was not dose-related
above 1.0 pg /kg. For this dose, the SVR in comparison with standard IFN for those
with genotype 2 or 3 and a low viral load was 62% versus 36%. For those with
genotype 1 and a high viral load it was 8% versus 2% (Lindsay et al. 2001).
1.7.3.2.2 Cirrhotic patients
In patients with cirrhosis or bridging fibrosis, 180 pg of PEG-IFN alpha-2a is
significantly more effective than standard IFN alpha-2a (SVR of 30% versus 8%)
(Fleathcote et al. 2000).
1.7.3.2.3 HIV coinfection
The overall SVR 180 pg of PEG-IFN alpha-2a for 48 weeks in co-infected patients is
31%, but 21% for genotype 1 and 57% for genotype 2 or 3 (Torriani et al. 2004).
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1.7.3.2.4 Other predictors of response
Multiple logistical regression has identified that a genotype other than 1, no cirrhosis
or bridging fibrosis at baseline, baseline viral load of 2xl06 copies per millilitre or
less, body-surface area of less than 2m2 and pretreatment ALT quotient greater than
3 were independently predictive of a SVR (Zeuzem et al. 2000).
1.7.3.3 Assessment of response
Response can be assessed by a quantitative HCV RNA PCR at 12 weeks which
either shows a two log reduction from the start of treatment or that it has become
negative (Zeuzem et al. 2000). If this does not occur, treatment can be discontinued,
as there is no prospect of achieving a SVR.
1.7.3.4 Adverse events
In the RCTs comparing PEG-IFN monotherapy with standard IFN monotherapy the
frequency and severity of the adverse events were similar in both groups and typical
of those previously reported for monotherapy. Dose modification due to neutropenia
occured in 11% of patients on PEG-IFN compared with 7% on standard IFN but
there were no discontinuations. Overall the discontinuation rate was 7% and dose
reduction rate 19% over 48 weeks of treatment (Zeuzem et al. 2000).
1.7.3.5 Long-term outcome
There are no studies only looking at the long-term outcome with PEG-IFN
monotherapy.
1.7.4 Combination pegylated Interferon and ribavirin
The introduction of PEG-IFN in combination with ribavirin is now the recommend
treatment for chronic HCV infection due to improved efficacy (Manns et al. 2001)
especially in the less responsive genotype 1 subgroup.
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1.7.4.1 Pharmacology
Each PEG-IFN alpha molecule has been combined with ribavirin. It does not appear
to affect the pharmacokinetics or pharmacodynamics of the individual molecules.
The same dosing regimes used in monotherapy are used in the combination with
PEG-IFN alpha 2a. While PEG-IFN alpha 2b is given at 1.5 pg/kg once a week in
the combination.
1.7.4.2 Assessment of response
In genotype 1 patients response can be assessed by a quantitative HCV RNA PCR at
12 weeks which either shows a two log reduction from the start of treatment or that it
has become negative (Lee et al. 2002). If this does not occur, treatment can be
discontinued, as there is no prospect of achieving a SVR.
1.7.4.3 Efficacy
1.7.4.3.1 Duration of treatment and genotype
The RCTs have established that genotype 1 and 4 patients should be treated for 48
weeks and 24 weeks for the other genotypes (Manns et al. 2001), (Fried et al. 2002).
More recently there has been evidence that with genotypes 2 or 3 the same SVR rates
can be achieved with 12 weeks treatment compared with 24 weeks in those that have
an early viral response at four weeks (Mangia et al. 2005)
The regimes described above achieve a SVR rate of 50% in the genotype 1 or 4 and
80% in genotype 2 and 3 irrespective of the type of PEG-IFN used (Manns et al.




Patients with bridging fibrosis or compensated cirrhosis do achieve lower SVR rates
(50-70% for genotype 2 and 3, and 20-30% for genotype 1) (Manns et al. 2001),
(Fried et al. 2002). At present there is little data on the effect of reducing the
complications of cirrhosis.
1.7.4.3.3 HIV co-infection
Treatment for 48 weeks achieves a SVR of 60% in genotype 2 and 3 and 14-29% in
patients with genotype 1. For patients with genotype 1 infection and low HIV viral
load (less than 800,000 IU/ml) the SVRs are higher at around 60% (Chung et al.
2004), (Torriani et al. 2004).
1.7.4.3.4 Other predictors of response
A high HCV viral load, age over 40, male sex and more extensive fibrosis or
cirrhosis on histology is associated with lower SVR rates (Manns et al. 2001), (Fried
et al. 2002). A meta-analysis of ethnic differences showed that patients of African
American or Hispanic origin had lower SVRs than Caucasians or Asian groups.
Asian patients have a much better response to treatment than any other ethnic group
(Hepburn et al. 2004). A weight greater than 75 kg has been shown to lower SVR in
a number of studies (Shepherd et al. 2004). Patients on a stable methadone program
have been shown to achieve lower but reasonable SVRs (Genotype 1 or 4; 38%
versus 55%; Genotype 2 or 3: 48% versus 57%). More patients drop out in the first
eight weeks compared with controls (24% versus 8%) but thereafter compliance is
the same (Mauss et al. 2004). Co-infection with HBV has not been shown to affect
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SVRs (Liu et al. 2003). A median daily alcohol use >30 g/day has been associated
with failure to respond to treatment (Chang et al. 2005).
1.7.4.4 Effect on histology
In the patients that had pre- and post-treatment liver biopsies, 73% had an
improvement in their necro-inflammatory score. In only 8% did fibrosis worsen and
overall the fibrosis progression rate fell. Reversal of cirrhosis was observed in 49%
of patients with baseline cirrhosis (Poynard et al. 2002b). In genotype 3 patients,
SVR is associated with disappearance of steatosis on biopsy (Poynard et al. 2003).
1.7.4.5 Effect on extra hepatic manifestations of HCV infection
A study looking at all sustained viral responders following HCV treatment found it
was associated with an improvement in fatigue (35% versus 22%) and cryoglobulin
(33% versus 6%), but fatigue frequently persists despite a virologic response
(Cacoub et al. 2002). Overall health related quality of life has been shown to improve
in those with a SVR compared with those that do no achieve this (Hassanein et al.
2004).
1.7.4.6 Adverse events
The adverse event profile of PEG-IFN plus ribavirin and standard IFN plus ribavirin
is similar. There are no new or unique adverse events, and there are no differences
between the difference forms of PEG-IFN, with the same percentage of severe
adverse events requiring discontinuation (9.7% v 9.6%), with depression being the
commonest cause (Manns et al. 2001), (Fried et al. 2002). In the trials a further
12.3% withdrew for other reasons. Overall dose reduction occurred in 8.2%, with
neutropenia being the commonest cause. It was also commoner with the PEG-IFN
combination versus standard IFN combination (3.5% versus 1.6%). There is a
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significant increase in injection-site reactions (4.9% versus 3.6%) but this does not
limit therapy.
1.7.4.7 Long-term outcome
Long-term data is sparse but it appears that viral relapse is uncommon after SVR. A
recent abstract presented at the annual meeting of the American Association for the
Study of Liver Diseases showed that 99.2% of patients with a SVR remained HCV
RNA PCR negative at five years (Swain et al. 2005).
1.7.4.8 Cost effectiveness
PEG-IFN plus weight-based dosing of ribavirin compared with no antiviral therapy,
increased life expectancy by 4.7 years (Siebert et al. 2003). Compared with standard
IFN and weight-based dosing of ribavirin, it increases it by 1 year with incremental
cost-effectiveness ratios of 6600 euros per Quality-adjusted life year. Subgroup
analysis by genotype, viral load, sex and histology demonstrated it to remain cost-




2.1 Edinburgh cohort studies
2.1.1 Patients
Patients in the Edinburgh cohort were identified by review of outpatient, inpatient,
liver biopsy and endoscopy records of the Centre of Liver and Digestive Disorders in
the Royal Infirmary of Edinburgh. The diagnosis of HCV was confirmed by
retrospective review of the patient's hospital casenotes and hospital laboratory
computer records. The specific inclusion and exclusion criteria for each study are
described in the methods section of each chapter.
2.1.2 Hepatitis C management database
A Microsoft Access database application was created to enable clinicians to manage,
audit practise and collect epidemiological and natural history data on a hospital
cohort of patients with HCV infection.
2.1.2.1 Main features
Providing rapid patient-specific information on all patients. This includes past
and present clinical status, investigations and treatments.
Identifying, tracking, summarising auditing patients undergoing treatment.
Surveillance management for patients at risk of HCC and varices.
Provide descriptive statistics on the population.
2.1.2.2 Basic database design
The database application was created using Microsoft Office 2000 developer edition.
It is a Microsoft Access relational database based around tables of fields that are
related by a patient reference number (PatRefNo). Figure 1 shows the main tables
and how they relate to each other.
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Figure 1 Relationships of the database tables
'tblPatentDetails' is the key table and contains a single record for each patient. In the
other tables each patient may have more than one record and therefore its uniqueness
is determined by the combination of the PatRefNo and another field such as the date
a test took place, if for example the table records blood results.The database user
interface was created using database objects called 'Forms'. Forms can display the
fields that make up the tables described above. They can be used for data entry or
display of data that has already been entered. The field boxes on the forms can also
be programmed, using visual basic for applications, to perform different actions
depending on the data that has been entered into it. Forms can also have command
buttons on them that can be programmed to perform actions, such as opening other
forms or modifying data. Queries are another database object that can be used to
view, change, and analyze data from one or more tables. Numerous queries have
been designed and used as a source of records for the forms, charts and reports of the
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database. All these features have been utilised in the database created. A full
description of the database structure and features are given in appendix 1.
2.1.3 Data collection
All details on the patients were collected and entered onto the Edinburgh Hepatitis C
database by retrospective review of the patient's hospital casenotes, hospital
computer laboratory and pathology records and endoscopy records. Once the
database was established in the outpatient clinics, where a patient's hospital record
review was complete, data such as the clinical findings from the last clinic visit for
were added in real time.
2.1.4 Standard patient assessment and follow up protocols
2.1.4.1 Initial assessment
History
Documentation of probable source of infection, probable date of infection (taken as
the first year of active intravenous drug use or the first date of exposure to a known
risk factor such as blood transfusion), the date of last exposure to a known risk factor
for HCV infection, current alcohol intake, previous maximum alcohol intake
sustained for greater than 5 years (one unit is equivalent to 9.6g of alcohol), onset of
any symptoms suggestive of a complication of cirrhosis, sex and date of birth.
Clinical examination
Detection of the presence or absence of ascites, encephalopathy, peripheral oedema,
splenomegally, hepatomegally and jaundice.
Laboratory assessment
Liver enzymes including ALT.
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Full blood count and Prothrombin time.
• Qualitative HCV RNA reverse transcription by nested PCR using 5'
noncoding region specific primers as previously described (Chan et al. 1992) was
undertaken.
• Genotyping (HCV RNA reverse transcription by nested PCR using 5'
noncoding region specific primers followed by restriction fragment length
polymorphism analysis (Simmonds et al. 1994) was not performed on all patients due
to changing policies over the period of study.
Serological markers for HBV and HIV infection were detected with standard
assays.
• Other liver diseases were excluded using standard assays.
Serum Hyaluronic acid was assayed using the Chugai Hyaluronic acid test
(Chugai Diagnostics Science CO., produced by REAADS Medical Products Inc.,
Westminster, Colorado, USA). A threshold of lOOng/ml was used to determine the
presence of cirrhosis except when excluded by subsequent investigations. This
threshold has been demonstrated to have 92% specificity and 72% sensitivity for
diagnosing cirrhosis in patients with HCV infection (Plevris et al. 2000).
Other investigations
The presence or absence of cirrhosis was determined by diagnostic
laparoscopy and histology in the majority up until 2001.
Ultrasonography of the abdomen was performed in the majority. Ultrasonic
diagnosis of cirrhosis was used except when excluded by subsequent investigations.
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2.1.4.2 Follow-up assessments
Patients were followed-up at regular outpatient appointments or during inpatient
admissions. Documentation of further biopsies, onset of complications of cirrhosis,
date of death or transplantation was made.
2.1.4.3 Surveillance
Hepatocellular carcinoma
Surveillance for HCC is carried out in cirrhotic patients with six monthly alpha-
fetoproteins and ultrasound scan (USS). HCC is confirmed by Computerised
Tomography scanning or laparoscopic ultrasound.
Oesophageal varices
Surveillance for oesophageal varices is carried out at diagnosis of cirrhosis and two
yearly in those without varices and six monthly in those that have grade 1 varices.
Grade 2 and above were treated prophylactically (Beta-blockers, banding or nitrates).
These episodes were recorded on the database.
2.1.5 Treatment
2.1.5.1 Antiviral treatment
After initial assessment a decision was usually made on the suitability for treatment.
As there were changes in the available treatment over the study period, the criteria on
which this decision was made also varied. Different treatments also had different
protocols of follow up and blood test sampling. However, usually the HCV RNA
PCR was checked before treatment and at six months after the end of treatment to
assess whether the patient was a sustained responder. Some patients also had a PCR
checked after 12 weeks of treatment and / or at the end of treatment to assess whether
they were a responder.
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A full blood count and liver enzymes were checked every two weeks. Adverse events
on treatment and what action and its effect were recorded. If the patient discontinued
treatment, the reason for this was recorded.
If the patient was not deemed suitable for treatment or the patient refused treatment
the reason for this was recorded on the database.
Categories of responder
All patients whilst on treatment were categorised with a responder status.
Currently on treatment if the patient is on treatment.
Non-responder is a patient who has never normalised his ALT or become
PCR negative or has not had a 2 log reduction in PCR titre at 12 weeks.
• Relapser is either a patient who has normalised his ALT or become PCR
negative but has relapsed on treatment necessitating discontinuation of treatment or
who has responded up to the time of discontinuing treatment but then relapsed in the
six months from discontinuation.
• End of treatment responder but not 6/12 is a patient who responded up to
the time of discontinuing treatment but has not been followed up for six months from
the time of discontinuation.
Sustained responder is a patient who was a responder who has remained
HCV PCR negative and normal ALT beyond six months from the time of
discontinuing treatment.
• Late relapser is a sustained responder who has subsequently relapsed.
Treatment incomplete is a patient in whom treatment was discontinued
prematurely and the patient has relapsed.
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• Awaiting start of treatment for those patients currently the waiting list for
treatment.
2.1.5.2 Oesophageal variceal bleeds
The practice for treating oesophageal variceal bleeds changed throughout the period
of the study. It included variceal band ligation, injection sclerotherapy, use of
vasoactive drugs and Transjugular Intrahepatic Porto-Systemic Shunts (TIPSS).
Episodes of variceal bleeding and their treatment were recorded.
2.1.5.3 Liver transplantation
Referral for liver transplantation was made on the established criteria for
transplantation. These would be persistent liver decompensation, a diagnosis of an
HCC that is within the criteria for transplantation or on quality of life issues. The
main contraindications for referral were on-going substance abuse (alcohol or drugs)
and HIV infection. In 2004 HIV infection was no longer considered a
contraindication for assessment.
2.2 Combination interferon and ribavirin treatment in
hospital practice in United Kingdom study.
2.2.1 Patients
All centres in the UK that were known to have had patients that were treated with
combination viraferon (IFN alpha-2b) and ribavirin from Schering-Plough between
1997 and 2000 were invited to participate in the study. All adult patients were
eligible for treatment if they were seropositive for HCV RNA on testing with the
PCR. Patients with decompensated cirrhosis, major psychiatric disorders, seizure
disorders, cardiovascular disease and those unable to practice contraception were
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excluded. All patients that were suitable from the Royal Infirmary of Edinburgh were
excluded. These patients were analysed separately and are described under the
Edinburgh cohort studies.
2.2.2 Data collection
Those centres that agreed to participate were supplied with a specially designed
database application that standardised and facilitated data collection.
Each patient's medical record was analysed for: Preliminary demographic data
including risk factors for HCV infection, alcohol history, known genotype and
coexisting diseases. Pre-treatment clinical details such as the results of liver biopsy,
including a modified Ishak score if available and a Childs-Pugh score. Monthly
dosing schedule and PCR results. Adverse events with treatment and whether these
triggered dose reduction or withdrawal. All data was anonymised and forwarded to a
national database for analysis.
2.3 Statistical analysis
2.3.1 Characteristics of study populations
A description of each study population analysed was made using SPSS and Excel
software. Chi-squared test or Fisher's exact test were used where appropriate to
establish significant associations between categorical covariates. Pearson's
correlation coefficient was used for continuous variables. T tests were performed to
establish significant differences in mean of continuous variables for different
categorical variables. All P values are two-tailed.
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2.3.2 Natural history survival analysis
2.3.2.1 Kaplan-Meier analysis
This was used to describe and illustrate the number of patients progressing to defined
end-points over time. The analysis for the time from infection to various end-points
was performed using either left truncation of the risk set six months prior to the date
of the first appointment or no left truncation. The former method takes account of the
fact that those referred to hospital are only a sample of the whole population that
have had the infection for a similar period of time. The latter method has been used
most frequently in other similar retrospective cohort studies in the literature (Poynard
et al. 1997). A median time to the end point was assessed where possible. The log
rank test was used to perform univariate analysis to investigate the influence of the
covariates above on the defined end-point. This analysis was performed using the
statistical package R.
2.3.2.2 Cox (proportional hazards) regression analysis
This was used to construct a model and perform multivariate analysis to investigate
the influence of covariates on the defined end-point. Again left truncation of the risk
set was performed where appropriate using the method described above. Independent
predictor variables (covariates) within the model were identified by a stepwise
forward conditional selection method, based on the significance of the score statistic.
The regression coefficients (b) for these covariates were calculated. For categorical
covariates, Exp(b) is equivalent to the increase in hazard (relative risk) in comparison
to the reference category. For continuous covariates, it is the increase in hazard for
an increase of 1 in the value of the covariate. This analysis was performed using the
statistical package R.
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2.3.3 Treatment for Hepatitis C analysis
2.3.3.1 Prediction of Sustained viral response
2.3.3.1.1 Univariate analysis
Chi-squared test or Fisher's exact test were used where appropriate to perform
univariate significance testing on categorical covariates. All P values are two-tailed.
2.3.3.1.2 Multivariate analysis
Binary logistic regression analysis was used to perform multivariate significance
testing on covariates.
2.3.3.2 Survival analysis on late relapse
Kaplan-Meier analysis was performed to demonstrate the occurrence of late relapse
in sustained responders using SPSS software.
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This chapter describes the HCV RNA PCR positive cohort in the Royal Infirmary of
Edinburgh. To try and reduce the effect of referral bias to a tertiary centre only those
patients that live within an Edinburgh 'EEl' postcode were included. The time to
referral, the basic demographics of the referred patients, the risk categories for
infection, the important cofactors for progression, the length of follow up and the
outcome are all analysed. The results of this analysis give indications of the likely





• HCV antibody positive.
• Attended Royal Infirmary of Edinburgh between January 1991 and December
2004.
Exclusion criteria
• Tertiary referrals from hospitals outside Edinburgh.
• Home address outwith the EH postcode.
3.3 Results
Of the 1007 patients assessed for HCV infection in the Royal Infirmary and on the
database, 794 met the criteria for inclusion into this cohort. Of these, 87 were HCV
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RNA PCR negative without treatment. A further 13 had never had an HCV RNA
PCR measured, all of which had normal ALT measurements. Therefore there were
694 patients in the cohort that were HCV RNA PCR positive.
The characteristics of this HCV RNA PCR positive cohort are analysed in detail in
this chapter. Table 1 gives a summary of the basic population.
Table 1 Population characteristics of HCV RNA PCR positive Royal Infirmary cohort.
3.3.1 Referral to the Royal Infirmary of Edinburgh
3.3.1.1 Source
The majority of patients were referred from General Practice within Edinburgh
(41.1%). Genitary Urinary Medicine (9.1%) and the Blood Transfusion service
(6.6%) were the other major sources of referrals (Table 2).
3.3.1.2 Type of referral
The majority of patients were first seen in the Royal Infirmary of Edinburgh as an
outpatient (Table 3).
3.3.1.3 Age at referral
The mean age at referral was 39.9 years old with a median of 38.7 years old (Table
Number of patients (n=694) Percentage
Men
Women





















Table 2 Source of referrals for HCV RNA PCR positive cohort.
Type of source Specific source Number Percent
General Practice GP 285 41.1
Other units within A&E 5 0.7




General Medicine 1 0.1






Other Hospital units Blood Transfusion Service 46 6.6
in Edinburgh Regional Infectious Disease Unit 37 5.3
West General Hospital 32 4.6
Royal Edinburgh Hospital 4 0.6
East General Hospital 3 0.4
Murrayfield Hospital 3 0.4
Leith Hospital 1 0.1
Royal Edinburgh Sick Childrens Hospital 1 0.1
Roodlands Hospital 1 0.1
Unknown 146 21.0





Table 3 Type of referral when patient was first seen in Royal Infirmary of Edinburgh.






3.3.2 Variables recorded at first appointment or first admission
3.3.2.1 Probable date of HCV infection
The date of probable infection could be estimated in 559 patients and is plotted as a
histogram in Figure 2.


































Year of probable infection
3.3.2.2 Age at HCV infection
In patients that had a probable date of infection, calculation of the patient's age at
infection was possible (Table 4). The mean was 22.1 years, but the patients with an
IDU risk category it was 20.3 years compared with 26.4 years for those that did not.
The median age at infection is 19.6 years for the cohort and 19.2 years for the
patients with an IDU risk category. The minimum infection age in the cohort was
0.1 years (vertical transmission) and the maximum is 70.2 years. The age at infection
distribution is positively skewed (1.83 with a standard error of skewedness of 0.10).
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Table 4 Descriptive statistics of the continuous variables age at infection, HCV
diagnosis and at first appointment or admission, weight, height and Body Mass Index.
Age at
Age at HCV Age at first Weight Height
infection Diagnosis appointment (kg) (m) BMI
Valid 458 635 694 326 559 317
Missing 236 59 0 368 135 377
Mean 22.07 38.63 39.93 72.67 1.71 24.60
Standard
Error of 0.43 0.45 0.42 0.73 0.005 0.25
Mean
Median 19.57 37.12 38.72 70.00 1.72 23.81
Standard
Deviation
10.07 11.26 11.01 15.63 0.09 4.45
Skewness 1.83 0.88 0.89 0.85 -0.12 1.15
Standard
Error of 0.10 0.10 0.09 0.11 0.13 0.14
skewness
Minimum 0.01 14.11 14.70 39.00 1.50 15.78
Maximum 70.19 81.36 81.67 147.00 1.93 43.28
kg: kilograms, m: metres, BMI: Body Mass Index
The only significant correlation between the age at HCV infection and the other
continuous variables was a negative one with the height of the patient (Table 5).
Table 5 Correlation between age at infection and the continuous variables.
Weight Height BMI
Age at HCV Pearson Correlation -0.015 -0.135 0.090
infection p-value (2-tailed) 0.771 0.022 0.134
Number 394 286 277
BMI: Body Mass Index
In Table 6a the age at HCV infection is categorised into three groups and cross-
tabulated with the patient's sex. Chi-squared testing approaches a significant
difference (p=0.082) between male and females in their age at infection distribution.
A higher proportion of males (56.0%) being infected at age under 20 years compared
with females (46.2%). For the whole HCV PCR positive cohort the modal age group
is 'Under 20 years' (52.8%).
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Table 6b is a cross-tabulation between the age at infection categories and whether
patients have IDU as their risk category for infection. Chi-squared testing reveals a
significant difference between those that have IDU as their risk category for infection
and those that do not (p<0.0001) in their age at infection distributions. Only 5.5% of
patients with IDU as their risk category were greater than 30 years at HCV infection
compared to 34.6% of those that did not.
Table 6 (a) Age at HCV infection by gender.
Female Male
i uiai
Under 20 Number 85 210 295
years 0//O 28.8% 71.2%
Age at 20 to 30 Number 68 118 186












Number 184 375 559
0//o 32.7% 67.1%
Pearson Chi-square (2df) =5.01, p-value =0.082
(b) Age at HCV infection by IDU risk category patients.
IDU Total
No Yes




years % 22.4% 77.6%
20 to 30 Number 40 146 186
years % 21.5% 78.5%
More than Number 56 22 78
30 years % 71.8% 28.2%
Total
Number 162 397 559
% 29.0% 71.0%
Pearson Chi-square (2df) = 80.78, p-value < 0.0001
3.3.2.3 Risk category for infection
64.1% had intravenous drug use as the probable source of infection (Figure 3).
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Figure 3 Pie chart risk category for infection.
Tatto/Bodv Accidental
Chi-square testing shows a significant difference in the sex ratios of patients again
categorised by whether their risk category is IDU and non-IDU (Table 7).
Table 7 IDU risk category by gender.
Risk category Sex Total
Female Male
No




Number 125 320 445
0//o 28.1% 71.9%
Total
Number 215 479 694
% 31.0% 69.0%
Pearson Chi-square (1 df) = 4.84, p-value = 0.03
3.3.2.4 Country in which HCV infection occurred
In the overwhelming majority of patients, Scotland was thought to have been the
country in the HCV infection was acquired (Table 8).
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Table 8 Country or continent in which HCV thought to have been acquired.
Country/Continent Number Percent
Africa 5 0.7
Indian subcontinent 13 1.9
Middle-East 2 0.3
North America 10 1.4
Northern Europe 13 1.9
Oceania 6 0.9
Rest of Europe 10 1.4
Rest of EIK 17 2.4
Scotland 503 72.5
South-East Asia 6 0.9
South America 1 0.1
Unknown 108 15.6
Total 694 100.0
3.3.2.5 Ethnicity of patient
Most patients were white (96.7%) with the next commonest racial group being
Pakistani (Table 9).




Any other 5 0.7
Black African 2 0.3
Bangladeshi 1 0.1




3.3.2.6 Genotype of the virus
Four hundred and eighty-two patients had their genotype determined. 51.7% of these
had a genotype 1 virus (Figure 4).
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Figure 4 Pie charts of virus genotype.
Table 10 shows that the patients genotype is significantly less likely to have been
ascertained for patients whose risk category for infection is IDU, but when known,
the genotype differs neither by sex nor by IDU / non-IDU status (data not shown).
Table 10 Genotype ascertainment by risk category.
Risk category Genotyped Total6 J No Yes
Number 62 187 249
% 24.9% 75.1% 100.0%
Number 150 295 445
% 33.7% 66.3% 100.0%
Number 212 482 694
% 30.5% 69.5% 100.0%
Chi-square(ldf)=5.84, p-value = 0.016
3.3.2.7 HIV status
Table 11 shows there is a significant association between HIV infection status and













Number 243 6 249
% 97.6% 2.4%
Number 404 41 445
% 90.8% 9.2%
Number 647 47 694
% 93.2% 6.8%
Pearson Chi-square (ldf) =11.71, P-value =0.001
3.3.2.8 HBV infection status
Two hundred and eleven patients have had previous HBV infection defined as being
HBcAb positive, at their first assessment (Table 12). However, only 8 had HBsAg
suggesting lack of clearance of the virus. Vaccination has only been performed in 35
of the 343 (10.2%) patients that had not previously had HBV infection.
Table 12 HBV infection status of HCV PCR cohort.
HBV status Number Percent
HBcAb negative, HBsAb negative (non immunised) 308 44.4
HBcAb negative, HBsAb positive (immunised) 35 5.0
HBcAb positive, HBeAg negative, HBsAg negative 201 29.0
HBsAg positive, HBeAg positive 2 0.3
HBsAg positive, HBV DNA negative 3 0.4
HBsAg positive, HBV DNA unknown 5 0.7
Unknown 140 20.2
Total 694 100.0
Table 13 shows there is a significant association between previous HBV infection
status and IDU risk category status within this HCV PCR positive cohort.
Table 13 IDU Risk category by HBV status.
. , Previous HBV . .




Number 202 47 249
% 81.1% 18.9%




Number 483 211 694
% 69.6% 30.4%
Pearson Chi-square (ldf) =24.39, P-value <0.0001
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3.3.2.9 Previous maximum alcohol intake
The previous maximum alcohol intake, which was maintained for at least 5 years,
was obtained in 565 patients. 42.1% of these had consumed more than 50 units of
alcohol per week (Figure 5).
Figure 5 Pie chart of previous maximum alcohol intake.
Previous maximum alcohol consumption varies between men and women (Table
14a). In this cohort 46.4 % of women drink alcohol modestly (1 to 21 units per
week). The other three alcohol consumption categories are equally frequent among
women. In contrast, for men, consumption of more than 50 units per week is the
modal category (51.8%) and very few men don't drink (7.0%). Chi-square testing
confirms that alcohol consumption distribution depends on sex of the patient
(p<0.0001).
Table 14b shows that 64.5% of patients with an IDU risk category status compared
with only 45.3% of those that do not, have a previous maximum consumption of
more than 21 units per week. Chi-square test confirms that the consumption
distribution depends also on IDU risk category status (p<0.0001).
Table 14c, suggests that the association of previous maximum alcohol consumption
with IDU risk category status is not accounted for purely by sex differences.
















0 Number 32 27 59
units/week % 54.2% 45.8%
Previous 1-21 Number 83 95 178
maximum units/week % 46.6% 53.4%
alcohol 22-50 Number 26 64 90
intake units/week % 28.9% 71.1%
>50 Number 38 200 238









Pearson Chi-square (3df) =59.72, P-value <0.0001




0 Number 29 30 59
units/week % 49.2% 50.8%
Previous 1-21 Number 75 103 178
maximum units/week % 42.1% 57.9%
alcohol 22-50 Number 29 61 90
intake units/week % 32.2% 67.8%
>50 Number 57 181 238
units/week O//o 23.9% 76.1%
Total
Number 190 375 565
O//o 33.6% 66.4%
Pearson Chi-square (3df) =22.21, P-value <0.0001
(c) Previous maximum alcohol consumption by IDU status in men.
IDU
Pearson Chi-square (3df) =9.48, P-value =0.024
Total
No Yes
0 Number 12 15 27
units/week % 44.4% 55.6%
Previous 1-21 Number 33 62 95
maximum units/week % 34.7% 65.3%
alcohol 22-50 Number 23 41 64
intake units/week % 35.9% 64.1%
>50 Number 46 154 200
units/week % 23.0% 77.0%
Total
Number 114 272 386
% 29.5% 70.5%
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3.3.2.10 Intravenous drug use status
At least 8.4% of patients had been injecting intravenous drugs within a year of their
last appointment or admission (Table 15). Of the 103 'Unknowns', 80 have
intravenous drug use as their risk category for infection but it is unknown whether
they are still injecting drugs or not.
Table 15 Intravenous drug use status of HCV PCR positive patients.
Intravenous drug status Number Percent
Injected in last 12 months 58 8.4
Last injected greater than 12months ago 307 44.2




At least 27.0% (120 out of 445) of HCV RNA PCR positive patients that have used
intravenous drugs were on a methadone maintenance program (Table 16).
Table 16 Methadone use in HCV RNA PCR positive cohort




Not applicable as no previous ^49 35 9
Intravenous drug use '
Total 694 100.0
3.3.2.11 Smoking status
At least 49.7% of patients are currently smoking or have previously smoked
cigarettes (Table 17).
105
Table 17 Smoking status in HCV RNA PCR positive patients.
Smoking status Number Percent
Current 309 44.5




3.3.2.12 Weight, Height and Body Mass Index
The mean weight at first appointment or admission was 72.7 kilograms and the mean
height 1.71 metres (Table 4). The Body Mass Index was calculated in those patients
that had both weight and height measurements available.
3.3.3 Time from infection to first appointment or admission
Using the probable date of HCV infection, a mean and median time from infection to
first appointment or admission can be calculated (Table 18).
Table 18 Descriptive statistics for time from infection to first appointment or
admission and length of follow up.
Time from infection to Length of follow up from first
first appointment or appointment or admission
admission (years) (years)
Mean 16.84 3.90
Standard Error of Mean 0.38 0.14
Median 17.02 2.85








There is a significant positive correlation between the time from infection to first
appointment or admission with the patient's weight and Body Mass Index (BMI) and
significant negative correlation with patient's age at HCV infection (Table 19).
Table 19 Correlation for time from infection to first appointment or admission and
length of follow up with continuous variables recorded at first appointment or
admission
Time from infection to



































p-value (2-tailed) <0.0001 0.824
Number 277 317
The mean time from infection to first appointment or admission was calculated for
each category within the categorical variables; age at HCV infection, sex of the
patient, whether the risk factor for infection was IDU or not, previous maximum
alcohol intake, HIV status, genotype of the virus and whether the patient was
cirrhotic. T testing revealed a significant difference in the means for the categories;
age at HCV infection, sex of the patient, previous maximum alcohol in take, HIV co-
infection, previous HBV infection and whether the patient was cirrhotic (Table 20).
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Table 20 Categorical covariates in which the mean time from first infection to first
appointment or admission is significantly different on T testing.
Standard
Standard Error

































































Previous No 384 15.57 9.07 0.46
<0.0001













3.3.4 Length of follow up from first appointment or admission
The length of follow up was the years between date of the patient's first appointment
or admission to the date of last follow up.
There were no significant correlation between the length of follow up and age at
HCV infection, weight, height and BMI of patient (Table 19)
The mean length of follow up was significantly shorter in those that previously drank
more than 50 units/week and those with no previous HBV infection This was also the
case in non-cirrhotics compared with cirrhotics (Table 21).
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Table 21 Categorical covariates in which the mean length of follow up from first
appointment or admission is significant different on T testing.
Standard
Standard Error











237 3.72 3.37 0.22
0.038
Previous No 475 3.70 3.58 0.16
0.043














The number of patients progressing to each end-point is recorded in Table 22. Any
complication of cirrhosis was defined as the presence of ascites, encephalopathy,
HCC or grade 2 oesophageal varices. Major complications of cirrhosis were the same
except the varices had to be bleeding.
Table 22 Number of HCV RNA PCR positive patients progressing to the end-points.
End-point Number Percent
Cirrhosis on biopsy 87 12.5
Cirrhosis clinically or on biopsy 157 22.6
Any complication of cirrhosis 83 12.0
A major complication of cirrhosis 73 10.5
Complications of cirrhosis
Grade II oesophageal varices 48 6.9
Bleeding oesophageal varices 25 3.6
Ascites 55 7.9
Encephalopathy 25 3.6
Hepatocellular carcinoma 23 3.3
Liver transplantation 13 1.9
Death 75 10.8
Causes of death
Liver related deaths 36 5.2
Non-liver related deaths 18 2.6
Unknown cause of death (out of hospital) 21 3.0
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3.3.6 Stage of disease at the end of follow-up
In Figure 6 a breakdown of the stage of the disease at the end of 2004 is displayed.
The amount of fibrosis on biopsy is based on the patient's last biopsy. This
potentially could have taken place years prior to the December 2004 time point. If
the patient had subsequently developed clinical evidence of cirrhosis or been
transplanted or had died they are classified as this.
























3.3.7 Stage of the disease of the alive cirrhotic patients at end of
follow-up
Of the 92 patients in the cohort that were cirrhotic, 70 were Childs Pugh A on the
latest blood results and clinical examination (Figure 7). Twenty-nine of the alive
cirrhotics (31.5%) had had at least one complication of cirrhosis.
110







The basic characteristics of the HCV RNA PCR population are very similar those
previously described from a tertiary care centre in an area of low prevalence (Foster
et al. 1997), (Poynard et al. 1997). Two thirds are male and 64% are likely to have
acquired the infection through IDU. In only 8% was it not possible to identify a
probable source of infection. Somewhat unusually the cohort is mainly white with
72.5% acquiring the infection in Scotland.
The commonest source of referral was local GPs, with only 6.6% coming from the
Blood transfusion service. Attendance as an outpatient was the first point of contact
with the service in the vast majority. Patients were presenting around the age of 40
years. It is not possible to be certain about the exact date of acquisition of infection in
any of the patients. However a probable date has been estimated from the date of first
exposure to a known risk factor for HCV infection. In patients that have IDU as their
risk category, the assumption is that in the majority infection is acquired in the first
year of use. This is based on the seroprevalence rate of 78% at one year amongst the
US IDU community cohort (Thomas et al. 1995a). The 90% prevalence rates
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amongst in the 15-19 year old age group in Glasgow IDU cohort in 1990 would also
suggest rapid acquisition (Goldberg et al. 1998). However this study also
demonstrates that this is not constant over time and therefore the variability in this
estimate is unknown. Most comparible studies have made this assumption (Poynard
et al. 1997). Using this estimate the majority of patients were infected in the early
1980s reflecting the high prevalence of drug use in this population. As expected
those that acquired the infection through drug use did so at a significantly younger
age. Men appear to acquire the infection at an earlier age compared with women
although this did not quite reach significance. Significantly more men acquired the
infection through IDU compared with women.
About half of the population tested for genotype had genotype 1, and so if treated
would require a year of treatment and would have a lower SVR rate. No association
between genotype and IDU or sex could be found, although IDU patients were
significantly less likely to have been tested for genotype which may have masked an
association.
Only 6.8% of the cohort was co-infected with HIV as the Regional infectious disease
unit in Edinburgh specialises in management of these patients. Those with co-
infection were more likely to have acquired the infection through IDU. One third of
the cohort had had previous HBV infection, reflecting the significant association of
previous HBV and IDU. However, only 1% appeared to have evidence of ongoing
infection. At present only 10.2% have been vaccinated against HBV despite the
recommendations of the World Health Organisation (World Health Organization
1998) and the National Institute of Health (National Institutes of Health 2002).
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The covariate used to categorise previous alcohol intake was previous maximum
alcohol intake maintained for greater than five years. This was acquired from review
of the patient's notes. The accuracy of this will have varied depending on the
thoroughness of the patient's initial assessment by different clinicians and the
patient's accuracy in their replies. As there has been no assessment of the accuracy of
this estimation, conclusions may be susceptible to error. However irrespective of
these caveats it is of great concern that 42% of all patients and 52% of men appear to
have drunk in excess of 50 units of alcohol for more than five years prior to
presentation. There was a significant difference between men and women in this
covariate, and those that acquired the infection through IDU and those that did not.
At least 8% of the cohort and potentially up to 20% had recently used intravenous
drugs with a quarter of those that acquired the infection by IDU on a methadone
program, while half the cohort has smoked in the past. With a median weight of 72
kg and a BMI of 24.7, suggest that just less than half the cohort is obese.
The median time from infection to first appointment or admission was about 17 years
with a median follow up thereafter of about 3 years. Therefore the bulk of the
population have not yet reached the point at which the complications of cirrhosis will
be seen. Interestingly those that presented a longer time after infection were more
likely to have a higher BMI. This may reflect the natural changes in body weight
with age, but may contribute to worsening in fibrosis with age via liver steatosis. In
this cohort, the older the age at infection, the shorter the time from infection to first
presentation. Men presented longer after infection than women, as did those with no
HIV co-infection and those with previous HBV. Those that had drunk more than 50
113
units / week presented later after infection than those that drank less than 21 unit /
week, but had less years of follow up after presentation.
At least 22% of the cohort has cirrhosis clinically, although only about half of these
have had it confirmed by biopsy or laparoscopy. At least one complication of
cirrhosis was seen in 12% of patients, which was most commonly the presence of
ascites in 7.9%. Grade 2 oesophageal varices have been found in about 7% of
patients overall, but only half of these have bled. Looking at major complications of
cirrhosis (excludes varices that have not bled), the rate was 10.5%. HCC has been
found in 15% of cirrhotics which reflects HCV cirrhosis being a significant risk
factor for this tumour. The concern with the high proportion of cirrhotic patients seen
in this cohort is that this simply is a result of referral bias. This undoubtedly is true to
a certain extent, however it is interesting to note that only 4.3% first presented as an
inpatient and the vast majority were referred by GPs via the outpatient department.
So far only 13 patients have met the criteria for transplantation and have been
transplanted. Eleven percent of the cohort has died and in those in whom we know
the cause, liver-related death is twice as common as non-liver-related death.
However in 25% we do not know the cause as the patient has died out of hospital.
At the end of the period of follow up at least 13% of the cohort were alive and
cirrhotic. This may be an underestimate as some patients may have progressed since
their last biopsy and a third of the cohort have not had a biopsy, although at the time
of clinical assessment there was no evidence of cirrhosis. Of the cirrhotics that were
alive at the end of follow-up, three-quarters were Childs A.
Overall this cohort is made up of a significant proportion of middle-aged men who
acquired the infection less than 20 years ago, principally through IDU, and have a
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significant history of alcohol abuse. The covariates that may influence progression
are often significantly correlated and also influence the time to presentation. A
significant proportion are already are presenting with cirrhosis and its complications,
the rate of which is likely to rise significantly in the next 10 years.
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Numerous retrospective / cross-sectional studies have been performed in various
parts of the world, recruiting patients with established chronic liver disease due to
HCV (Freeman et al. 2003a). Most have concentrated on the time to develop biopsy-
proven cirrhosis from the probable infection date. There has been considerable
variation in the results depending on which country or community the research was
performed in and whether the research was community or hospital based. These
differences may reflect the differing frequencies of the known risk factors in each
patient cohort and referral bias. The variation between countries has implications for
estimating the health impact of the infection and the provision of resources required.
Many of the retrospective studies do not take into consideration that the patients
analysed are a sample of whole HCV RNA PCR positive population and have simply
performed Kaplan—Meier survival analysis without left truncation of the risk set at
the time of presentation. This study will look at the progression to cirrhosis analysed
with and without this left truncation.
There are problems with the date of diagnosis of cirrhosis as an end-point. As there is
no definitive clinical method to diagnose its onset accurately, the time to biopsy-
proven cirrhosis will usually be a considerable overestimate. This is compounded by
many of the studies including those that had already developed cirrhosis
complications (clearly a later stage of the disease) at the date of diagnosis cirrhosis
end-point. In this study only the time to uncomplicated cirrhosis is analysed. The
time at which a biopsy is taken is also very susceptible to referral bias. Therefore in
this study the end-point of clinically diagnosed cirrhosis, as defined in the methods
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section, is also analysed. Clearly this may include some patients that do not actually
have cirrhosis due the lack of sensitivity and specificity of these clinical methods.
In this study to reduce the effect of referral bias to a tertiary centre, only those
patients that live within an Edinburgh 'EH' postcode were included. The time to
referral, the basic demographics of the referred patients, the risk categories for
infection, the important cofactors for progression, the length of follow up and the
outcome are all analysed. The influences of various host and viral factors on the
progression to cirrhosis and its complications were also assessed.
4.2 Methods
4.2.1 Patients
4.2.1.1 The time from infection to clinically diagnosed uncomplicated
Childs A cirrhosis study.
Inclusion criteria
• A probable date of infection that could be estimated.
• Recorded date of first appointment or admission.
• Qualitative HCV RNA PCR positive, six months after the presumed time of
infection.
Exclusion criteria
• Tertiary referrals from hospitals outside Edinburgh.
• Home address outwith the EH postcode.
• Evidence of Autoimmune, Primary Biliary Cirrhosis, Primary Sclerosing
Cholangitis, Haemochromatosis or Wilson's disease.
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• The presence, at the time of diagnosis of cirrhosis, of a complication of
cirrhosis including oesophageal varices (grade 2 or more), a variceal bleed,
ascites, encephalopathy, bilirubin greater than 35, albumen less than 35 or a
prothrombin time greater than 4 seconds prolonged.
• The presence, at the time of diagnosis of cirrhosis, of an HCC.
4.2.1.2 The time from infection to biopsy- or laparoscopy-proven
uncomplicated Childs A cirrhosis study.
Inclusion criteria
• As above.




The time from infection to clinically diagnosed uncomplicated Childs A
cirrhosis study.
The date of first diagnosis of cirrhosis was determined either by biopsy, laparoscopy,
a hyaluronic acid greater than 100 or ultrasonographic evidence of cirrhosis (course
or nodular echotexture). In those that were non-cirrhotic, the date of last follow-up
was used as the censor point.
The time from infection to biopsy-proven uncomplicated Childs A cirrhosis
study.
The date of first diagnosis of cirrhosis was determined only by biopsy or at
laparoscopy. In those that were non-cirrhotic, the date of the last biopsy was used as
the censor point.
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4.2.3 Covariates analysed to predict occurrence of end-points
Age at infection, previous maximum alcohol intake, smoking, methadone use,
previous HBV, HIV co-infection, sex, previous IFN treatment, probable source of
infection, genotype of the virus, BMI and weight.
4.3 Results
4.3.1 The time from infection to clinically diagnosed
uncomplicated Childs A cirrhosis study
4.3.1.1 Cohort demographics
Of the 694 HCV RNA PCR positive patients discussed in chapter 3, 500 met the
inclusion and exclusion criteria for this study. The characteristics of this study
population are summarised in Table 23.




Previous hepatitis B infection 145 29.0
Anti HIV positive 32 6.4
Treatment following initial assessment 201 40.2
Sustained responders to treatment 68 13.6
Previous /current smoker at first assessment 271 54.2
Methadone use at first assessment 97 19.4
Patients biopsied 290 58.0
4.3.1.2 Variables recorded at first appointment or first admission
4.3.1.2.1 Probable date of HCV infection
The date of probable infection is plotted as a histogram in Figure 8. The mode date of
probable infection is 1980.
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4.3.1.2.2 Age at HCV infection
The median age at infection is 19.4 years for the cohort and 19.1 years for the
patients with an IDU risk category (Table 24). The age at infection distribution is
positively skewed.
Table 24 Descriptive statistics of the continuous variables age at infection, HCV
diagnosis and at first appointment or admission, weight, height and Body Mass Index.
Age at Age at Age at first Weight Height
infection Diagnosis appointment (Kg) (m) BMI
Valid 500 470 500 360 263 256
Missing 0 30 0 140 237 244
Mean 21.56 37.03 38.53 71.75 1.71 24.14
Standard
Error of Mean
0.43 0.47 0.45 0.79 0.01 0.261
Median 19.42 35.75 37.40 70.00 1.71 23.51
Standard
Deviation
9.62 10.20 10.10 14.92 0.094 4.18
Skewness 1.95 0.84 0.82 0.64 -0.09 1.20
Standard
Error of 0.11 0.11 0.11 0.13 0.15 0.15
skewness
Minimum 0.01 14.11 14.70 39.00 1.50 15.78
Maximum 70.19 81.36 81.67 131.00 1.93 43.28
Kg: Kilogram, m: Metres, BMI: Body Mass Index
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There were no significant correlations between the age at HCV infection and the
other continuous variables.
If the age at HCV infection is categorised into three groups and cross-tabulated with
the patient's sex, there is no significant difference between males and females in
their age at infection distribution on Chi-square testing. There is a higher proportion
of males (57.4%) being infected at age under 20 years compared to females (48.5%).
For the whole HCV PCR positive cohort the modal age group is 'Under 20 years'
(54.4%).
Table 25 is a cross-tabulation between the age at infection categories and whether
patients have IDU as their risk category for infection. Chi-squared testing reveals a
significant difference between those that have IDU as their risk category for infection
and those that do not (p<0.0001) in their age at infection distributions. Only 5.2% of
patients with IDU as their risk category were greater than 30 years at HCV infection
compared to 29.9% of those that did not.
Table 25 Age at HCV infection by IDU risk category patients.
IDU Total
No Yes




years % 22.4% 77.6%
20 to 30 Number 35 133 168
years 0//o 20.8% 79.2%
More than Number 41 19 60
30 years % 68.3% 31.7%
Total
Number 137 363 500
% 27.4% 72.6%
Pearson Chi-square (2df) = 57.56, p-value < 0.0001
4.3.1.2.3 Risk category for infection
72.6% had intravenous drug use as the probable source of infection (Figure 9).
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Chi-square testing does not show a significant difference in the sex ratios of patients
categorised by whether their risk category is IDU or non-IDU.
4.3.1.2.4 Ethnicity of patient
Most patients were white (97.4%) with the next commonest racial group being
Pakistani (1.2%).
4.3.1.2.5 Genotype of the virus
Three hundred and fifty-seven patients had their genotype determined of which
54.8% of these had a genotype 1 virus (Figure 10).








Table 26 shows that the patient's genotype is significantly less likely to have been
ascertained for patients whose risk category for infection is IDU, but when known,
the genotype differs neither by sex nor by IDU / non-IDU status (data not shown).


















Pearson Chi-square (ldf)= 11.35, p-value = 0.01
4.3.1.2.6 HIV status
There is no significant association between HIV infection status and IDU risk
category status within this cohort.
4.3.1.2.7 HBV infection status
One hundred and forty-five patients have had previous HBV infection, defined as
being HBcAb positive, at their first assessment (Table 27). However only 5 had
ongoing infection suggested by the presence of HBsAg.
Table 27 HBV infection status of HCV PCR cohort.
HBV status Number Percent
HBcAb negative, HBsAb negative (non immunised) 229 45.8
HBcAb negative, HBsAb positive (immunised) 27 5.4
HBcAb positive, HBeAg negative, HBsAg negative 140 28.0
HBsAg positive, HBeAg positive 1 0.2
HBsAg positive, HBV DNA negative 1 0.2




There is a significant association between previous HBY infection status and IDU
risk category status within this cohort (data not shown).
4.3.1.2.8 Previous maximum alcohol intake
The previous maximum alcohol intake, which was maintained for at least 5 years,
was obtained in 417 patients. Overall 31.0% had consumed more than 50 units of
alcohol per week (Figure 11).
Figure 11 Pie chart of previous maximum alcohol intake.
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Previous maximum alcohol consumption varies between men and women (Table
28a). In this cohort 50.0% of women drink alcohol modestly (1 to 21 units per week).
The other three alcohol consumption categories are equally frequent among women.
In contrast, for men, consumption of more than 50 units per week is the modal
category (47.3%) and very few men don't drink (6.2%). Chi-square testing confirms
that alcohol consumption distribution depends on sex of the patient (p<0.0001).
Table 28b shows that 68.8% of patients with an IDU risk category status compared
with only 36.9% of those that do not, have a previous maximum consumption of
more than 21 units per week. Chi-square test confirms that the consumption
distribution depends also on IDU risk category status (p<0.0001).
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Table 28 (a) Previous maximum alcohol consumption by sex.
Sex
Female Male
0 Number 24 17 41
units/week % 58.5% 41.5%
Previous 1-21 Number 71 78 149
maximum units/week % 47.7% 52.3%
alcohol 22-50 Number 22 50 72
intake units/week % 30.6% 69.4%
>50 Number 25 130 155
units/week % 16.1% 83.9%
Total
Number 142 275 417
% 34.1% 65.9%
Pearson Chi-square (3df) =45.78, P-value <0.0001
(b) Previous maximum alcohol consumption by IDU risk category status.
No Yes
0 Number 17 24 41
units/week % 41.5% 58.5%
Previous 1-21 Number 53 96 149
maximum units/week % 35.6% 64.4%
alcohol 22-50 Number 16 56 72
intake units/week % 22.2% 77.8%
>50 Number 25 130 155
units/week % 16.1% 83.9%
Total
Number 111 306 417
% 26.6% 73.4%
Pearson Chi-square (3df) =20.18, P-value <0.0001
4.3.1.2.9 Weight, Height and Body Mass Index
The mean weight at first appointment or admission was 71.7 kilograms and the mean
height 1.71 metres (Table 24). The Body Mass Index was calculated in those patients
that had both weight and height measurements available.
4.3.1.3 Time from infection to first appointment or admission
Using the probable date of HCV infection, a mean and median time from infection to
first appointment or admission can be calculated (Table 29).
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Table 29 Descriptive statistics for time from infection to first appointment or
admission and length of follow up.
Time from infection to
first appointment or
admission (years)




Standard Error of Mean 0.40 0.17
Median 16.38 3.01
Standard Deviation 8.85 3.78
Skewness 0.35 1.20
Standard Error of skewness 0.11 0.11
Minimum 0.03 0.00
Maximum 49.60 26.91
There is a significant positive correlation between the time from infection to first
appointment or admission with the patient's weight and BMI and significant negative
correlation with patient's age at HCV infection.
The mean time from infection to first appointment or admission was calculated for
each category within the categorical variables. T testing revealed a significant
difference in the means for the categories; age at HCV infection, previous maximum
alcohol intake, HIV status, previous HBV infection and cirrhosis status (Table 30).
4.3.1.4 Length of follow up from first appointment or admission
The length of follow up was the years between date of the patient's first appointment
or admission to the date of last follow up.
There were no significant correlation between the length of follow up and age at
HCV infection, weight, height and BMI of patient.
The mean length of follow up was significantly shorter in those that previously drank
more than 50 units/week compared with those that did not. This was also the case in
non-cirrhotics compared with cirrhotics (Table 31).
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Table 30 Categorical covariates in which the mean time from first infection to first


































































































Table 31 Categorical covariates in which the mean length of follow up from first







































Sixty patients (12.0%) progressed to cirrhosis. Table 32 demonstrates how the
diagnosis of cirrhosis was made.
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Table 32 Number of patients progressing to cirrhosis and the mode of first diagnosis
of cirrhosis.
Outcome Mode of first diagnosis Number Percent
Cirrhotic Biopsy 33 6.6





The Kaplan-Meier graph for the time from infection to uncomplicated Child A
cirrhosis is plotted in Figure 12.
Figure 12 Kaplan-Meier graphs for the proportion of patients free of Childs A cirrhosis
(a) without left truncation at date of first appointment or admission (b) with left
truncation at date of first appointment or admission. Dotted lines represent 95%
confidence intervals.
(a) (b)
4.3.1.7 Cox regression analysis
The independent risk factors identified for progression to cirrhosis were a previous
maximum alcohol intake of greater than 50 units per week, an older age at infection
and HIV coinfection. The relative effect these factors exert (Exp(b)) within the
constructed model are documented in Table 33.
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Age at infection 0.000044 1.06 1.03 1.09
Previous maximum alcohol
0.0011 2.06 1.46 4.64
intake of greater than 50u/wk
HIV coinfection 0.00039 6.09 2.25 16.52
Rsquare= 0.068 Maximum possible= 0.626
4.3.2 The time from infection to biopsy or laparoscopy proven
uncomplicated Childs A cirrhosis
4.3.2.1 Cohort demographics
Of the 694 HCV RNA PCR positive patients, 287 met the inclusion and exclusion
criteria for this study. The characteristics of this study population are summarised in
Table 34.




Anti HIV positive 31 10.8
Previous hepatitis B infection 93 32.4
Treatment following initial assessment 157 54.7
Sustained responders to treatment 54 18.8
Previous /current smoker at first assessment 135 47.0
Methadone use at first assessment 43 15.0
4.3.2.2 Variables recorded at first appointment or first admission
4.3.2.2.1 Probable date of HCV infection
The date of probable infection is plotted as a histogram in Figure 13. The modal date
of probable infection was 1983.
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Figure 13 A histogram of the year of probable HCV infection.
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Year of probable infection
4.3.2.2.2 Age at HCV infection
The median age at infection is 19.2 years for the cohort (Table 35). The age at
infection distribution is positively skewed.
Table 35 Descriptive statistics of the continuous variables age at infection, HCV
diagnosis and at first appointment or admission, weight, height and Body Mass Index.
Age at Age at Age at first Weight Height
infection diagnosis appointment (Kg) (m) BMI
Valid 287 272 287 174 126 122
Missing 0 15 0 113 161 165
Mean 21.05 36.68 37.41 72.49 1.72 24.29
Standard Error
of Mean
0.54 0.57 0.56 1.15 0.01 0.34
Median 19.17 35.75 36.45 70.00 1.74 23.69
Standard
Deviation
9.18 9.33 9.41 15.13 0.09 3.75
Skewness 1.87 0.77 0.72 1.01 -0.38 0.88
Standard Error
of skewness
0.14 0.15 0.14 0.18 0.22 0.22
Minimum 0.01 14.29 17.53 43.00 1.52 17.86
Maximum 63.68 74.44 74.74 147.00 1.93 37.87
Kg: Kilograms, m: Metres, BMI: Body Mass Index
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There was a significant positive correlation between the age at HCV infection and
the BMI of the patient (Pearson correlation 0.184, p=0.042).
There is a significant difference between males and females in their age at infection
distribution (Table 36a). This is also demonstrated for those that have IDU as their
risk category for infection, compared with those that did not (Table 36b).




Under 20 Number 39 128 167
years % 23.4% 76.6%
Age at 20 to 30 Number 33 58 91
HCV years % 36.3% 63.7%












Pearson Chi-square (2df) =8.29, p-value =0.016








years 0//o 24.6% 75.4%
20 to 30 Number 22 69 91
years % 24.2% 75.8%
More than Number 23 6 29









Pearson Chi-square (2df) = 37.43, p-value < 0.0001
4.3.2.2.3 Risk category for infection
70.0% had intravenous drug use as the probable source of infection (Figure 14)
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4.3.2.2.4 Ethnicity of patient
Most patients were white (95.8%) with the next commonest racial group being
Pakistani (1.7%).
4.3.2.2.5 Genotype of the virus
One hundred and eighty-eight patients had their genotype determined, of which
54.3% had a genotype 1 virus (Figure 15).
Figure 15 Pie charts of virus genotype, previous maximum alcohol intake and







Table 37 shows that the patient's genotype is significantly less likely to have been
ascertained for patients whose risk category for infection is IDU, but when known,
the genotype differs neither by sex nor by IDU / non-IDU status (data not shown).








Number 82 119 201
% 40.8% 59.2%
Total
Number 99 188 287
% 34.5% 65.5%
Pearson Chi-square(ldf)=l 1.79, p-value = 0.001
4.3.2.2.6 HIV status
There is no significant association between HIV infection status and IDU risk
category status within this cohort.
4.3.2.2.7 HBV infection status
One hundred patients have had previous HBV infection, defined as being HBcAb
positive, at their first assessment. However only 5 had evidence of ongoing infection,
suggested by the presence of HBsAg. There is a significant association between
previous HBV infection status and an IDU risk category status (p=0.007).
4.3.2.2.8 Previous maximum alcohol intake
The previous maximum alcohol intake, which was maintained for at least 5 years,
was obtained in 255 patients. Overall 33.4% had consumed more than 50 units of
alcohol per week (Figure 16).
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Figure 16 Pie chart of previous maximum alcohol intake.
16%
Previous maximum alcohol consumption varies between men and women (Table
38a). In this cohort 51.3 % of women drink alcohol modestly (1 to 21 units per
week). The other three alcohol consumption categories are equally frequent among
women. In contrast, for men, consumption of more than 50 units per week is the
modal category (45.3%) and very few men don't drink (5.6%). Chi-square testing
confirms that alcohol consumption distribution depends on sex of the patient
(p<0.0001), and an IDU risk category (Table 38b).
Table 38 (a) Previous maximum alcohol consumption by sex
Female Male
0 Number 12 10 22
units/week % 54.5% 45.5%
Previous 1-21 Number 39 53 92
maximum units/week % 42.4% 57.6%
alcohol 22-50 Number 10 35 45
intake units/week % 22.2% 77.8%
>50 Number 15 81 96
units/week % 15.6% 84.4%
Total
Number 76 179 255
% 29.8% 70.2%
Pearson Chi-square (3df) =23.87, P-value <0.0001
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(b) Previous maximum alcohol consumption by IDU risk category status
No Yes
0 Number 8 14 22
units/week % 36.4% 63.6%
Previous 1-21 Number 37 55 92
maximum units/week % 40.2% 59.8%
alcohol 22-50 Number 11 34 45
intake units/week % 24.4% 75.6%
>50 Number 16 80 96









Pearson Chi-square (3df) =13.90, P-value =0.003
4.3.2.2.9 Weight, Height and Body Mass Index
The mean weight at first appointment or admission was 72.5 kilograms and the mean
height 1.72 metres (Table 35). The BMI was calculated in those patients that had
both weight and height measurements available.
4.3.2.3 Time from infection to first appointment or admission
Using the probable date of HCV infection, a mean and median time from infection to
first appointment / admission or to biopsy can be calculated (Table 39). The mean
and median time from infection to the biopsy that was used as the censor point in the
survival analysis is also displayed. The mean time from first appointment or
admission to biopsy was 1.38 years. To demonstrate the full length of follow up after
the first appointment or admission, the mean and median time to the last follow up is
displayed. The date of the last follow up was on average 3.75 years after the last
biopsy.
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Table 39 Descriptive statistics for time from infection to first appointment or
admission, to biopsy and length of follow up irrespective of biopsy.
Time from Time from infection Time from first
infection to first to first cirrhotic appointment or
appointment or biopsy or last biopsy admission to last
admission if non cirrhotic follow up irrespective
(years) (years) of biopsy (years)












Minimum 0.00 1.41 0.00
Maximum 41.83 42.42 20.05
There is a significant positive correlation between the time from infection to first
appointment or admission with the patient's weight and BMI and significant negative
correlation with patient's age at HCV infection. The same was true of the time from
infection to biopsy.
The mean time from infection to first appointment or admission was calculated for
each category within the categorical variables. T testing revealed a significantly
greater mean time with a younger age at infection, a higher previous alcohol intake,
negative HIV status, previous HBV infection and being cirrhotic (Data not shown).
The same analysis was performed looking at the mean time to biopsy. It revealed a
significantly greater mean time with a younger age at infection, a higher previous
alcohol intake, negative HIV status, and being cirrhotic (Table 40)
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Table 40 Categorical covariates in which the mean time from first infection to first
cirrhotic biopsy or last biopsy if non-cirrhotic, is significantly different on T testing.
Standard Standard
Deviatio Error















29 12.23 5.52 1.02
0
units/week










45 18.20 7.66 1.14
0.012
intake More than


























4.3.2.4 Length of follow up from first appointment or admission
The length of follow up was the years between the date of the patient's first
appointment or admission to the date of last follow up, irrespective of when the
biopsy was taken that was used for censoring. There were no significant correlations
between the length of follow up and age at HCV infection, weight, height and BMI
of patient. The mean length of follow up was significantly shorter in those previously
drinking more than 50 units/week compared with those that did not (Table 41).
Table 41 Categorical covariates in which the mean length of follow up from first
appointment or admission is significant different on T testing
Standard Standard











96 4.45 3.10 0.32
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4.3.2.5 Outcome
Fifty patients (17.4%) were cirrhotic on liver biopsy.
4.3.2.6 Kaplan-Meier analysis
The Kaplan-Meier graph for the time from infection to a biopsy of uncomplicated
Child A cirrhosis is plotted in Figure 17.
Figure 17 Kaplan-Meier graphs for the proportion of patients free of Childs A cirrhosis
on biopsy, (a) without left truncation at date of first appointment or admission (b) with
left truncation at date of first appointment or admission. Dotted lines represent 95%





4.3.2.7 Cox regression analysis
The independent risk factors identified for progression to cirrhosis on biopsy were a
previous maximum alcohol intake of greater than 50 units per week, an older age at
infection and previous HBV infection. The relative effect these factors exert
(Exp(b)) within the constructed model are documented in Table 42.
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Table 42 Results of Cox regression analysis for independent risk factors for
progression to cirrhosis on biopsy.
Variable Significance
(p value) Exp(B) -
95% Confidence Interval
Lower Upper
Age at infection 0.000043 1.07 1.03 1.10
Previous maximum alcohol
0.0025 2.80 1.44 5.46
intake of greater than 50u/wk
Previous HBV infection 0.013 2.46 1.21 5.00
R square= 0.09 Maximum possible= 0.57
4.4 Discussion
This study attempts to define the progression to cirrhosis in HCV RNA PCR positive
patients that have a probable date of infection presenting to a regional centre in
Scotland.
4.4.1 Comparison between the two cohorts
The two cohorts are subsets of the whole population of HCV RNA PCR positive
patients. Therefore for this analysis to be applicable to this whole population, the two
cohorts described in this chapter have to be reasonable matched to it. To make
comparisons in the progression to cirrhosis between the two cohorts, they also have
to be similarly matched.
In the two cohorts about 70% of patients were likely to have acquired the infection
through IDU. This is slightly higher than the PCR positive cohort. This reflects the
inclusion criteria of a probable date of infection, which excludes those in whom it
was not possible to identify a probable source of infection. The ethnicity was similar
in both cohorts and was mainly white.
In both cohorts, patients were presenting around the age of 38 years, with a similar
median age of infection at around 19 years. As with the HCV RNA PCR positive
population, those that acquired the infection through IDU did so at a significantly
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younger age. Men appeared to acquire the infection at an earlier age compared with
women although this did not quite reach significance in clinical diagnosis of cirrhosis
cohort but did in the biopsy cohort.
The infecting virus was genotype 1 in about 54% of the both cohorts, which was
slightly more than the HCV RNA PCR positive population (51.7%). Only 6.4% of
the clinical diagnosis of cirrhosis cohort was co-infected with HIV, which was
similar to the HCV RNA PCR positive population, while this was higher at 10.8% in
the biopsy study. One third of both cohorts had had previous HBV infection.
However, only 1 % appeared to have evidence of ongoing infection in each cohort.
Around 32% of all patients in both cohorts had drunk in excess of 50 units of alcohol
for more than five years, prior to presentation. This was less than that seen in the
HCV RNA PCR positive cohort (42%). Proportionately fewer men drank at this level
in these cohorts with 47% in the clinical diagnosis of cirrhosis cohort and 45% in the
biopsy cohort. Men drank significantly more than women, as did those that acquired
the infection through IDU compared with those that did not. The median weight and
BMI was the same in both cohorts and similar to the HCV RNA PCR positive
population.
The median time from infection to first appointment or admission was about 16.4
years with a median follow up thereafter to the censoring point of about 3.1 years in
the clinical diagnosis cohort, but 15.6 years and 1.4 years in the biopsy cohort
respectively. Therefore censoring in the biopsy study was occurring on average 2.5
years earlier in the course of the infection.
In the clinical diagnosis of cirrhosis cohort 12% were cirrhotic, of which 55% were
first diagnosed on biopsy, while in the biopsy cohort 17.4% were cirrhotic. This
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suggests a significant bias in the selection of those biopsied towards patients with
more advanced disease.
The survival curves were created in two ways to allow comparison with previous
studies (without left-truncation) and to use a more statistically accurate method (with
left-truncation).
In both cohorts the Kaplan-Meier graph, without left truncation at the time of
presentation, for the proportion free of cirrhosis were very similar. In neither was it
possible to estimate the median time to cirrhosis as it did not cross the 0.5 proportion
line, but it is likely to be in excess of 35 years. However when Kaplan-Meier analysis
is performed without left-truncation, it assumes that all patients that are HCV RNA
PCR positive in the South-east of Scotland have been censored and are presenting at
random times from infection to the Royal Infirmary. Clearly this is not the case as
only a proportion are being referred and this referral process is significantly affected
by the vast majority of those that have been found to have advanced disease in the
cohort, first presenting at or just before the time of this diagnosis of advanced disease
(data not shown).
When left truncation is used, it takes into account that this is a sample of the whole
population. The problem with the randomness of presentation still remains however.
In both cohorts the survival line, falls much more rapidly as at each census point
there are fewer patients. In the clinical diagnosis of cirrhosis cohort the median time
to cirrhosis is 26 years (CI 16-36 years) while in the biopsy cohort it is 16 years (CI
are too wide to be calculated due to the small number of patients at each census-
point). These wide CIs clearly demonstrate that for this analysis to be attempted a
considerably larger cohort of patients is required, for it to be interpretable.
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When Cox regression analysis with left-truncation was performed in the clinically
diagnosed cirrhosis cohort, the best model establishes an older age at infection, a
previous alcohol intake of greater than 50 units / week and HIV co-infection as
independent predictors of progression to cirrhosis. While for the biopsy cohort the
same factors were found except that it includes previous HBV infection rather than
HIV co-infection. However neither of these two models had a high R square score
compared with the maximum possible, suggesting that other covariates, not tested in
this analysis, are required to more accurately predict progression to cirrhosis.
However the covariates also significantly affect the mean time from infection to
presentation and to biopsy. This may lead to distortion in the apparent effect a
covariate is having on the progression to cirrhosis. The older the age at infection, the
shorter the time from infection to first presentation was true of both cohorts. This
may lead to an underestimation of the effect of age on progression. In both cohorts
those that had drunk more than 50 units / week presented longer after infection
compared with those that had drunk less than 21 unit / week. This may lead to an
overestimation of the effect of alcohol on progression.
4.4.2 Comparison with previous literature
The first large retrospective series published analysed the biopsies of 1157 French
patients with chronic HCV infection who had a probable date of infection and
excluded HIV positive patients (Poynard et al. 1997). This cohort of patients has
subsequently been expanded to include 2313 liver biopsies but drew similar
conclusions (Poynard et al. 2001). The median time from infection to biopsy in the
French cohort was 12.4 years. The median time to biopsy confirmed cirrhosis was 30
years estimated by Kaplan-Meier analysis without left-truncation, with 17.9% of the
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cohort being cirrhotic. Cox regression analysis identified the age at infection of
greater than 40 years, male sex and a daily alcohol intake of greater than 50 grams
(equivalent to approximately 40 units / week) predicted early cirrhosis development.
In neither Edinburgh cohort was the sex of the patient identified as an independent
risk factor. However male sex is significantly associated with heavier drinking, an
earlier age at infection and therefore this may overestimate the effect of male sex on
progression in a cohort.
As alcohol can cause cirrhosis alone it has been important to establish if its effect in
patients with HCV is purely additive or synergistic. The Italian study looked at
lifetime daily alcohol intake in both anti-HCV positive and negative patients
admitted for the first time to a district hospital for liver decompensation (Corrao &
Arico 1998). It found there was a dose-effect relationship with the risk of liver
cirrhosis, and below 50 grams / day there was an additive structure and a
multiplicative structure for consumption greater than 125 grams / day. Another
important question is whether there is a safe level of alcohol intake for people with
HCV? The more recent study looking at lifetime daily alcohol intake suggested that
this was less than 50 grams per day (Monto et al. 2004). In this Edinburgh study it
was only when the previous alcohol intake was greater than 50 units per day did it
become an independent predictor of progression to cirrhosis, lower cut offs were not
significant (data not shown).
HIV infection has been identified as an independent risk factor for progression to
cirrhosis in the clinical diagnosis cohort but not in the biopsy cohort. This is despite
those with HIV co-infection presenting sooner after infection, which would
underestimate its influence. This is in accordance with the meta-analysis to quantify
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the effect of HIV co-infection on progressive liver disease in persons with HCV
(Graham et al. 2001). The prevalence in each of the cohorts is different with co-
infection being commoner in the biopsy cohort, but how this influenced the analysis
is not at present known. If all HIV positive patients were excluded from analysis then
no new independent risk factor could be identified (data not shown).
Previous HBV infection was an independent predictor of progression to cirrhosis in
the biopsy cohort but not the clinical diagnosis of cirrhosis cohort, despite of the
prevalence being much the same in both cohorts. This is unusual as only a very small
proportion of these patients were HBsAg positive. This result corresponds to the
study of HBcAb positive but HBsAg negative patients, in which 46% of patients
HBV DNA was present in the liver and this correlated with increased risk of
cirrhosis compared with those in whom it was not detected (Cacciola et al. 1999).
However in the biopsy cohorts those with previous HBV infection had their biopsy
significantly longer after infection than those that did not.
In the large retrospective studies, the genotype of the virus and the absolute level of
the viraemia were not shown to be independent predictors of progression in Western
populations (Poynard et al. 1997). Although the level of viraemia was not assessed in
the Edinburgh cohorts, no particular genotype was identified as an independent
covariate for progression to cirrhosis.
The weight and BMI of the patient have not been shown to influence the progression
to cirrhosis in the Edinburgh cohorts, despite this being shown in other studies via
liver steatosis (Hourigan et al. 1999). Both variables are subject to change over time
and therefore their influence may not be constant. In both cohorts those that
presented a longer time after infection were more likely to have a higher BMI. As
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suggested in chapter 3 this may reflect the natural changes in body weight with age.
It may however lead to an overestimation of its effect on progression that is being
demonstrated in these other studies.
4.4.3 Limitations of the study
The major disadvantage of this form of retrospective study is the effect of referral
bias. This cannot be avoided in any study that is hospital based and there is little
doubt that this has occurred with these cohorts. Selection of those requiring liver
biopsy introduces a further bias present in the biopsy cohort and to a lesser degree in
the clinical diagnosis of cirrhosis cohort study. In previous studies large numbers of
patients recruited were actually being entered into treatment trials, which again
increase the selection bias of the cohort. In this study all patients were included
whether being considered for treatment or not.
Another disadvantage is that during follow-up some patients were undergoing
treatment. However the presence or absence of treatment was not identified as an
independent risk factor for progression to cirrhosis. But in other studies there is now
good evidence that treatment prior to cirrhosis can affect fibrosis progression
(Poynard et al. 2002b).
The entry requirement for the study of having a probable date of infection, has led to
a slight overrepresentation of patients thought to have acquired the infection through
IDU. In these patients the duration of infection has to be an estimate as it is based on
the assumption that infection is acquired in the first year of use. As discussed in
chapter 3 the variability in this estimate is unknown.
The covariate used to assess the influence of alcohol on progression was previous
maximum alcohol intake maintained for greater than five years. As discussed in
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chapter 3, there are clear limitations to the accuracy of this to quantify the level of
alcohol exposure, it was felt that it would provide a clinically applicable
categorisation.
Finally a proportion of the cohort may have acquired their cirrhosis and its
complications predominantly from the effect of alcohol, as no patients were excluded
on the basis of their alcohol intake. However in clinical practise it is usually not
possible to differentiate which is the more important factor. Also to ignore those that
consume large amounts of alcohol will distort the clinical relevance of the study, as
such a high proportion of the patients that are referred are in this group.
4.4.4 Conclusion
Despite the acknowledged limitations of the study, it does provide further evidence
of the key roles of the age of the patient at infection and the level of alcohol
consumption in the progression to cirrhosis and its complications. It shows that
previously established risk factors for progression, such as the sex of a patient, are
not the same in all cohorts of patients. This raises some concerns about applying the
results of previous cohort studies to other populations, when trying to make accurate
predictions of health impact of HCV infection for a local cohort. It also demonstrates
how significantly linked the covariates that are considered to influence the
progression to cirrhosis are, and therefore the difficulty in statistically demonstrating
their effect. It shows the time to presentation significantly varies according to each
covariate and how this might confound the results of the analysis. Finally the
importance of left truncation of the risk set at the time of presentation has been
emphasised and shown to influence the outcome of analysis. However for this
approach to be adopted, much larger cohorts are required.
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Accurate prediction of the onset of the complications of cirrhosis is necessary to
ensure appropriate surveillance procedures are in place to detect them, as well as
allocation of sufficient health resources to manage these patients.
The studies described in chapter 4 concentrate on the length of time from infection to
progression to cirrhosis, however it can be argued that the most important end-points
are the onset of cirrhosis complications including the development of HCC, liver-
related death or transplantation, as these trigger and necessitate medical intervention.
They also have the added advantage that, by their nature, their onset should be easier
to define accurately. In the large retrospective, hospital based studies the percentage
of patients that progress to decompensation (Makris et al. 1996) or HCC (Tong et al.
1995), (Roudot-Thoraval et al. 1997) is often recorded. However no Kaplan-Meier
survival analysis has been performed to demonstrate the length of time from
infection to these end-points.
An alternative approach that has been taken is to follow-up a relatively homogeneous
starting population of uncomplicated Childs A cirrhotics and document the onset of
these end-points. A number of studies with this design have been performed (Hu &
Tong 1999), (Fattovich et al. 1997), (Serfaty et al. 1998), (Benvegnu et al. 2004).
The inclusion criteria have varied between these studies making direct comparison
difficult. The inclusion of varying proportions of patients that have undergone
treatment may also have influenced outcome.
In the studies described in this chapter both approaches are taken in a well-defined
and relatively static hospital based population in which the consumption of alcohol
was high. In the study from infection to the complications of cirrhosis, the analysis
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was performed with and without left-truncation at the time of first appointment or
admission to analyse its effect. In this study to reduce the effect of referral bias to a
tertiary centre, only those patients that live within an Edinburgh 'EH' postcode were
included. For the study looking at the progression from a diagnosis of cirrhosis, two
cohorts were examined. In one the diagnosis of cirrhosis could be made clinically as
in chapter 4, in the other the diagnosis was only biopsy- or laparoscopy proven. The
influences of various host and viral factors on the progression to the complications of
cirrhosis were also assessed.
5.2 Methods
5.2.1 Patients
5.2.1.1 The time from infection to the complications of cirrhosis study
Inclusion criteria
• A probable date of infection that could be estimated.
• Recorded date of first appointment or admission.
• Qualitative HCV RNA PCR positive, six months after the presumed time of
infection
Exclusion criteria
• Tertiary referrals from hospitals outside Edinburgh.
• Home address out with the EH postcode.
• Evidence of Autoimmune, Primary Biliary Cirrhosis, Primary Sclerosing
Cholangitis, Haemochromatosis or Wilson's disease.
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5.2.1.2 The time from clinically diagnosed uncomplicated Childs A
cirrhosis to the complications of cirrhosis study
Inclusion criteria
• A date of diagnosis of cirrhosis determined either by biopsy, laparoscopy, a
hyaluronic acid greater than 100 or ultrasonographic evidence of cirrhosis
(course or nodular echotexture).
• Qualitative HCV RNA PCR positive, six months after the presumed time of
infection
Exclusion criteria
• The presence, at the time of diagnosis of cirrhosis, of a complication of
cirrhosis including oesophageal varices (grade 2 or more), a variceal bleed,
ascites, encephalopathy, bilirubin greater than 35, albumen less than 35 or a
prothrombin time greater than 4 seconds prolonged.
• The presence, at the time of diagnosis of cirrhosis of an HCC.
• Evidence of Autoimmune, Primary Biliary Cirrhosis, Primary Sclerosing
Cholangitis, Haemochromatosis or Wilson's disease.
5.2.1.3 The time from biopsy or laparoscopy proven uncomplicated
Childs A cirrhosis to the complications of cirrhosis study
Inclusion criteria
• A date of diagnosis of cirrhosis determined by liver biopsy or laparoscopy.




• The presence, at the time of diagnosis of cirrhosis, of a complication of
cirrhosis including oesophageal varices (grade 2 or more), a variceal bleed,
ascites, encephalopathy, bilirubin greater than 35, albumen less than 35 or a
prothrombin time greater than 4 seconds prolonged.
• The presence, at the time of diagnosis of cirrhosis of an HCC.
• Evidence of Autoimmune, Primary Biliary Cirrhosis, Primary Sclerosing
Cholangitis, Haemochromatosis or Wilson's disease.
5.2.2 End-points
• Any complication of cirrhosis: presence of ascites, encephalopathy,
oesophageal varices (grade 2 and above), and HCC.
• A major complication of cirrhosis: ascites or encephalopathy, an oesophageal
variceal bleed or the diagnosis of HCC.
• Oesophageal variceal bleed.
• HCC.
• Liver-related death or transplantation.
If none of the end-points occurred, the censor point for the patient was the date of
last follow-up.
5.2.3 Covariates analysed to predict occurrence of end-points
Age at infection, sex of patient, previous maximum alcohol intake, previous
smoking, previous methadone use, weight, BMI, previous HBV infection, HIV co-
infection, previous IFN treatment, probable source of infection and genotype of the
virus.
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For the uncomplicated Childs A cirrhosis cohorts, age at diagnosis of cirrhosis was
also analysed.
5.3 Results
5.3.1 The time from infection to the complications of cirrhosis
study
5.3.1.1 Cohort demographics
Of the 694 HCV RNA PCR positive patients, 551 met the inclusion and exclusion
criteria for this study. The characteristics of this study population are summarised in
Table 43.




Anti HIV positive 40 7.3
Previous hepatitis B infection 170 30.9
Treatment following initial assessment 222 40.2
Sustained responders to treatment 75 13.6
Previous /current smoker at first assessment 295 53.5
Methadone use at first assessment 106 19.2
5.3.1.2 Variables recorded at first appointment or first admission
5.3.1.2.1 Probable date of HCV infection
The date of probable infection is plotted as a histogram in Figure 18. The modal date
of probable infection was 1980.
153
Figure 18 A histogram of the year of probable HCV infection.
5.3.1.2.2 Age at HCV infection
The median age at infection is 19.6 years for the cohort (Table 44). The age at
infection distribution is positively skewed.
Table 44 Descriptive statistics of the continuous variables age at infection, HCV
diagnosis and diagnosis of cirrhosis, years from infection to cirrhosis, weight, height
and Body Mass Index.
Years
Age at from
Age at diagnosis infection
Age at HCV of to Weight Height
infection diagnosis cirrhosis cirrhosis (kg) (m) BMI
Valid 551 515 109 109 393 286 277
Missing 0 36 442 442 158 265 274
Mean 21.94 37.93 47.32 21.91 72.32 1.71 24.43
Standard 1.02 0.88
Error of 0.42 0.47 0.77 0.005 0.264
Mean






Skewness 1.86 0.88 0.93 0.20 0.67 -0.11 1.14
Minimum 0.01 14.11 27.93 1.19 39 1.50 15.78
Maximum 70.19 81.36 81.35 44.73 131 1.93 43.28
Kg: kilograms, m: metres, BMI: Body Mass Index
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There was a significant negative correlation between the age at HCV infection and
the height of the patient (Pearson correlation -0.135, p=0.022).
There is no significant difference between males and females in their age at infection
distribution on Chi-square testing. But there was between those that have IDU as
their risk category for infection and those that do not (p<0.0001) (Table 45).
Table 45 Age at HCV infection by IDU risk category patients.
IDU Total
No Yes




years % 22.3% 77.7%
20 to 30 Number 39 146 185
years 0//o 21.1% 78.9%
More than Number 52 22 74
30 years % 70.3% 29.7%
Total
Number 156 395 551
% 28.3% 71.7%
Pearson Chi-square (2df) = 74.22, p-value < 0.0001
5.3.1.2.3 Risk category for infection
70.0% had intravenous drug use as the probable source of infection (Figure 19)
Figure 19 Pie chart risk category for infection
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On Chi-square testing the difference in the sex ratios of patients categorised by
whether their risk category is IDU and non-IDU does approach significance (p=
0.068).
5.3.1.2.4 Ethnicity of patient
Most patients were white (97.3%) with the next commonest racial group being
Pakistani (1.3%).
5.3.1.2.5 Genotype of the virus
Three hundred and ninety patients had their genotype determined, of these 56.0%
had a genotype 1 virus (Figure 20).
Figure 20 Pie charts of virus genotype.
The patients genotype is significantly (p= 0.006) less likely to have been ascertained
for patients whose risk category for infection is IDU, but when known, the genotype
differs neither by sex nor by IDU / non-IDU status (data not shown).
5.3.1.2.6 HIV status
There is an association between HIV infection status and IDU risk category status
within this cohort that approaches significance (p=0.067).
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5.3.1.2.7 HBV infection status
One hundred and seventy patients have had previous HBV infection, defined as
being HBcAb positive, at their first assessment. However, only 6 had HBsAg
suggesting a lack of viral clearance. There is a significant association between
previous HBV infection status and IDU risk category status within this cohort
(pO.OOOl).
5.3.1.2.8 Previous maximum alcohol intake
The previous maximum alcohol intake, which was maintained for at least 5 years,
was obtained in 466 patients. Overall 34.5% had consumed more than 50 units of
alcohol per week (Figure 21).
Figure 21 Pie chart of previous maximum alcohol intake.
14%
Previous maximum alcohol consumption varies between men and women (Table 46
a). In this cohort 48.4 % of women drink alcohol modestly (1 to 21 units per week).
In contrast, for men, consumption of more than 50 units per week is the modal
category (50.5%) and very few men don't drink (5.4%). Chi-square testing confirms
that alcohol consumption distribution depends on sex of the patient (pO.OOOl).
Table 46b shows that 64.0% of patients with an IDU risk category status compared
with only 40.8% of those that do not, have a previous maximum consumption of
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more than 21 units per week. Chi-square test confirms that the consumption
distribution depends also on IDU risk category status (pO.OOOl).
Table 46c, suggests that the association of previous maximum alcohol consumption
with IDU risk category status is not accounted for purely by sex differences.
Table 46 (a) Previous maximum alcohol consumption by sex.
Sex
Female Male
0 Number 25 17 42
units/week % 59.5% 40.5%
Previous 1-21 Number 74 82 156
maximum units/week % 47.4% 52.6%
alcohol 22-50 Number 22 56 78
intake units/week % 28.2% 71.8%
>50 Number 32 158 190
units/week % 16.8% 83.2%
Total
Number 153 313 466
% 32.8% 67.2%
Pearson Chi-square (3df) =51.4, P-value <0.0001
(b) Previous maximum alcohol consumption by IDU risk category status
No Yes
0 Number 18 24 42
units/week % 42.9% 57.1%
Previous 1-21 Number 59 97 156
maximum units/week % 37.8% 62.2%
alcohol 22-50 Number 19 59 78
intake units/week % 24.4% 75.6%
>50 Number 34 156 190
units/week % 17.9% 82.1%
Total
Number 130 336 466
% 27.9% 72.1%
Pearson Chi-square (3df) =22.2, P-value <0.0001
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(c) Previous maximum alcohol consumption by IDU status in men.
0 Number 7 10 17
units/week % 41.2% 58.8% 100.0%
Previous 1-21 Number 25 57 82
maximum units/week % 30.5% 69.5% 100.0%
alcohol 22-50 Number 16 40 56
intake units/week % 28.6% 71.4% 100.0%
>50 Number 28 130 158









Pearson Chi-square (3df) =8.62, P-value =0.035
5.3.1.2.9 Weight, Height and Body Mass Index
The mean weight at first appointment or admission was 72.3 kilograms and the mean
height 1.71 metres (Table 44). The Body Mass Index was calculated in those patients
that had both weight and height measurements available.
5.3.1.3 Time from infection to first appointment or admission or
cirrhosis complication end points
Using the probable date of HCV infection, a mean and median time from infection to
first appointment or admission can be calculated (Table 47). There is a significant
positive correlation between the time from infection to first appointment or
admission with the patient's weight and Body Mass Index (BMI) and significant
negative correlation with patient's age at HCV infection.
The mean time from infection to first appointment or admission was calculated for
each category within the categorical variables. A significant difference was found in
the means for the categories; age at HCV infection, sex of the patient, previous
maximum alcohol intake, previous HBV infection and HIV status (Table 48).
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Table 47 Descriptive statistics for the time from infection to first appointment or
admission and from infection to the cirrhosis complication end points or last follow
up, if they did not occur.






























































































Mean 16.83 21.23 21.33 21.29 21.35 21.35 21.18 21.26 21.39
Standard
Error
0.38 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40
Median 17.00 21.60 21.63 21.60 21.63 21.67 21.56 21.60 21.62
Standard
Deviation
8.96 9.34 9.42 9.41 9.43 9.43 9.31 9.38 9.40
Skewness 0.342 0.02 0.04 0.04 0.03 0.02 0.02 0.03 0.03
Standard
Error of 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
skewness
Minimum 0.03 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92
Maximum 49.60 50.22 50.22 50.22 50.22 50.22 50.22 50.22 50.22
Table 48 Categorical covariates in which the mean time from first infection to first








Under 20 292 19.75 8.21 0.48
years






74 10.63 7.76 0.90 „ 0.001
0 units/week 42 16.56 9.92 1.53
1 to 21 156 14.98 8.38 0.67 f 0.296
Previous units/week
maximum 22 to 50 78 18.53 8.06 0.91 r 0.002
alcohol units/week
intake More than 190 18.50 9.19 0.67 r <0.0001
50 j
units/week
Sex of Female 180 15.72 8.61 0.64
0.038
patient Male 371 17.38 9.09 0.47
Previous No 15.56 9.03 0.46 15.56
<0.0001















The number of patients progressing to each end-point is recorded in Table 49. Liver
related deaths include 3 deaths post liver transplant. In four patients the cause of
death was unknown.
Table 49 Number of patients progressing to the end-points.
End point Number Percentage
Grade 2 oesophageal varices 28 5.1
Bleeding oesophageal varices 14 2.5
Ascites 32 5.8
Encephalopathy 12 2.2
Hepatocellular carcinoma 15 2.7
Any cirrhosis complication 49 8.9
Major cirrhosis complication 40 7.3
Liver transplantation 10 1.8
Liver related deaths 26 4.7
Non-liver related deaths 23 4.2
Unknown deaths 4 0.01
The complication or combinations of complications present at the first diagnosis of
any complication of cirrhosis and at the first episode of a major complication of
cirrhosis are recorded in figure 22a and 22b respectively.
5.3.1.4.1 Kaplan-Meier analysis
The Kaplan-Meier graph for each of the end-points is plotted with (Figure 22) and
without (Figure 23) left truncation at date of first appointment or admission.
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Figure 22 The complication or combinations of complications present at the time of
(a) the first diagnosis of any complication of cirrhosis, and (b) the first episode of
major complication of cirrhosis.
(a)
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Figure 23 Kaplan-Meier graphs, without left truncation at date of first appointment or
admission, for the proportion of patients free of (a) grade 2 oesophageal varices (b)
bleeding oesophageal varices (c) ascites (d) encephalopathy (e) hepatocellular
carcinoma (f) any complication of cirrhosis, (g) a major complication of cirrhosis (h)
liver related death or liver transplantation. The survival curve was curtailed when five
patients are left at risk. Where present the dotted lines represent 95% confidence
intervals.
(a) (b)




Figure 24 Kaplan-Meier graphs, with left truncation at date of first appointment or
admission, for the proportion of patients free of (a) grade 2 oesophageal varices (b)
bleeding oesophageal varices (c) ascites (d) encephalopathy (e) hepatocellular
carcinoma (f) any complication of cirrhosis, (g) a major complication of cirrhosis (h)
liver related death or liver transplantation. The survival curve was curtailed when five
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5.3.1.4.2 Median time to complications of cirrhosis
As none of the survival curve for the end-points passed below 0.5, a median could
not be calculated.
5.3.1.4.3 Cox regression analysis
5.3.1.4.3.1 Oesophageal varices
The independent risk factors identified for progression to grade 2 oesophageal
varices were a previous maximum alcohol intake of greater than 50 units per week,
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an older age at infection and the risk category not being intravenous drug use. For
first bleeding oesophageal varices they were a previous maximum alcohol intake of
greater than 50 units per week and an older age at infection. The relative effect these
factors exert (Exp(b)) within the constructed model are documented in Table 50.
Table 50 Results of Cox regression analysis for independent risk factors for
progression to (a) Grade 2 oesophageal varices (b) Bleeding oesophageal varices.
M
_ . Significance 95% Confidence Interval
(p value) EXP(B) Lower Upper
Age at infection 0.026 1.05 1.01 1.09
Previous maximum alcohol
intake of greater than 50u/wk
0.0000087 7.77 3.15 19.18
Intravenous drug risk
category
0.0078 0.31 0.13 0.74
R square= 0.067 Maximum possible= 0.39
(b)
Variable Significance T?Yn/T>\ 95% Confidence Interval
(p value) Lower Upper
Age at infection 0.0033 1.10 1.03 1.17
Previous maximum alcohol
0.0010 43.6 4.58 415.07
intake of greater than 50u/wk
R square= 0.063 Maximum possible= 0.229
5.3.1.4.3.2 Ascites
The independent risk factors identified for progression to ascites were a previous
maximum alcohol intake of greater than 50 units per week, an older age at infection
and no previous treatment with an IFN-based regime. The relative effects these
factors exert within the constructed model are documented in Table 51.
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Table 51 Results of Cox regression analysis for independent risk factors for
progression to ascites.
Variable Significance
(p value) Exp(B) -
95% Confidence Interval
Lower Upper
Age at infection 0.0000023 1.10 1.06 1.15
Previous maximum alcohol
0.000024 8.42 3.13 22.64
intake of greater than 50u/wk
Treated with interferon based
0.0029 0.28 0.12 0.65
regime
R square= 0.125 Maximum possible= 0.433
5.3.1.4.3.3 Encephalopathy
The independent risk factors identified for progression to encephalopathy were a
previous maximum alcohol intake of greater than 50 units per week and an older age
at infection. The relative effects these factors exert within the constructed model are
documented in Table 52.
Table 52 Results of Cox regression analysis for independent risk factors for
progression to encephalopathy.
. ,, Significance 95% Confidence IntervalVariable f . . Exp(B) —(p value) Lower Upper
Age at infection 0.0130 1.08 1.02 1.15
Previous maximum alcohol
0.0053 9.61 1.96 47.08
intake of greater than 50u/wk
R square= 0.034 Maximum possible= 0.197
5.3.1.4.3.4 Hepatocellular carcinoma
The independent risk factors identified for progression to HCC were a previous
maximum alcohol intake of greater than 50 units per week, an older age at infection
and and no previous treatment with an IFN-based regime. The relative effects these
factors exert within the constructed model are documented in Table 53.
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Table 53 Results of Cox regression analysis for independent risk factors for
progression to hepatocellular carcinoma.
Variable Significance
(p value) Exp(B) -
95% Confidence Interval
Lower Upper
Age at infection 0.00000065 1.17 1.10 1.24
Previous maximum alcohol
0.0073 8.83 1.80 43.33
intake of greater than 50u/wk
Treated with interferon based
0.028 0.74 0.05 0.84
regime
R square= 0.1 Maximum possible= 0.225
5.3.1.4.3.5 Any complication of cirrhosis
The independent risk factors identified for progression to any complication of
cirrhosis were a previous maximum alcohol intake of greater than 50 units per week
and an older age at infection. The relative effects these factors exert within the
constructed model are documented in Table 54.
Table 54 Results of Cox regression analysis for independent risk factors for
progression to any complication of cirrhosis.
. , . Significance „ 95% Confidence IntervalVHridblc / i \ Pi ) * it(p value) Lower Upper
Age at infection 0.000000043 1.09 1.05 1.12
Previous maximum alcohol
„ 0000tl34 4 51 2J9 8 51
intake of greater than 50u/wk
R square= 0.1 Maximum possible= 0.578
5.3.1.4.3.6 Major complication of cirrhosis
The independent risk factors identified for progression to a major complication of
cirrhosis were a previous maximum alcohol intake of greater than 50 units per week,
an older age at infection and no previous treatment with an IFN-based regime. The
relative effects these factors exert within the constructed model are documented in
Table 55.
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Table 55 Results of Cox regression analysis for independent risk factors for
progression to major complication of cirrhosis.
... Significance _ 95% Confidence IntervalVariable f . . Exp(B) 7 —(p value) Lower Upper
Age at infection 0.000000058 1.01 1.06 1.14
Previous maximum alcohol
intake of greater than 50u/wk
0.000012 6.27 2.76 14.23
Treatment with interferon
based regime
0.0061 0.36 0.18 0.75
R square= 0.133 Maximum possible= 0.504
5.3.1.4.3.7 Liver transplantation or death
The independent risk factors identified for progression to liver transplantation or
liver-related death, were an older age at infection, a previous maximum alcohol
intake of greater than 50 units per week, no previous treatment with an IFN-based
regime and previous HBV infection. The relative effects these factors exert within
the constructed model are documented in Table 56.
Table 56 Results of Cox regression analysis for independent risk factors for
progression to liver transplantation or death.
. .. Significance 95% Confidence IntervalVariable f . , Exp(B) —(p value) Lower Upper
Age at infection 0.0000000062 1.11 1.07 1.15
Previous maximum alcohol
0.00013 5.98 2.40 14.93
intake of greater than 50u/wk
Treatment with an interferon-
based regime
0.000056 0.15 0.06 0.38
Previous HBV infection 0.03 2.33 1.08 5.02
R square= 0.164 Maximum possible= 0.459
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5.3.2 The time from clinically diagnosed uncomplicated Childs A
cirrhosis to the complications of cirrhosis study
5.3.2.1 Cohort demographics
Of the 694 HCV RNA PCR positive patients, 102 met the inclusion and exclusion
criteria for this study. The characteristics of this study population are summarised in
Table 57.




Anti HIV positive 9 8.8
Previous hepatitis B infection 35 34.3
Treatment following diagnosis of cirrhosis 61 59.8
Sustained responders to treatment 17 16.7
Previous /current smoker at first assessment 44 33.1
Methadone use at first assessment 15 14.7
5.3.2.2 Variables recorded at first appointment or first admission
5.3.2.2.1 Probable date of HCV infection
The date of probable infection is plotted as a histogram in Figure 25. The modal date
of probable infection was 1970.
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Year of probable infection
5.3.2.2.2 Age at HCV infection
The median age at infection is 21.9 years for the cohort. The age at infection
distribution is positively skewed (Table 58).
Table 58 Descriptive statistics of the continuous variables age at infection, HCV
diagnosis and diagnosis of cirrhosis, years from infection to cirrhosis, weight, height
and Body Mass Index.
Age at Age at Years from
Age at HCV diagnosis infection to Weight Height
infection Diagnosis of cirrhosis cirrhosis (kg) (m) BMI
Valid 83 94 102 83 65 46 42
Missing 19 8 0 19 37 56 60
Mean 25.38 44.32 46.74 21.13 78.21 1.71 26.25
Standard
Error
1.30 1.01 0.97 1.01 1.93 0.01 0.74
Median 21.92 43.45 46.39 20.49 76.00 1.72 25.33
Standard
Deviation
11.81 9.76 9.77 9.23 15.54 0.08 4.79
Skewness 1.18 0.49 0.65 0.29 0.45 -0.55 0.56
Standard
Error of 0.26 0.25 0.24 0.26 0.30 0.35 0.36
skewness
Minimum 5.47 22.71 26.03 1.19 52.00 1.52 18.34
Maximum 63.68 74.44 78.01 44.73 120.00 1.89 37.87
Kg: Kilograms, m: metres, BMI: Body Mass Index
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There is no significant difference between males and females in their age at infection
distribution on Chi-square testing, but there is between those that have IDU as their
risk category for infection and those that do not Table 59.
Table 59 Age at HCV infection by IDU risk category patients
IDU Total
No Yes




years % 22.9% 77.1%
20 to 30 Number 7 16 23
years % 30.4% 69.6%
More than Number 20 5 25
30 years % 80.0% 20.0%
Total
Number 35 48 83
0//o 42.2% 57.8%
Pearson Chi-square (2df) = 21.32, p-value < 0.0001
5.3.2.2.3 Risk category for infection
52.0% had intravenous drug use as the probable source of infection (Figure 26)
Figure 26 Pie chart risk category for infection
Tatto/Body Perinatal
On Chi-square testing there was no difference in the sex ratios of patients categorised
by whether their risk category is IDU and non-IDU.
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5.3.2.2.4 Ethnicity of patient
Most patients were white (94.0%) with the next commonest racial group being
Pakistani (3.9%).
5.3.2.2.5 Genotype of the virus
Seventy-seven patients had their genotype determined of these 40.0% had a genotype
1 virus (Figure 27).
Figure 27 Pie charts of virus genotype.
4
1%
Table 60 shows that the patients genotype is significantly less likely to have been
ascertained for patients whose risk category for infection is IDU, but when known,
the genotype differs neither by sex nor by IDU / non-IDU status (data not shown).
Table 60 Genotype ascertainment by risk category
Risk category Genotyped Total& J No Yes
IDU
Number 7 41 48
°
% 14.6% 85.4%




, Number 25 77 102T0*"
% 24.5% 75.5%
Fisher's Exact test P-value = 0.038
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5.3.2.2.6 HIV status
Table 61 shows that there is an significant association between HIV infection status
and IDU risk category status within this cohort.





Number 48 0 48
% 100.0% 0%
Yes










Fisher's Exact test P-value =0.003
5.3.2.2.7 HBV infection status
Thirty-five patients have had previous HBV infection, defined as being HBcAb
positive, at their first assessment. However, only 7 had HBsAg suggesting ongoing
infection. Table 62 shows there is a significant association between previous HBV
infection status and IDU risk category status within this cohort.
Table 62 IDU Risk category by HBV status.




Number 38 10 48
% 79.2% 20.8%




Number 67 35 102
% 65.7% 34.3%
Fisher's Exact test P-value =0.012
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5.3.2.2.8 Previous maximum alcohol intake
The previous maximum alcohol intake, which was maintained for at least 5 years,
was obtained in 95 patients. Overall 46.1% had consumed more than 50 units of
alcohol per week (Figure 28).
Figure 28 Pie chart of previous maximum alcohol intake.
15%
Previous maximum alcohol consumption does not vary significantly between men
and women (Table 63a). For men and women, consumption of more than 50 units
per week is the modal category.
Table 63b shows that 76.9.0% of patients with an IDU risk category status compared
with only 51.2% of those that do not, have a previous maximum consumption of
more than 21 units per week. Chi-square test confirms that the consumption
distribution depends also on IDU risk category status (p=0.008).
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Table 63 (a) Previous maximum alcohol consumption by sex
Female Male
1 UlitI
0 Number 5 5 10
units/week % 50.0% 50.0%
Previous 1-21 Number 6 17 23
maximum units/week % 26.1% 73.9%
alcohol 22-50 Number 2 13 15
intake units/week % 13.3% 86.7%
>50 Number 9 38 47
units/week % 19.1% 80.9%
Total
Number 22 73 95
% 23.2% 76.8%
Pearson Chi-square (3df) =5.40, P-value =0.145




0 Number 7 3 10
units/week % 70.0% 30.0%
Previous 1-21 Number 14 9 23
maximum units/week % 60.9% 39.1%
alcohol 22-50 Number 9 6 15
intake units/week % 60.0% 40.0%
>50 Number 13 34 47
units/week % 27.7% 72.3%
Total
Number 43 52 95
% 45.3% 54.7%
Pearson Chi-square (3df) =11.92, P-value =0.008
5.3.2.2.9 Weight, Height and Body Mass Index
The mean weight at first appointment or admission was 78.2 kilograms and the mean
height 1.71 metres (Table 58). The Body Mass Index was calculated in those patients
that had both weight and height measurements available.
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5.3.2.3 Time from the diagnosis of cirrhosis to the cirrhosis
complication end points or last follow up.
The mean and median time from the diagnosis of cirrhosis to the cirrhosis
complication or last follow up if the complication did not occur is displayed in Table
64.
Table 64 Descriptive statistics for the time from the diagnosis of cirrhosis to the
cirrhosis complication end points or last follow up, if they did not occur.































































































o 5 w S3 C w □ O
Mean 4.24 4.87 4.84 4.81 4.82 4.06 4.77 4.90
Standard
Error of 0.34 0.38 0.37 0.37 0.38 0.33 0.37 0.37
Mean
Median 3.39 4.06 4.06 4.03 4.06 3.39 4.06 4.07
Standard
Deviation
3.45 3.83 3.74 3.72 3.80 3.33 3.74
3.77
Skewness 0.902 1.048 0.824 1.021 0.968 0.931 0.838 1.02
Standard
Error of 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24
skewness
Minimum 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11
Maximum 15.14 20.27 17.18 19.48 19.30 15.14 17.18 19.79
5.3.2.4 Outcome
The number of patients progressing to each end-point is recorded in Table 65. Two
of the liver related deaths occurred in patients that had had a transplant. In one
patient the cause of death was not known.
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Table 65 Number of patients progressing to the end-points.
End point Number Percentage
Grade 2 oesophageal varices 13 12.7
Bleeding oesophageal varices 3 2.9
Ascites 10 9.8
Encephalopathy 5 4.9
Hepatocellular carcinoma 12 11.8
Any cirrhosis complication 27 26.5
Major cirrhosis complication 17 16.7
Liver transplantation 5 4.9
Liver related deaths 13 12.7
Non-liver related deaths 4 3.9
Unknown deaths 1 1.0
The complication or combinations of complications present at the first diagnosis of
any complication of cirrhosis and at the first major complication of cirrhosis are
recorded in figure 29a and 29b respectively.
Figure 29 The complication or combinations of complications present at the time of
(a) the first diagnosis of any complication of cirrhosis, and (b) the first episode of
major complication of cirrhosis.
(a)






Type of complication of cirrhosis
5.3.2.4.1 Kaplan-Meier analysis
The Kaplan-Meier graph for each of the end-points is plotted with (Figure 30).
Figure 30 Kaplan-Meier graphs, without left truncation at date of first appointment or
admission, for the proportion of patients free of (a) grade 2 oesophageal varices (b)
bleeding oesophageal varices (c) ascites (d) encephalopathy (e) hepatocellular
carcinoma (f) any complication of cirrhosis, (g) a major complication of cirrhosis (h)
liver related death or liver transplantation. The survival curve was curtailed when five
patients are left at risk. Dotted lines represent 95% confidence intervals.
(a) (b)
Years from Childs A cirrhosis diagnosis Years from Childs A cirrhosis diagnosis
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5.3.2.4.2 Median time to endpoint
As none of the survival curve for the end-points passed below 0.5, a median could
not be calculated.
5.3.2.4.3 Cox regression analysis
5.3.2.4.3.1 Oesophageal varices
No independent risk factors identified for progression to grade 2 oesophageal
varices. Previous HBV infection was the closest to approach significance with a p
value of 0.065. For first bleeding oesophageal varices no independent risk factors
could be identified due to the low number of events.
5.3.2.4.3.2 Ascites
The independent risk factor identified for progression to ascites no previous
treatment with an IFN-based regime. The relative effect that this factor exerts
(Exp(b)) within the constructed model is documented in Table 66.
Table 66 Results of Cox regression analysis for independent risk factors for
progression to ascites.
... Significance _ 95% Confidence IntervalVariable f . Exp(B)(p value) Lower Upper
Previous treatment with , A „ „
~ . . U.UZi U.lo U.UJz U. / /
interieron-based regime
R square= 0.061 Maximum possible= 0.496
5.3.2.4.3.3 Encephalopathy
No independent risk factors could be identified due to the low number of events.
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5.3.2.4.3.4 Hepatocellular carcinoma
The independent risk factor identified for progression to HCC was an older age at
diagnosis of Childs A cirrhosis. The relative effect this factor exerts within the
constructed model are documented in Table 67.
Table 67 Results of Cox regression analysis for independent risk factors for
progression to hepatocellular carcinoma.
... Significance ^ 95% Confidence IntervalVariable ? . . Exp(B) —(p value) Lower Upper
Age at diagnosis of Childs A ~ ~ fTfi
cirrhosis
R square= 0.116 Maximum possible= 0.546
5.3.2.4.3.5 Any complication of cirrhosis
The independent risk factors identified for progression to any complication of
cirrhosis were an older age at diagnosis of Childs A cirrhosis and previous HBV
infection. The relative effects these factors exert within the constructed model are
documented in Table 68.
Table 68 Results of Cox regression analysis for independent risk factors for
progression to any complication of cirrhosis.
... Significance „ 95% Confidence IntervalVariable 6 . Exp(B) —(p value) Lower Upper
Age at diagnosis of cirrhosis 0.0320 1.09 1.00 1.09
Previous HBV infection 0.0061 4.87 1.39 7.34
R square= 0.089 Maximum possible= 0.878
5.3.2.4.3.6 Major complication of cirrhosis
The independent risk factors identified for progression to a major complication of
cirrhosis were an older age at diagnosis of cirrhosis and a previous maximum alcohol
intake of greater than 50 units per week. The relative effects these factors exert
within the constructed model are documented in Table 69.
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Table 69 Results of Cox regression analysis for independent risk factors for
progression to major complication of cirrhosis.
Variable Significance
(p value) Exp(B) -
95% Confidence Interval
Lower Upper
Age at diagnosis of cirrhosis 0.0079 1.08 1.02 1.15
Previous maximum alcohol
0.0140 4.97 1.38 17.88
intake of greater than 50u/wk
R square= 0.104 Maximum possible= 0.732
5.3.2.4.3.7 Liver transplantation or death
The independent risk factors identified for progression to liver transplantation or
death were an older age at diagnosis of cirrhosis and no previous treatment with an
IFN based regime. The relative effects these factors exert within the constructed
model are documented in Table 70.
Table 70 Results of Cox regression analysis for independent risk factors for
progression to liver transplantation or death.
... Significance _ 95% Confidence IntervalVariable ? .
, Exp(B)(p value) Lower Upper
Age at diagnosis of cirrhosis 0.030 1.06 1.01 1.11
Previous treatment with
0.028 0.21 0.05 0.84
interteron-based regime
R square= 0.13 Maximum possible= 0.588
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5.3.3 The time from biopsy or laparoscopy proven uncomplicated
Childs A cirrhosis to the complications of cirrhosis study
5.3.3.1 Cohort demographics
Of the 694 HCV RNA PCR positive patients, 41 met the inclusion and exclusion
criteria for this study. The characteristics of this study population are summarised in
Table 71.




Anti HIV positive 6 14.6
Previous hepatitis B infection 17 41.5
Treatment following initial assessment 24 58.5
Sustained responders to treatment 6 14.6
Previous /current smoker at first assessment 20 48.8
Methadone use at first assessment 7 17.1
5.3.3.2 Variables recorded at first appointment or first admission
5.3.3.2.1 Probable date of HCV infection
The date of probable infection is plotted as a histogram in Figure 31.













Year of probable infection
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5.3.3.2.2 Age at HCV infection
The median age at infection are 18.3 years for the cohort. The age at infection
distribution is positively skewed (Table 30).
Table 72 Descriptive statistics of the continuous variables age at infection, HCV
diagnosis and diagnosis of cirrhosis, years from infection to cirrhosis, weight, height
and Body Mass Index.
Age at Age at
HCV diagnosis Years from
Age at Diagnosi of infection to Weight Height
infection s cirrhosis cirrhosis (kg) (m) BMI
Valid 36 39 41 36 25 17 15
Missing 5 2 0 5 16 24 26




















Minimum 5.47 28.90 29.56 4.08 52.00 1.66 19.38
Maximum 63.66 68.35 68.56 42.42 120.00 1.86 37.87
Kg: Kilograms, m: metres, BMI: Body Mass Index
There is no significant difference between males and females in their age at infection
distribution on Chi-square testing, but there is between those that have IDU as their
risk category for infection and those that do not (Table 73).
Table 73 Age at HCV infection by IDU risk category patients.
IDU Total
No Yes




years % 21.7% 78.3%
20 to 30 Number 0 6 6
years 0//o .0% 100.0%
More than Number 5 2 7
30 years % 71.4% 28.6%
Total
Number 10 26 36
% 27.8% 72.2%
Pearson Chi-square (2df) = 9.374, p-value = 0.009
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5.3.3.2.3 Risk category for infection
70.0% had intravenous drug use as the probable source of infection (Figure 32)
Figure 32 Pie chart risk category for infection
Homosexual
contact
On Chi-square testing there is no difference in the sex ratios of patients categorised
by whether their risk category is IDU and non-IDU.
5.3.3.2.4 Ethnicity of patient
Most patients were white (95.1%).
5.3.3.2.5 Genotype of the virus
Thirty-one patients had their genotype determined, of these 46.0% had a genotype 1
virus (Figure 33).
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The patient's genotype is equally likely to have been ascertained for patients whose
risk category for infection is IDU.
5.3.3.2.6 HIV status
Table 74 shows that like the HCV RNA PCR positive cohort there is an association
that approaches significance between HIV infection status and IDU risk category
status.
Table 74 Risk category by HIV status.
No Yes
No




Number 20 6 26
% 76.9% 23.1%
Total
Number 35 6 41
% 85.4% 14.6%
Fisher's Exact test P-value =0.070
5.3.3.2.7 HBV infection status
Seventeen patients have had previous HBV infection, defined as being HBcAb
positive, at their first assessment. However, only 1 had HBsAg suggesting lack of
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clearance of the virus. Previous HBV infection status is not significantly associated
with IDU risk category status within this cohort.
5.3.3.2.8 Previous maximum alcohol intake
The previous maximum alcohol intake, which was maintained for at least 5 years,
was obtained in 40 patients. Overall 63.5% had consumed more than 50 units of
alcohol per week (Figure 34).
Figure 34 Pie chart of previous maximum alcohol intake.
64%
Previous maximum alcohol consumption does not vary significantly between men
and women in this cohort. For men and women, consumption of more than 50 units
per week is still the modal category. The consumption distribution does not depend
on IDU risk category status in this cohort either.
5.3.3.2.9 Weight, Height and Body Mass Index
The mean weight at first appointment or admission was 78.5 kilograms and the mean
height 1.74 metres (Table 72). The Body Mass Index was calculated in those patients
that had both weight and height measurements available.
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5.3.3.3 Time from infection to first appointment or admission or
cirrhosis complication end points
The mean and median time from the diagnosis of cirrhosis to the cirrhosis
complication or last follow up if the complication did not occur is displayed in Table
75.
Table 75 Descriptive statistics for the time from the diagnosis of biopsy proven
cirrhosis to the cirrhosis complication end points or last follow up, if they did not
occur.

















































































Mean 4.57 5.16 5.06 5.15 5.09 4.47 4.99 5.07
Standard
Error of 0.59 0.70 0.65 0.69 0.69 0.59 0.66 0.68
Mean
Median 3.22 4.08 4.08 4.08 4.08 3.22 4.08 4.08
Standard
Deviation
3.75 4.48 4.21 4.41 4.42 3.75 4.25 4.38
Skewness 0.91 1.27 1.01 1.18 1.17 0.97 1.01 1.29
Standard
Error of 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37
skewness
Minimum 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11
Maximum 15.14 20.27 17.18 19.48 19.30 15.14 17.18 19.79
5.3.3.4 Outcome
The number of patients progressing to each end-point is recorded in Table 76. One of
the liver related deaths occurred after liver transplantation.
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Table 76 Number of patients progressing to the end-points.
End point Number Percentage
Grade 2 oesophageal varices 4 9.8
Bleeding oesophageal varices 0 0
Ascites 4 9.8
Encephalopathy 1 2.4
Hepatocellular carcinoma 5 12.2
Any cirrhosis complication 10 24.4
Major cirrhosis complication 7 17.1
Liver transplantation 3 7.3
Liver related deaths 4 9.8
Non-liver related deaths 3 7.3
The complication or combinations of complications present at the first diagnosis of
any complication of cirrhosis and at the first major complication of cirrhosis are
recorded in figure 35a and 35b respectively.
Figure 35 The complication or combinations of complications present at the time of




Type of complication of cirrhosis
191
(b)
Type of complication of cirrhosis
5.3.3.4.1 Kaplan-Meier analysis
The Kaplan-Meier graph for each of the end-points is plotted with (Figure 19) and
without (Figure 36) left truncation at date of first appointment or admission.
Figure 36 Kaplan-Meier graphs, without left truncation at date of first appointment or
admission, for the proportion of patients free of (a) grade 2 oesophageal varices (b)
bleeding oesophageal varices (c) ascites (d) encephalopathy (e) hepatocellular
carcinoma (f) any complication of cirrhosis, (g) a major complication of cirrhosis (h)
liver related death or liver transplantation. The survival curve was curtailed when five
patients are left at risk. Dotted lines represent 95% confidence intervals.
(a) (b)
Years from biopsy proven Childs A cirrhosis diagnosis Years from biopsy proven Childs A cirrhosis diagnosis
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5.3.3.4.2 Median time to endpoints
As none of the survival curve for the end-points passed below 0.5, a median could
not be calculated.
5.3.3.4.3 Cox regression analysis
5.3.3.4.3.1 Oesophageal varices
For progression to grade 2 oesophageal varices no independent risk factors could be
identified due to the low number of events. For first bleeding oesophageal varices no
independent risk factors could be identified, as there were no events.
5.3.3.4.3.2 Ascites
No independent risk factors could be identified due to the low number of events.
5.3.3.4.3.3 Encephalopathy
No independent risk factors could be identified, as there were no events.
5.3.3.4.3.4 Hepatocellular carcinoma
The independent risk factor identified for progression to HCC was an older age at
diagnosis of biopsy proven Childs A cirrhosis. The relative effect this factor exerts
(Exp(b)) within the constructed model is documented in Table 77.
Table 77 Results of Cox regression analysis for independent risk factors for





Age at diagnosis of biopsy
proven Childs A cirrhosis
0.0096 1.30 1.07 1.58
R square= 0.253 Maximum possible= 0.471
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5.3.3.4.3.5 Any complication of cirrhosis
The independent risk factor identified for progression to any complication of
cirrhosis was an older age at diagnosis of biopsy proven Childs A cirrhosis. The
relative effect this factor exerts within the constructed model is documented in Table
78.
Table 78 Results of Cox regression analysis for independent risk factors for
progression to any complication of cirrhosis.
... ... Significance „ 95% Confidence IntervalVariable ? . . Exp(B) —(p value) Lower Upper
Age at diagnosis of biopsy 0 015 u] , 03 120
proven cirrhosis
R square= 0.134 Maximum possible= 0.781
5.3.3.4.3.6 Major complication of cirrhosis
The independent risk factors identified for progression to a major complication of
cirrhosis was an older age at diagnosis of biopsy proven Childs A cirrhosis. The
relative effect this factor exerts within the constructed model is documented in Table
79.
Table 79 Results of Cox regression analysis for independent risk factors for
progression to major complication of cirrhosis.
_. . Significance _ 95% Confidence IntervalVariable f . Exp(B) —(p value) Lower Upper
Age at diagnosis of biopsy 0.0092 U5 1.04 1.29
proven cirrhosis
R square= 0.167 Maximum possible= 0.612
5.3.3.4.3.7 Liver transplantation or death
The independent risk factors identified for progression to liver transplantation or
death were an older age at diagnosis of biopsy proven Childs A cirrhosis and no
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previous treatment with an IFN-based regime. The relative effects these factors exert
within the constructed model are documented in Table 80.
Table 80 Results of Cox regression analysis for independent risk factors for
progression to liver transplantation or death.
Variable Significance
(p value) Exp(B) -
95% Confidence Interval
Lower Upper
Age at diagnosis of biopsy 0.0095 1.18 1.04 1.34
proven cirrhosis
Previous treatment with
0.0330 0.12 0.02 0.85
interferon-based regime
R square= 0.356 Maximum possible= 0.648
5.4 Discussion
This study attempts to define the onset of the complications of cirrhosis in three
cohorts of HCV RNA PCR positive patients referred and followed up in a regional
centre in Scotland.
5.4.1 The time from infection to the complications of cirrhosis
study
The infection to cirrhosis complications cohort is a subset of the whole population of
HCV RNA PCR positive patients. Therefore for this analysis to be applicable to this
whole population, this cohort has to be reasonable matched to it.
In the cohort, 71% of patients were likely to have acquired the infection through
IDU. This is slightly higher than the whole HCV RNA PCR positive population. This
reflects the inclusion criteria of a probable date of infection, which excludes those in
whom it was not possible to identify a probable source of infection. Proportionately
more men acquired the infection through IDU compared with women but it does not
quite reach significance. As with the whole population, those that acquired the
infection through drug use did so at a significantly younger age. Unlike the whole
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population there was no significant difference between men and women in their age
at infection. A higher percentage (56%) had genotype 1 infection compared with the
whole population. IDU patients were significantly less likely to have been tested for
genotype. The cohort had a similar prevalence of HIV co-infection and previous
HBV infection at 7.3% and 30.9% respectively. The median weight and BMI were
also similar. A lower percentage of all patients (34.5%) but the same percentage of
men (50.5%), have drunk in excess of 50 units of alcohol for more than five years
prior to presentation. There was a significant difference between men and women in
this covariate, and those that acquired the infection through IDU and those that did
not.
The median time from infection to first appointment or admission was about 17
years, which is no different from the HCV RNA PCR positive population. Those
that presented a longer time after infection were more likely to have a higher BMI.
The older the age at infection, the shorter the time from infection to first
presentation. Those that had drunk more than 50 units / week presented later after
infection than those that drank less than 21 unit / week. Those with HIV co-infection
presented significantly earlier after infection than those that did not, while men
presented significantly later than women. The median time from infection to the
censored time-point was about 21.6 years for all end-points.
The end-point 'Any complication of cirrhosis' occurred in 8.9% of the cohort, while
'A major complication of cirrhosis' occurred in 7.3%. At least Grade 2 oesophageal
varices developed in 5.1% and 2.5% had a variceal bleed. HCC occurred in 2.7% and
a liver related death or transplantation in 6.5%.
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In none of the Kaplan-Meier graphs, without truncation, did the survival line pass
below the 0.5 proportion and therefore a median time to the end-point could not be
calculated. However from the graphs it can be deduced that it would be in excess of
35 years in all end-points. When left-truncation at the time of presentation was used
the survival curves fall more steeply but only in the 'Any complication of cirrhosis'
end-point does it appear to approach a median at approximately 35 years.
Cox regression analysis with left-truncation was performed to establish independent
predictors of progression to each end-point. For every end-point it was found to be an
older age at infection and a previous alcohol intake of greater than 50 units / week.
No previous treatment with an IFN-based regime was an independent predictor for
the end-points; 'Ascites', 'HCC', 'A major complication of cirrhosis' and 'Liver
death or transplantation'. Not having IDU as the risk factor for infection was an
independent predictor of progression to grade 2 oesophageal varices. Finally
previous HBV infection was an independent predictor of liver-related death or
transplantation.
5.4.2 The time from clinically diagnosed uncomplicated Childs A
cirrhosis to the complications of cirrhosis study
Not surprisingly the clinically diagnosed cirrhotic cohort was different from the
whole HCV RNA PCR positive population, as only a select proportion progress to
this starting point. A larger proportion was male (79% versus 69%), a larger
proportion had IFN-based treatment (60% versus 39%), fewer were currently
smoking or had smoked (33% versus 50%) and a larger proportion had acquired the
infection through IDU (52% versus 64%). There was no significant difference in the
sex ratios of patients categorised by whether their risk category is IDU and non-IDU.
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A smaller proportion had genotype 1 infection (40% versus 52%) and both the
median weight and BMI were slightly higher (76kg versus 70kg and 25.3 versus
23.8). A larger percentage of all patients (46% versus 42%) but the same percentage
of men had drunk in excess of 50 units of alcohol for more than five years prior to
presentation. There was a significant difference between men and women in this
covariate, and those that acquired the infection through IDU and those that did not.
The median time to the censored time-point depended on the end-point. It varied
from 3.39 years for the 'Grade 2 oesophageal varices' end-point to 4.07 years for
'Liver-related death or transplantation' end-point.
'Any complication of cirrhosis' occurred in 26.5% of the cohort, while 'A major
complication of cirrhosis' occurred in 16.7%. Grade 2 oesophageal varices
developed in 12.7% and 2.9% had a variceal bleed. HCC occurred in 11.8% and a
liver related death or transplantation in 17.6%.
In none of the Kaplan-Meier graphs did the survival line pass below the 0.5
proportion and therefore a median time to the end point could not be calculated.
However from the graphs it can be deduced that it would be in excess of 10 years in
all end-points.
Cox regression analysis was performed to establish independent predictors of
progression to each end-point. For every end-point it was found to be an older age at
diagnosis of Childs A cirrhosis except 'Grade 2 oesophageal varices',
'Encephalopathy' and 'Ascites'. No previous treatment with an IFN-based regime
was an independent predictor in 'Ascites' and 'Liver death or transplantation'. A
previous alcohol intake of greater than 50 unit / week was an independent predictor
of the 'A major complication of cirrhosis' end-point. Previous HBV infection was an
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independent predictor of the 'Any complication of cirrhosis end-point'. No
independent predictors of progression to the end-points 'Grade 2 oesophageal
varices' or 'Bleeding varices' or 'Encephalopathy'.
5.4.3 The time from biopsy or laparoscopy proven uncomplicated
Childs A cirrhosis to the complications of cirrhosis study
The biopsy- or laparoscopy-proven cirrhotic cohort is a subset of the clinically
diagnosed cirrhotic cohort. The inclusion criteria for this cohort produces some
differences between it and the larger clinically diagnosed cohort. A larger proportion
was HIV co-infected (15% versus 9%), had acquired the infection through IDU (64%
versus 52%) and had genotype 1 infection (46% versus 40%). A larger proportion of
all patients (64% versus 46%) and of men (66% versus 52%) had drunk in excess of
50 units of alcohol for more than five years prior to presentation. There was a no
significant difference between men and women in this covariate, and those that
acquired the infection through IDU and those that did not.
The median time to the censored time-point depended on the end-point. It varied
from 3.32 years for the 'Grade 2 oesophageal varices' end-point to 4.08 years for
'Liver-related death or transplantation' end-point.
'Any complication of cirrhosis' occurred in 24.4% of the cohort, while 'A major
complication of cirrhosis' occurred in 17.1%. Grade 2 oesophageal varices
developed in 9.8% and none had a variceal bleed. HCC occurred in 12.2% and a liver
related death or transplantation in 17.1%. In none of the Kaplan-Meier graphs did the
survival line pass below the 0.5 proportion and therefore a median time to the end
point could not be calculated. However from the graphs it can be deduced that it
would be in excess of 10 years in all end-points.
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Cox regression analysis was performed to establish independent predictors of
progression to each end-point. For every end-point it was found to be an older age at
diagnosis of Childs A cirrhosis except 'Grade 2 oesophageal varices',
'Encephalopathy' and 'Ascites', where no independent predictors of progression to
these end-points could be found. No previous treatment with an IFN-based regime
was an independent predictor for 'Liver-related death or transplantation'.
5.4.4 Comparison with previous literature
There have been some previous retrospective studies to establish the progression
from infection to cirrhosis complications (Makris et al. 1996) or HCC (Tong et al.
1995), (Roudot-Thoraval et al. 1997), (Kiyosawa et al. 1990). None have used
Kaplan-Meier survival analysis. Often misleadingly a mean interval from infection to
the end-point, not based on Kaplan-Meier analysis has been quoted (Kiyosawa et al.
1990), (Tong et al. 1995). There are two community-based studies that approximate
to the cohort analysed in this chapter in their basic characteristics. An American
study drawn from an area of high drug use showed at mean duration of 23 years,
2.4% had developed a complication of cirrhosis but no HCC had been diagnosed. In
a multivariate model, risk of a complication of cirrhosis was higher for persons aged
38 years or older at enrollment and who reported ingestion of more than 260 g of
alcohol per week (Thomas et al. 2000). In the Australian acute hepatitis study at a
mean duration of infection of 23 years, 6% had a complication of cirrhosis but again
no HCC had been diagnosed (Rodger et al. 2000). As with all community-based
studies the incidence of the complications of cirrhosis are much lower compared with
hospital studies. This is the case in the infection to cirrhosis complication cohort.
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There have been a number of studies describing the natural history of a cohort of
uncomplicated cirrhotics with HCV that are described in the introduction. The Italian
study of 254 uncomplicated compensated cirrhotic patients (biopsy-proven and
clinically determined) most closely follows the methodology of the clinically
diagnosed cirrhotic group used in this chapter. It followed-up patients for a median
of 7.6 years and 30.7% developed at least one complication of cirrhosis. HCC
developed in 20.5% and was the commonest first complication. 17.7% developed
ascites and 4.7% had a variceal bleed and 16.3% died a liver-related death
(Benvegnu et al. 2004). During follow-up 45.3% received IFN-based therapy and a
lower rate of complications were seen in this group (25.2% versus 35.9%).
The study that most closely resembles the biopsy- or laparoscopy- proven cirrhotic
cohort followed 112 patients for a median of 4.5 years. It included 49 patients who
were treated with IFN. The cumulative probabilities for decompensation and
development of HCC were 22.2% and 10.1% in five years, with an estimated yearly
incidence of 4.4% and 2.0% respectively (Hu & Tong 1999). The cumulative
survival probability was 82.8% from entry and 51.1% from decompensation in five
years. Independent variables predicting decompensation were albumin level and
older age at infection. As albumin is a known marker for the severity of cirrhosis, its
influence may simply have been due to this (those with lower albumins had more
advanced cirrhosis at recruitment for the study and required less progression to get
reach decompensation). The largest study to date, in biopsy-proven cirrhotics with no
complications of cirrhosis followed 255 for a median period of 7 years (Fattovich et
al. 2001). Kaplan-Meier 5-year risk of HCC was 5%, of decompensation was 12%
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and of event-free survival was 85%. Genotype lb did not affect the occurrence of
HCC, but did increase the risk of liver decompensation three fold.
To attempt a comparison with the two cirrhotic cohorts described in this chapter, the
proportion at five years after the diagnosis of uncomplicated cirrhosis with these
reported end-points has been estimated from the Kaplan-Meier graphs. The risk of
HCC is about 9-12%, the risk of a major complication of cirrhosis is about 11% and
the risk of liver related death is about 8-10%.
5.4.5 Predicting occurrence of complications
Age at the diagnosis of cirrhosis consistently was associated with progression to the
complications of cirrhosis in all three cohorts. Presumably this is a similar to the
effect of age pre-cirrhosis (Poynard et al. 1997). However this might be confounded
if the older the patient the more likely they are to have had the infection for longer
and therefore potentially the more advanced the disease, despite the efforts to have a
homogeneous starting population.
The role of IFN-based treatment in preventing the complications of cirrhosis is
controversial. The concern has always been that the association with a better
prognosis reported in studies above (Serfaty et al. 1998) may simply reflect those
with less severe disease being more likely to receive treatment. A meta-analysis of
similar studies has also suggested the effect is low and the observed benefit might be
due to spurious associations (Camma et al. 2001). However, although in the clinical
diagnosis of cirrhosis cohort a SVR to treatment was not statistically demonstrated to
independently influence progression to HCC, no HCC developed in those that
achieved an SVR (data not shown).
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As discussed in chapter 4, alcohol can cause cirrhosis and its complications alone,
therefore it has been important to establish if its effect in patients with HCV is purely
additive or synergistic. There is some evidence that it hastens the development of
HCC (Donato et al. 1997), especially in association with Diabetes Mellitus (Hassan
et al. 2002) and reduces survival (Wiley et al. 1998),(Fattovich et al. 1997),(Niederau
et al. 1998). In this study previous alcohol use was documented to identify a history
of alcohol abuse, as discussed in chapter 3 this is an estimate and with a potential for
error. There was no measure of the alcohol ingested during the course of the study.
So those that may have abused alcohol in the past may have heeded the
recommendations to moderate intake at the initial assessment, making this covariate
a poor surrogate marker for ongoing excessive alcohol use. Alcohol intake at the
time of diagnosis of cirrhosis was also analysed as a covariate to predict progression
to end-points but was not found to be a significant in Cox regression (data not
shown).
Obesity does not appear to be an additional risk factor for HCC in HCV (Nair et al.
2002). This is confirmed by the studies described in this chapter where BMI was not
found to be an independent predictor of any of the end-points.
This study has suggested a number of independent risk factors for progression that
are difficult to explain such as a non-IDU risk category for progression to grade 2
oesophageal varices. Whilst these are valid statistically, it is likely they have come
about due the significant correlations between the tested covariates despite the use of
a multivariate method or potentially with untested ones. The R square scores are all
low compared with the maximum possible and therefore the models and covariates
used do not explain well the variation in progression seen.
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5.4.6 Limitations of the study
Patients diagnosed with asymptomatic, grade 2 and above oesophageal varices were
included for the end-point 'Any complication of cirrhosis', as they may require
medical intervention. This diagnosis is therefore dependent on an endoscopy being
performed, and therefore the accuracy of diagnosing their onset maybe limited.
However with the oesophageal varices surveillance program described in the
methods section, the time lag from onset to diagnosis is minimised. Primary
prophylaxis was also practiced on these patients, which might explain the low
incidence of bleeding varices. Secondary prophylaxis may also have reduced deaths
from bleeding.
A significant proportion of all cohorts underwent treatment during the follow-up
period, and this was an independent risk factor in progression to a number of end-
points in Cox regression analysis.
The entry requirement for the infection to cirrhosis complications study, of having a
probable date of infection, has led to a slight overrepresentation of patients thought
to have acquired the infection through intravenous drug abuse. In these patients the
duration of infection has to be an estimate, as it is based on the assumption that
infection is acquired in the first year of use. The variability in this estimate is
unknown as discussed in chapter 3.
The effect of referral bias has been discussed in detail in chapter 4. Clearly it is likely
to have had an influence on outcome in the infection to cirrhosis complications
cohort. It may also influence the outcome of the cirrhosis cohorts as those that have
been referred into hospital may have faster progressing disease, especially as they are
likely to already have advanced disease at the time of referral.
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5.4.7 Conclusion
Despite the acknowledged limitations of the study, it does provide evidence the age
of the patient does influence progression to cirrhosis complications. The influence of
other covariates is less clear due to confounding. It attempts for the first time to
estimate the duration of infection to the onset of clinically important complications
for a hospital-based cohort. It confirms that at five years after the diagnosis of
uncomplicated cirrhosis the risk of HCC is about 9-12%, the risk of a major
complication of cirrhosis is about 11% and the risk of liver related death is about 8-
10%. Larger cohorts with longer follow up are required to clarify these issues further.
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Treatment for patients with HCV infection has been given in the Royal Infirmary of
Edinburgh since the initial reports of the efficacy of IFN monotherapy (Hoofnagle et
al. 1986), (Davis et al. 1989). Since that time patients have been treated with a
variety of regimes inside and outside of clinical trials. There have been three main
treatments (Standard IFN monotherapy, Combination standard IFN and ribavirin and
Combination PEG-IFN and ribavirin) and these will be analysed in detail. Although
other regimes have been used the numbers involved have been small and therefore
these will not be analysed.
Before the Medicines Control Agency granted the license for combination IFN and
ribavirin therapy in the UK in 2000, a large number of individuals in the UK were
prescribed it on a compassionate basis. Its use was not subject to the rigors of a trial,
although strict exclusion criteria were adhered to, based on the known contra¬
indications to the treatment. Data has been retrospectively collected from centres
that used the treatment in this way, to establish its safety and efficacy, in a hospital
practice setting. These data are also presented and analysed for comparison with the
Edinburgh results.
The changes in clinical practice over the period the study encompasses, has made the
data more difficult to analyse and interpret. It has therefore not been possible to
divide the patients into 6 months and 12 month treatment cohorts, instead an
intention-to-treat analysis of the whole cohort has been carried out and an as-treated
analysis of those that have received at least 5.3 months of treatment to see the
response rates that are possible if the patient completes this length of treatment. The
treatment course for combination PEG-IFN and ribavirin is well established with
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those with genotype 1 requiring 48 weeks and non-genotype 1 requiring 24 weeks.
The intention at the start of treatment was to adhere to this regime. However, for




All the patients that have been referred to the Royal Infirmary of Edinburgh between
January 1990 and December 2004 and have received treatment have been included in
this study.
UK combination interferon and ribavirin cohort
As described in the methods chapter.
6.2.2 Data collection
This has been as previously described in the methods chapter for the Edinburgh and
UK cohort.
6.2.3 Treatment analysis subgroups
Whole population
An intention to treat analysis of the whole population.
Patients that had received at least 5.3 months of treatment
An as-treated analysis to demonstrate the response rates in those that completed at
least six months of treatment.
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Patients that had or had not received previous interferon based treatment
An intention to treat analysis, to avoid introducing bias due to previous treatment
failure.
6.2.4 Primary end-point
A sustained virological response, defined as the absence of serum HCV RNA six
months after treatment was completed.
6.2.5 Covariates analysed to predict primary end-point
Length of treatment, age, sex, genotype, presence or absence of cirrhosis, previous
alcohol abuse, continuing alcohol intake, smoking history, previous HBV, duration




6.3.1.1 Description of whole cohort
Four hundred and sixty-one treatment episodes have been initiated in the cohort
during the time period. Figure 37 gives a breakdown of the number of patients
initiated on each type of regime each year.
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Three hundred and thirty patients have been initiated on treatment, and of these 236
have had only one treatment, 68 have had two treatments, 18 have had three
treatments, five had four treatments and three had five treatments. Four hundred and
eleven of the treatment episodes have sufficient follow-up and HCV RNA PCR data
to allow a responder status to be determined. The overall response rates for each
regime are given in Table 81.
Since 1992 on average 45.5% patients referred and seen for the first time each year
have been thought to be suitable and listed for treatment (Figure 38).
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Table 81 Overall response rates for each treatment regime.
Response
Type of treatment Treatment Non „ . Sustained Late „ , ,
, . , Relapser , , Total
incomplete responder responder relapser
Interferon 12 39 51 9 6 117
monotherapy
Combined standard 30 50 26 63 1 170
interferon and
ribavirin
Combination 29 24 15 41 109
pegylated Interferon
and ribavirin
Thymus Humoral 8 8
Factor
Induction interferon 4 4
and ribavirin
Interferon and 1 1
Amantadine
Pegylated 1 1 2
Interferon, ribavirin
and histamine
Figure 38 Graph of the number of patients that eventually listed for treatment of
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6.3.1.2 Standard Interferon monotherapy
6.3.1.2.1 Characteristics of the population
One hundred and seventeen patients were treated with standard IFN monotherapy. It
has not been possible to differentiate those treated with IFN alpha-2a from those
treated with IFN alpha-2b. Therefore a single analysis for IFN monotherapy has been
performed. The base-line characteristics of these treated patients are described in
Table 82. The proportions of the genotypes were similar to that previously described
for the UK. 95.6% of patients were Caucasian and 3.2% had an Asian Subcontinent
racial background. There were some patients that have had the same treatment
regime more than once and some patients have had first standard IFN monotherapy,
then combination standard IFN and ribavirin and finally combination PEG-IFN and
ribavirin if the treatments before have failed. Therefore they are included in each of
previous treatment rows.
6.3.1.2.2 Outcome of treatment
The primary end-point of a SVR was achieved in 15 patients (12.8%) of the 117
patients. However 6 of these subsequently had a relapse (Late relapsers). No
response to treatment or relapse either during or in the 6 months following treatment
occurred in 90 patients. Twelve patients received less than three months of treatment
prior to discontinuation either due to major adverse event or patient choice and
therefore it was not possible to determine their responder status. A breakdown of the
reasons for discontinuing treatment in these patients and the sustained responders is
given in Table 83.
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Table 82 Baseline characteristics of patients treated with standard interferon
monotherapy, Combination standard interferon and ribavirin and Combination








Number 117 170 109
Mean Age +/- SEM (yrs) 39.0 +/- 0.9 41.9+/-0.7 44.1 +/-0.8
Mean duration of 16.0+/-0.8 20.0 +/- 0.9 23.7+/-0.9
infection +/- SEM (yrs)
Mean Weight +/- SEM 74.0 +/-2.0 72.8 +/-1.2 77.5 +/-1.7
(Kgs)
Male:Female ratio 91:26 110:60 78:31
Previous treatments
Std IFN monotherapy 14 40 27
Std IFN and ribavirin N/A 6 32
PEG-IFN and ribavirin N/A N/A 4
Any IFN based 14(12.0%) 43 (25.3%) 49 (45.0%)
treatment
Cirrhotic 33 (28.2%) 41 (24.1%) 34(31.2%)
All Childs A All Childs A All Childs A
Previous alcohol abuse 33 (28.2%) 37(21.8%) 25 (22.9%)
Methadone 11 11 6
HBsAg positive 3 1 5
HIV positive 3 4 5
Previous minor 9 6 9
psychiatric history
Genotyped 92 130 106
1 37 (40.2%) 59 (45.4%) 55 (51.9%)
2 16(17.4%) 9 (6.9%) 7 (6.6%)
3 37 (40.2%) 57 (43.8%) 41 (38.7%)
4 2 (2.2%) 3 (2.3%) 3 (2.8%)
6 2(1.5%)
Risk category
IDU 55 (47.0%) 86 (50.6%) 49 (45.0%)
Blood/Tissue transfer 25 (21.4%) 28 (16.5%) 16(14.7%)
Haemophiliac 10(8.5%) 8 (4.7%) 11 (10.1%)
Tattoo / Body piercing 6 (5.1%) 8 (4.7%) 6 (5.5%)
Perinatal 2(1.2%) 1 (0.9%)
Homo-/Bisexual contact 1 (0.8%) 2(1.2%)
Heterosexual contact 5 (4.3%) 9 (5.3%) 7 (6.4%)
Accidental needle 2(1.6%) 9 (5.3%) 5 (4.6%)
Other 1 (0.9%)
Unknown 13 (11.1%) 18 (10.6%) 13 (11.9%)
Abbreviations: SEM: Standard error of mean, Std IFN: Standard interferon, PEG-
IFN: pegylated interferon.
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Table 83 The reason for stopping treatment with standard interferon monotherapy,
when this occurred and the responder status of the patient.
Reason for stopping treatment and length of treatment
(months)
Responder type PCR Completed planned adverse Patient Totals
data treatment or PCR data choice
event




Non-responder 18 12 7 1 38
Non-responder
(dose reduced 1 1
due major
adverse event)








6 1 9 Q
Responder
z y
Late Relapser 4 2 6
For all patients with genotype 1 infections, 10.8% achieved a SVR compared with
9.4% with genotype 2 or 3 infections, while in those that had received at least 5.3
months of treatment this was 6.2% and 12.1% respectively (Table 84).
In IFN nai've patients with genotype 1 infection, the rate was 8.3% compared with
8.9% in those with genotype 2 or 3 infections (Table 85). Too few patients
underwent IFN monotherapy retreatment to analyse response rates.
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Table 84 The number of patients in each responder type and the infecting genotype











18 3 13 1 4 39
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Table 85 The number of patients in each responder type according to whether they
had previous interferon treatment and the infecting genotype, when treated with
interferon monotherapy.
„ , Responder Genotype . .







18 3 12 1 3 37























1 1 1 3
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6.3.1.2.3 Predictors of sustained response
Binary logistical regression was performed with the covariates detailed above. This
identified a younger age at treatment (p<0.0001), to be the only independent
predictor of SVR in both the IFN naive and previous IFN groups.
6.3.1.2.4 Adverse events
Fifty (42.7%) of the 117 patients had no adverse events recorded during and after
treatment. Four patients (3.4%) had their treatment discontinued prematurely due a
serious adverse event. This was due to depression in two patients and due to
thrombocytopenia in two patients.
A further 16 patients (13.7%) discontinued their treatment prematurely without the
occurrence of a serious adverse event. This was therefore defined as by patient
choice but obviously the adverse effects of the medication may have been a
contributory factor. A younger age pre-treatment and hypothyroidism during
treatment independently predicted this outcome.
Five patients (4.3%) had the dose of their medication reduced due to a serious
adverse event. The reason for dose reduction in one patient was anaemia, low mood
in another and the rest were due to flu-like symptoms.
The prevalence of the common adverse effects of treatment that occurred in patients
is given in Table 86, while Table 87 gives rarer ones.
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Table 86 The common side effects in patients treated with standard interferon
monotherapy, Combination standard interferon and ribavirin and Combination
pegylated interferon and ribavirin.
Combination Combination
standard pegylated









Headache 6 5.1 8 4.7 9 8.3
Fatigue 30 25.6 26 15.3 21 19.3
Malaise 21 17.9 39 22.9 21 19.3
Myalgia 2 1.7 5 2.9 1 0.9
Arthralgia 1 0.9 9 5.3 5 4.6
Musculoskeletal pain 1 0.6 1 0.9
Fever 1 0.6
Psychiatric
Anxiety 1 0.6 1 0.9
Impaired concentration
Low mood 15 12.8 24 14.1 25 22.9
Emotional lability 5 4.3 13 7.6 6 5.5
Insomnia 2 1.7 8 4.7 7 6.4
Irritability 2 1.8
Dermatological
Alopecia 1 0.9 6 3.5 1 0.9
Pruritis 1 0.9 8 4.7 5 4.6
Rash 4 3.4 21 12.4 15 13.8
Dry skin 1 0.9 7 4.1 7 6.4
Inflammation at 1 0.9 4 2.4 2 1.8
injection site
Exacerbation of 3 1.8 1 0.9
psoriasis
Gastrointestinal
Anorexia 5 4.3 16 9.4 12 11.0
Dyspepsia
Vomiting 3 1.8 1 0.9
Nausea 3 2.6 13 7.6 12 11.0
Diarrhoea 2 1.2 6 5.5
Abdominal pain 2 1.8
Weight loss 9 5.3 6 5.5
Respiratory
Cough 1 0.6 1 0.9




Hypothyroid 1 0.9 2 1.2 1 0.9
Hyperthyroid J 1.8
Ocular





Table 87 The other side effects that were recorded in patients treated with standard
interferon monotherapy, Combination standard interferon and ribavirin and




























CNS Parasthesia in legs
























Fifteen patients treated with IFN monotherapy achieved a SVR at six months post
treatment. Figure 39 shows that 4 of these patients relapsed and became HCV RNA
PCR positive between 17 and 24 months of further follow-up.
Figure 39 A Kaplan Meier graph demonstrating the proportion of patients, treated with
standard interferon monotherapy, that remain as sustained responders during the































6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102 108 114 120
Months of follow up post treatment
Cumulative 0 4 5 5 6 6
relapsing
patients
At risk 15 11 9 5 2 0
patients
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6.3.1.3 Combination standard interferon and ribavirin
6.3.1.3.1 Characteristics of the population
170 were treated with this treatment. All received IFN alpha-2b. The base-line
characteristics of these treated patients are described in Table 82. The proportions of
the genotypes were similar to that previously described for the UK. 91.7% of patients
were Caucasian and 3.3% had an Asian Subcontinent racial background.
6.3.1.3.2 Outcome of treatment
The primary end-point of a sustained HCV clearance was achieved in 64 patients
(37.6%) including one patient that subsequently had a late relapse. No response to
treatment or relapse either during or in the 6 months following treatment occurred in
76 patients. Thirty patients received less than three months of treatment prior to
discontinuation either due to major adverse event or patient choice and therefore it
was not possible to determine their responder status. A breakdown of the reasons for
discontinuing treatment in these patients and the sustained responders is given in
Table 88.
For all patients with genotype 1 infections, only 11.9% achieved a SVR compared
with 50.0% with genotype 2 or 3 infections, while in those that had received at least
5.3 months of treatment this was 17.9% and 71.4% respectively (Table 89).
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Table 88 The responder type and the reason for stopping and length of treatment with
combination standard interferon and ribavirin.
Reason for stopping treatment and length of
treatment (months)
Major
Responder type PCR Completed treatment or , Patient Totals
j * i,/-i. j . adverse .data PCR data . choice
event
































2 1 3 4 64
Table 89 The number of patients in each responder type and the infecting genotype
when treated with combination standard interferon and ribavirin.
Subgroup Responder Type 7 — Totals1 2 3 4 6 Unknown
Treatment
7 1 14 1 7 30
incomplete
/ 1
Whole Non-responder 32 10 2 6 50
cohort Relapser 13 2 6 2 3 26
(n=170) Sustained
Responder and 7 6 27 24 64
Late relapsers
Patients Treatment 1 1
that incomplete
received Non-responder 18 4 1 3 26
>5.3 Relapser 13 2 6 2 3 26
months of Sustained
treatment Responder and 7 5 25 22 59
(n-112) Late relapsers
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In IFN nai've patients the SVR rate was 11.6% and 52.2% for genotype 1 and
genotype 2 or 3 infections respectively, compared with 12.5% and 45.0% in those
that had previous IFN treatment (Table 90).
Table 90 The number of patients in each responder type according to whether they
had previous interferon treatment and the infecting genotype, when treated with














































6.3.1.3.3 Predictors of sustained response
Binary logistical regression with the covariates detailed above was performed and
identified for IFN naive patients a lower pre-treatment weight (p<0.0001) and a
genotype 2 or 3 infection (p=0.01) to be independent predictors of SVR.
When the same analysis was stratified by genotype, for genotype 1 infections a lower
pre-treatment weight (p=0.003) was found to be an independent predictor of SVR,
but for the genotype 2 or 3 infections no independent predictors could be identified.
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6.3.1.3.4 Adverse events
Sixty-seven patients (39.4%) of the 170 patients had no adverse events recorded
during and after treatment. Nine patients (10.9%) had their treatment discontinued
prematurely due a serious adverse event. The commonest cause was depression,
which occurred in 5 patients. Two patients developed anaemia severe enough to
discontinue all treatment. Binary logistical regression was performed and identified a
lower weight as the only pre-treatment independent predictor of premature treatment
termination due to a serious adverse event. Anxiety, inflamed injection site and low
mood were the symptoms on treatment that independently predicted this outcome.
A further 23 patients (13.5%) discontinued their treatment prematurely without the
occurrence of a serious adverse event. This was therefore defined as by patient
choice but obviously adverse effects of the medication may have been a contributory
factor. In two there was ongoing low mood, in two there were thyroid abnormalities
and another one there was weight loss. A younger age pre-treatment and cough,
malaise and weight loss during treatment independently predicted this outcome.
There were 22 episodes of dose reduction due to side-effects in 15 patients (8.8%).
Three of these subsequently had their treatment discontinued prematurely. Anaemia
was the reason for dose reduction in 8 of these episodes, neutropenia in 3, depression
in 2, nausea in 2 and dyspnoea in 2.
The prevalence of common adverse effects of treatment that occurred in patients are
given in Table 86. A younger pre-treatment age (and not a previous psychiatric
history) was predictive of low mood whilst on treatment. A younger pre-treatment
age was independently predictive of the occurrence of thyroid disorders whilst on
treatment. Rarer adverse events are given in Table 87.
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6.3.1.3.5 Late relapse
Sixty-four patients achieved a SVR at six months post treatment. At 2 years after
treatment 42 patients out of 43 remained sustained responders (97.7%). The one late
relapse in the whole cohort was documented to have occurred at 11.5 months after
treatment with a positive HCV RNA PCR. At 3 years post treatment 19 patients
remained sustained responders with no further relapses. The longest sustained
responder has been followed up for 91 months post treatment without relapse.
6.3.1.4 Combination pegylated interferon and ribavirin
6.3.1.4.1 Characteristics of the population
One hundred and nine patients were treated with this treatment. The base-line
characteristics of these treated patients are described in Table 82. 96.3% of patients
were Caucasian and 2.8% had an Asian Subcontinent racial background.
6.3.1.4.2 Outcome of treatment
The primary end-point of a sustained HCV clearance was achieved in 41 patients
(37.6%) of the 109 patients. No response to treatment or relapse either during or in
the 6 months following treatment occurred in 39 patients. Twenty-nine patients
discontinued their treatment prematurely either due to major adverse event or patient
choice, at such a time that it has not been possible to determine their responder
status. A breakdown of the reasons for discontinuing treatment in these patients and
the sustained responders is given in Table 91.
For all patients with genotype 1 infections, only 20.0% achieved a SVR compared
with 56.2% with genotype 2 or 3 infections, while in those that had received at least
5.3 months of treatment this was 41.6% and 67.7% respectively (Table 92).
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Table 91 The number of patients in each responder type and the reason for
discontinuing treatment with combination pegylated interferon and ribavirin.
Reason for stopping treatment and length of treatment
(months)
Responder type PCR Completed treatment or Major Patient Total
data PCR data adverse event choice
<5.3 5.4-6.9 6.9-11.4 >11.4 <5.3 >5.3 <5.3 >5.3

































Table 92 The number of patients in each responder type and the infecting genotype
when treated with combination Pegylated interferon and ribavirin.





(n=109) Relapser 9 5 1 15
18 4 6 1 29
17 6 1 24
Sustained
11 3 24 1 2 41







months of Relapser 9 5 1 15
treatment Sustained
(n=101) Responder
10 2 19 1 2 34
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In IFN naive patients the SVR rate was 29.0% and 59.3% for genotype 1 and
genotype 2 or 3 infections respectively, compared with 8.3% and 45.8% in those that
had previous IFN treatment (Table 93).
Table 93 The number of patients in each responder type according to whether they
had previous interferon treatment and the infecting genotype, when treated with
















































6.3.1.4.3 Predictors of sustained response
Binary logistical regression with the covariates detailed above was performed
separately on those that had had previous IFN treatment and those that had not. This
identified for IFN naive patients a genotype 2 or 3 infection (p=0.047) to be the only
independent predictor of SVR. For those that had received previous IFN based
treatment a genotype 2 or 3 infection (p=0.011) and a younger age pre-treatment
(p=0.033) were found to be independent predictors of SVR.
When the same analysis was stratified by genotype, no independent predictors could
be identified either for genotype 1 infections or for the genotype 2 or 3 infections.
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6.3.1.4.4 Adverse events
Twenty-six patients (23.8%) of the 109 patients had no adverse events recorded
during and after treatment. Seven patients (6.4%) had their treatment discontinued
prematurely due a serious adverse event. One developed depression, one patient
developed anaemia severe enough to discontinue all treatment and one discontinued
due to weight loss. Binary logistical regression was performed and identified a lower
weight as the only pre-treatment independent predictor of premature treatment
termination due to a serious adverse event. Vomiting and weight loss were the
symptoms on treatment that independently predicted this outcome.
A further 19 patients (17.4%) discontinued their treatment prematurely without the
occurrence of a serious adverse event. This was therefore defined as by patient
choice but obviously adverse effects of the medication may have been a contributory
factor. In three there was ongoing low mood, in two there was ongoing anaemia, in
two there were severe flu-like symptoms and in another one there were thyroid
abnormalities. A lower weight pre-treatment and dyspnoea during treatment
independently predicted this outcome.
There were 56 episodes of dose reduction of their medication due to side effects in
41 patients (37.6%). Five of these subsequently had their treatment discontinued
prematurely. Neutropenia was the reason for dose reduction in 23 of these episodes,
thrombocytopenia in 16, anaemia in 8 and weight loss in 2.
The prevalence of common adverse effects of treatment that occurred in patients is
given in Table 86. Only a younger pre-treatment age and a history of alcohol abuse
(>50 units/week) were predictive of treatment being discontinued due to depression.
A previous psychiatric history was not predictive. Rarer events are given in Table 87.
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6.3.1.4.5 Late relapse
Forty-one patients achieved a SVR at six months post treatment. No patients have
relapsed so far after a median of 9.3 months follow-up post treatment. Only three
patients have been followed up for two years post treatment and all remain sustained
responders.
6.3.2 Combination interferon and ribavirin treatment in hospital
practice in the United Kingdom
6.3.2.1 Characteristics of the Patients
1220 patients received combination IFN alpha-2b and ribavirin in the 69 centres
around the UK on a compassionate basis from Schering-Plough between 1997 and
2000. The patients from the Royal Infirmary of Edinburgh were excluded and have
been analysed separately above. Data was received on 238 patients that had had
treatment from six other centres. Two hundred and nineteen of these had follow-up
allowing responder status to be determined. The base-line characteristics of these
treated patients are described in Table 94. The proportions of the genotypes was
similar to that previously described for the UK. 92.2% of patients were Caucasian
and 2.3% had an Asian Subcontinent racial background.
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Table 94 Base-Line characteristics of patients with follow-up post treatment that
allows response to be determined.
Characteristic
Mean Age +/-SEM (years) 40.6 +/- 0.6
Mean duration of infection+/-SEM 15.9+/-0.7
(years)
Mean Weight +/-SEM (Kilograms) 76.5 +/-1.1
Male:Female ratio 155:64
Previous interferon based treatment 69
Cirrhotic 19 (8.7%) All Childs A
Previous alcohol abuse 63 (28.8%)
HBsAg positive 5
HIV positive 1









Intravenous Drug Abuser 94 (42.9%)
Transfusion / Blood Products 59 (26.9%)
Sporadic / ETnknown 45 (20.5%)
Tattoo 9 (4.1%)
Occupational 6 (2.7%)
High Risk Sexual Practices 5 (2.3%)
Abbreviations: SEM: Standard error of mean
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6.3.2.2 Outcome
The primary end-point of a sustained HCV clearance was achieved in 108 patients
(49.3%) of the 219 patients with follow-up. Three of these subsequently relapsed
(Late relapsers). No response to treatment or relapse either during or in the 6 months
following treatment occurred in 103 patients. Eight patients discontinued their
treatment prior to three months due to major adverse event or patient choice, and
therefore it was not possible to determine their responder status. A breakdown of the
reasons for discontinuing treatment in these patients and the sustained responders is
given in Table 95.
Table 95 The number of patients in each responder type and the reason for
discontinuing treatment in all patients in whom responder status could be assessed.
Reason for stopping treatment and length of
treatment (months)
Responder type PCR Completed treatment or Major Patient Totaladverse
data PCR data auverse chofce
event





last HCV RNA 2 15 9 5 2 3 36
PCR on treatment
Non-responder
(dose reduced due . , ^
. , I j o
major adverse
event)











For all patients with genotype 1 infections, 19.2% achieved a SVR compared with
59.6% with genotype 2 or 3 infections, while in those that had received at least 5.3
months of treatment this was 22.5% and 67.4% respectively (Table 96).
Table 96 The number of patients in each responder type and the infecting genotype.
Subgroup Responder Genotype TotalsType 1 2 3 4 5 Other Unknown






18 3 5 1 15 42










17 3 5 1 11 37








9 6 23 1 61 100
treatment
(n=170)
In IFN nai've patients the rate was 15.6% and 58.1% for genotype 1 and genotype 2
or 3 infections respectively, compared with 25.0% and 61.9% in those that had
previous IFN treatment (Table 97).
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Table 97 The number of patients in each responder type according to whether they
had previous interferon treatment and the infecting genotype, when treated with
combination standard interferon and ribavirin.
„ . Responder Genotype . .
Subgroup , — „——— ——r Totals







14 1 4 1 7 27
responder
naive Relapser 12 6 2 22 42
(n=150) Sustained
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6.3.2.3 Predictors of sustained response
Binary logistical regression was performed separately on those that had had previous
IFN treatment and those that had not. This identified for IFN naive patients a
genotype 2 or 3 infection (<0.0001), a lower pre-treatment weight (p=0.005) and a
longer treatment course (p=0.037) to be independent predictors of SVR. For those
that had received previous IFN based treatments a genotype 2 or 3 infection
(p=0.017) was found to be the only independent predictor of SVR.
When the same analysis was stratified by genotype, for IFN naive genotype 1
infections a younger age at treatment was an independent predictor of SVR, while
those with previous IFN based treatment it was a lower pre-treatment weight and a
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longer treatment course. For the genotype 2 or 3 infections no independent predictors
of SVR could be identified for IFN nai've or previous IFN based treatment patients.
6.3.2.4 Adverse events
Seventeen patients (7.1%) of the 238 patients had no adverse events recorded during
and after treatment. Twenty-four patients (10.1%) had their treatment discontinued
prematurely due a serious adverse event. The commonest cause was depression,
which occurred in three patients. Two patients developed anaemia severe enough to
discontinue all treatment and one discontinued due to neutropenia and one due to
thrombocytopenia. In 16 patients the reason was not classified. Binary logistical
regression was performed and identified a lower pre-treatment weight (p<0.0001),
previous minor psychiatric history (p<0.0001) and no previous IFN based treatment
(p=0.009) as pre-treatment independent predictors of premature treatment
termination due to a serious adverse event. Sinusitis, vomiting, emotional labiality
and the absence of fever were the symptoms on treatment that independently
predicted this outcome.
A further 45 patients (18.9%) discontinued their treatment prematurely without the
occurrence of a serious adverse event. This was therefore defined as by patient
choice but obviously adverse effects of the medication may have been a contributory
factor. A younger age at treatment and previous IFN based treatment independently
predicted this outcome pre-treatment and sinusitis, the absence of anxiety and
dyspnoea whilst on treatment.
Thirty-four patients (14.3%) had the dose of their medication reduced due to a
serious adverse event. Four of these subsequently had their treatment discontinued
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prematurely. Anaemia was the reason for dose reduction in 16 patients (6.7%),
neutropenia in 4, depression in 2 and thrombocytopenia in 1.
The prevalence of the adverse effects of treatment that occurred in over 10% of
patients is given in Table 98. A previous history of thyroid disorders, a lower pre-
treatment weight and no previous IFN treatment were independently predictive of the
occurrence of thyroid disorders whilst on treatment.
Table 98 The common side effects whose presence or absence was recorded for all
patients that completed treatment (n=238).











Impaired concentration 44 11.7
Low mood 65 21.3







Dry skin 69 28.9







Abdominal pain 21 8.8









Other side effects of treatment that occurred less commonly are recorded in Table 99.
Table 99 The other side effects that were recorded (n=239)
System Side effect Number of patients
Hepatic Right upper quadrant pain 3
Bilirubin elevation 1
Elevated ALT and Alk Phos 1
Hepatitis 1
















CNS Parasthesia in arms 1
Tinnitus 1
Tremor 1
Psychiatric Suicide attempt 1
Hallucinations 1
Miscellaneous Nose bleeds 3
Psoriasis exacerbation 1











One hundred and eight patients from the whole cohort achieved a SVR at six months
post treatment. Figure 40 shows that 3 of 51 patients (5.9%) followed up for a further
18 months relapsed and became HCV RNA PCR positive.
Figure 40 A Kaplan Meier graph demonstrating the proportion of patients, treated with
Combination standard interferon and ribavirin that remain as sustained responders

































108 89 66 50
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6.4 Discussion
The studies described in this chapter are not randomised controlled trials and
therefore should be interpreted with caution. Despite this, the study may demonstrate
the SVR rates that are likely to be achieved in the less controlled environment of
clinical practise.
6.4.1 Standard Interferon monotherapy
The primary end-point of SVR was achieved in 12.8% of patients which is similar to
that reported in the Cochrane review (SVR for 6 months 7% and for 12 months 14%)
(Myers et al. 2002). In the genotype 1 infected patients an overall SVR rate for the
whole cohort of 10.8% is less than 17% reported in the trials (Davis & Lau 1997)
where the intention to treat was 12 months. Analysing those that had at least six
months of treatment the SVR rate was 6.2% which is difficult to explain as longer
treatment has been shown to improve outcome for genotype 1 (Davis & Lau 1997). It
has not been possible to look at a cohort of those that had at least 12 months of
treatment, as this would automatically exclude any non-responders at six months.
In the genotype 3 infected patients an overall SVR rate of 9.4% is less than 54.9%
reported in the trials (Davis & Lau 1997) where the intention to treat was at least 6
months. Analysing those that had at least 5.3 months of treatment the SVR rate was
little better at 12.1%.
The only predictor found for SVR was a younger age at treatment, which has not
been found in other studies.
Overall discontinuation of therapy due to a severe adverse event occurred in 3.4%.
This compares to 4% seen in the trials with depression, as in this study, being the
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commonest cause (Poynard et al. 1996). In addition to this a further 13.7%
discontinued therapy prematurely due to patient choice, without a severe adverse
event. This group, which was not clearly documented in the trials, makes the overall
discontinuation rate much higher. Higher motivation levels in the trial patients might
explain this, combined with stricter application of when a patient could discontinue
treatment. Dose reduction occurred in 4.3% of patients which is less than the 9%
seen the trials. As with the trials, the flu-like side effects predominated with fatigue
occurring in 25.6% of individuals being the commonest. The incidence of these other
side effects was significantly less than reported in the trails (Poynard et al. 1996) as
reporting is likely not to have been so complete.
The long-term outcome of patients who are sustained responders to IFN
monotherapy has been documented. The proportion who remain HCV RNA PCR
negative has ranged from 96% at a mean follow-up of 4 years to 92% (Marcellin et
al. 1997) at a mean of 5.4 years (Reichard et al. 1999).
This study includes follow-up of 15 sustained responders, and at 2 years post
treatment only 73.3% remained negative.
6.4.2 Combination standard interferon and ribavirin
Previous randomised controlled trials have established that a combination of three
times a week IFN and twice daily ribavirin is an effective treatment for chronic HCV
infection (McHutchison et al. 1998b; Poynard et al. 1998).
6.4.2.1 Edinburgh cohort
The primary end-point of a sustained HCV clearance was achieved in 64 patients
(37.6%). In the genotype 1 infected patients an overall SVR for the whole cohort of
11.9% is less than 28-31% reported in the trials where the intention to treat was 12
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months. This may reflect that some genotype 1 patients were discontinued prior to
six months of treatment for being PCR positive and a further patients were
discontinued at six months when PCR negative and subsequently relapsed. A
proportion of these may have gone on to be sustained responders if treatment had
been continued. Analysing those that had at least six months of treatment the SVR
rate was 17.9% which is similar to the 16-18% seen the six month treatment group in
the trials, although the groups are not directly comparable. It has not been possible to
look at a cohort of those that had at least 12 months of treatment, as this would
automatically exclude any non-responders at six months.
In the genotype 3 infected patients an overall SVR rate of 50.0% is less than 64-69%
reported in the trials where the intention to treat was at least 6 months. However
analysing those that had at least 5.3 months of treatment the SVR rate was 71.4%.
Surprisingly the SVR rate in those that had had previous IFN monotherapy was not
significantly different from those that had not. This probably reflects how few
patients achieved a SVR with this form of treatment and therefore the composition,
including genotype ratios, of the two groups was similar.
For IFN naive patients, binary logistical regression identified a genotype 2 or 3
infection, a lower pre-treatment weight and a longer treatment course to be
independent predictors of SVR. The previous trials have established this effect of
genotype but also a low degree of fibrosis at baseline and female sex, which was not
seen in this study. The length of treatment would obviously not have been looked at
as the trial cohorts were divided into six and 12-month groups at the outset. When
the same analysis was performed but stratified for genotype, for IFN naive genotype
1 infections a younger age at treatment was an independent predictor of SVR. The
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European randomised controlled trial also identified young age as an independent
predictor of response (Poynard et al. 1998). The effect of baseline viral load was not
assessed in this study but has been shown to be predictive of SVR if 2x106 copies per
millilitre or less (McHutchison et al. 1998b; Poynard et al. 1998).
Overall discontinuation of therapy due to a severe adverse event occurred in 10.9%.
This compares to 8% for 24 weeks of treatment and 19-21% for 48 weeks of
treatment seen in the trials with depression, as in this study, being the commonest
cause (McHutchison et al. 1998b; Poynard et al. 1998). A lower pre-treatment weight
was identified as an independent predictor of discontinuation for a serious adverse
event. In addition to this a further 13.5% discontinued therapy prematurely due to
patient choice, without a severe adverse event. Again this group, which was not
clearly documented in the trials, makes the overall discontinuation rate much higher.
Only 22.6% of these patients achieved a SVR. Dose reduction occurred in 8.8% of
patients which is comparable to the 7%-10% seen the trials. Anaemia triggered this
in 4.6% of patients compared with 7-9% seen in the trials. As with the trials, the flu-
like side effects predominated with malaise occurring in 22.9% of individuals being
the commonest. It is likely that there was incomplete recording of these minor side
effects as the frequencies are so much lower.
It has been assumed that the persistence of the SVR following combination treatment
will be equivalent to that in IFN monotherapy. The only data so far reported,
followed up 25 sustained responders of which 84% remained HCV RNA PCR
negative at a mean of 9.4 months (Barnes et al. 1999). This study includes follow-up
of 64 sustained responders, of whom 43 had a HCV RNA PCR at 2 years post
treatment, and 97.7% remained negative.
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6.4.2.2 UK cohort
The primary end-point of a sustained HCV clearance was achieved in 108 patients
(49.3%) of the 219 patients with follow-up. This is much higher than the Edinburgh
cohort, as are the SVRs in the other subsets. In the genotype 1 infected patients an
overall SVR for the whole cohort of 19.2% is less than 28-31% reported in the trials
where the intention to treat was 12 months. Again this may reflect that some
genotype 1 patients were discontinued prior to six months of treatment for being
PCR positive and a further patients were discontinued at six months when PCR
negative and subsequently relapsed. A proportion of these may have gone on to be
sustained responders if treatment had been continued. Analysing those that had at
least six months of treatment the SVR rate was 22.5% which is similar to the 16-18%
seen the six month treatment group in the trials, although the groups are not directly
comparable.
In the genotype 3 infected patients an overall SVR rate of 59.6% is less than 64-69%
reported in the trials where the intention to treat was at least 6 months. However
analysing those that had at least 5.3 months of treatment the SVR rate was 67.4%.
As with the Edinburgh cohort the SVR rate in those that had had previous IFN
monotherapy was not significantly different from those that had not.
For IFN nai've patients, binary logistical regression identified a genotype 2 or 3
infection, a lower pre-treatment weight and a longer treatment course to be
independent predictors of SVR. When the same analysis was performed but stratified
for genotype, for IFN na'ive genotype 1 infections a younger age at treatment was an
independent predictor of SVR. For those with a previous IFN based treatment, it was
a lower pre-treatment weight and a longer treatment course. This would be in
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keeping with the trials that have shown that 12 months treatment achieves greater
SVR rates than six. The effect of pre-treatment weight in IFN monotherapy was
analysed in the two international trials. It revealed a lower weight increased SVR
rates independently of genotype (McHutchison et al. 2001a). Similar associations
were found in the Edinburgh cohort.
Overall discontinuation of therapy due to a severe adverse event occurred in 10.1%.
This compares to 8% for 24 weeks of treatment and 19-21% for 48 weeks of
treatment seen in the trials with depression, as in this study, being the commonest
cause (McHutchison et al. 1998b; Poynard et al. 1998). In addition to this a further
18.9% discontinued therapy prematurely due to patient choice, without a severe
adverse event. However despite this early discontinuation 72.7% of these patients
achieved a SVR, suggesting it occurred late in their planned treatment course. Dose
reduction occurred in 14.3% of patients which is comparable to the 7%-10% seen the
trials. Anaemia triggered this in 6.7% of patients compared with 7-9% seen in the
trials. As with the trials, the flu-like side effects predominated with fatigue occurring
in 62.3% of individuals being the commonest. The incidence of these other side
effects was comparable except there was less myalgia, fever, nausea, insomnia,
pharyngitis and alopecia reported in this study (McHutchison et al. 1998b).
This study includes follow-up of 108 sustained responders, of whom 51 had a HCV
RNA PCR at 2 years post treatment, and 94.1% remained negative.
There are a number of reasons to interpret the results with caution. Data was
submitted on only 366 patients out of the total possible cohort of 1220 patients, and
therefore selection bias may have also been introduced, although for each
participating centre, all potential patients were identified and complete data
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submitted. The reason for this low proportion was that many more centres expressed
an interest in participating at the outset, but did not submit data when it became clear
how much work was involved.
6.4.3 Combination pegylated interferon and ribavirin
The primary end-point of a sustained HCV clearance was achieved in 41 patients
(37.6%) of the 109 patients with follow-up. In the genotype 1 infected patients an
overall SVR for the whole cohort of 20% is less than 50% reported in the trials
(Manns et al. 2001), (Fried et al. 2002) where the intention to treat was 12 months.
Analysing those that had at least six months of treatment the SVR rate was 41.6%.
In the genotype 3 infected patients an overall SVR rate of 56.2% is less than 80%
reported in the trials where the intention to treat was at least 6 months. However
analysing those that had at least 5.3 months of treatment the SVR rate was 67.7%.
In IFN nai've patients the SVR rate was 29.0% and 59.3% for genotype 1 and
genotype 2 or 3 infections respectively, compared with 8.3% and 45.8% in those that
had previous IFN treatment. The large numbers that were receiving retreatment
explains, in part, the lower overall SVRs.
Binary logistical regression identified for IFN naive patients a genotype 2 or 3
infection to be the only independent predictor of SVR. For those that had received
previous IFN based treatment a genotype 2 or 3 infection (p=0.011) and a younger
age pre-treatment (p=0.033) were found to be independent predictors of SVR. When
the same analysis was stratified by genotype, no independent predictors could be
identified either for genotype 1 infections or for the genotype 2 or 3 infections. No
effect of pre-treatment weight could be identified. In the PEG-IFN alpha-2b plus
ribavirin trial an association with pre-treatment weight in genotype 1 infected
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patients was observed and attributed to a dose-dependent response to ribavirin
(Manns et al. 2001). However for genotype 3 patients this factor was not predictive
of SVR. In a PEG-IFN alpha-2a plus ribavirin trial SVR rates appeared independent
of the ribavirin dose in genotype 3 infected patients (Hadziyannis et al. 2002).
Overall discontinuation of therapy due to a severe adverse event occurred in 6.4%.
This compares to 9.7% for 48 weeks of treatment seen in the trials (Manns et al.
2001), (Fried et al. 2002). Binary logistical regression identified a lower weight as
the only pre-treatment independent predictor of premature treatment termination due
to a serious adverse event. In addition to this a further 17.4% discontinued therapy
prematurely due to patient choice, without a severe adverse event compared to 12.3%
in the trials. A lower weight pre-treatment and dyspnoea during treatment
independently predicted this outcome. Only 8% of these patients achieved a SVR.
Dose reduction occurred in 37.6% of patients which is much higher than the 8.2%
seen the trials and much higher that that seen with combination standard IFN and
ribavirin. Neutropenia triggered this in 21.1% of patients compared with 3.5% seen
in the trials. This is also much commoner than with combination standard IFN and
ribavirin. As with the trials, the flu-like side effects predominated with fatigue
occurring in 19.3% of individuals. However they were no commoner than with
combination standard IFN and ribavirin. The commonest side effect was low mood at
22.9%, which was much commoner than with combination standard IFN and
ribavirin. There was not a higher prevalence of injection site inflammation that was
seen in the trials.
This study includes follow-up of 41 sustained responders. No patients have relapsed
so far after a median of 9.3 months follow-up post treatment. Only three patients
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have been followed up for two years post treatment and all remain sustained
responders.
6.4.3.1 Conclusion
This study has demonstrated that the improvements in efficacy in treatment for
chronic HCV infection seen in the randomised clinical trials are likely to be
converted into improvements when used in routine hospital practise as the guidelines
suggest.
Overall IFN monotherapy rates were similar to published meta-analysis although the
SVR rates in non-genotype 1 patients appeared considerably lower. The adverse
events appeared similar, although as with all treatment regimes a higher number of
patients terminated treatment early compared with the trials. The long-term outcome
was also similar.
The results from the combination standard IFN and ribavirin treatment analysis were
lower in the Edinburgh cohort compared with the UK cohort. The UK cohort had
lower SVR rates compared with the trials for genotype 1 patients, but similar for
non-genotype 1 patients. Although there were higher discontinuation rates, when this
was not for a serious adverse event, the SVR rate remained high. These differences
may relate to treatment regimes not being established when the treatment was
initially used, as is demonstrated with the improved SVR rates when at least 6
months of treatment has been given. Adverse events were lowest in the Edinburgh
cohort but this may relate to underreporting. Dose reduction rates were similar to
trials. Both cohorts demonstrate that SVR is very durable.
Overall the SVR rates for PEG-IFN were lower than the trials but improved
significantly and were comparable when only IFN naive patients were analysed.
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Discontinuations were similar to trials but higher than combination standard IFN and
ribavirin. Dose reductions were much higher than those in the trials primarily for
neutropenia and anaemia. This is important as these patients can be treated with GM-
CSF and erythropoetin, which markedly increases the cost of treatment. The
incidence of low mood appeared higher in the PEG-IFN and ribavirin group
compared with combination standard IFN and ribavirin. There was no evidence to




At the end of each chapter there is a detailed discussion of the analysis and placed in
the context of previous published research in the relevant area.
7.1 Natural History of HCV infection
The patients that are referred to the Royal Infirmary of Edinburgh have been
described in detail in this thesis. There is a significant proportion that has been found
to be HCV RNA PCR negative at initial assessment and presumably have cleared the
infection at the acute stage of the disease. No analysis has been performed on these,
as referral of these patients is even more inconsistent than the HCV RNA PCR
positive cohort. Therefore they may be even less representative of the HCV RNA
PCR negative in the community. HCV RNA PCR positive cohort is made up of a
significant proportion of middle-aged men who acquired the infection less than 20
years ago, principally through IDU, who have a significant history of alcohol abuse.
This population, in its make-up is very different from the prospective community-
based cohorts, such as the Irish anti-D cohort (Kenny-Walsh 1999). Therefore,
unsurprisingly the outcome is very different and it is unlikely to be entirely down to
referral bias in the hospital-based cohorts. A significant proportion are already
presenting with cirrhosis and its complications, demonstrating the considerable
burden on healthcare resources these patients are creating.
Analysis of the covariates that may influence progression in the HCV RNA PCR
positive cohort, demonstrates how often they are significantly correlated. Importantly
the covariates also significantly influence the time to presentation and therefore may
lead to either an under- or over-estimation of their effect. In chapter 4 and 5 the
progression to cirrhosis and the complications of cirrhosis respectively were analysed
using Cox regression. Although Cox regression analysis is a multivariate method, its
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use in this setting, where there is such high correlation of covariates, to identify
independent predictors of progression is not foolproof. It merely produces the best
model with the covariates available to recreate the observed results. In all models
produced the R square scores were very low compared with the maximum possible
suggesting the models are not good and there maybe other covariates untested that
will improve the predictive value of the model.
The importance of left truncation of the risk set at the time of presentation has been
emphasised and shown to influence the outcome of analysis. This is required as those
referred are only a sample of the HCV RNA PCR positive population in the
Edinburgh 'EH' postcode region. For this sample to be a valid representation of the
whole population, referral has to be random. Clearly this is not the case as only a
proportion are being referred and this referral process is significantly affected by the
vast majority of those that have been found to have advanced disease in the cohort,
presenting at or just before the time of this diagnosis of advanced disease. As
mentioned above the covariates also affect the time of presentation. Therefore
hospital-based cohorts, such as this, are very susceptible to this referral bias and it
will have influenced the results. The left truncation method does require much larger
cohorts, due to fewer patients being in the risk set at any given census time-point,
compared with analysis without left-truncation.
Despite the acknowledged limitations of these studies, in particular the difficulty of
recording accurately the date of infection and the previous alcohol history, they do
provide further evidence of the key roles of the age of the patient at infection and the
level of alcohol consumption in the progression to cirrhosis. It shows that previously
established risk factors for progression, such as the sex of a patient, are not the same
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in all cohorts of patients. This raises some concerns about applying the results of
previous cohort studies to other populations, when trying to make accurate
predictions of health impact of HCV infection for a local cohort.
The studies looking at the onset of the complications of cirrhosis do provide evidence
the age of the patient does influence progression to these end-points. The influence
of other covariates is less clear due to confounding. A beneficial effect of previous
IFN-based treatment, especially in those that have a SVR on HCC occurrence is
suggested, however selection of those that were treated was not random and therefore
susceptible to bias. It attempts for the first time to estimate the duration of infection
to the onset of clinically important complications for a hospital-based cohort. It
confirms that at five years after the diagnosis of uncomplicated cirrhosis the risk of
HCC is about 9-12%, the risk of a major complication of cirrhosis is about 11% and
the risk of liver related death is about 8-10%. This progression is with conventional
primary prophylaxis of varices, treatment of bleeding varices and treatment of about
halve the cohort with IFN-based regimes. Clearly this is likely to have modified the
outcome. Larger cohorts with longer follow up are required to clarify these issues
further.
7.2 Treatment of HCV infection
This study has demonstrated a steady improvement in efficacy in treatment for
chronic HCV infection with the introduction of each new treatment regime as
suggested by randomised clinical trials. About 45% of all patients referred and
assessed each year were deemed suitable for treatment and listed.
Overall IFN monotherapy rates were similar to published meta-analysis although the
SVR rates in non-genotype 1 patients appeared considerably lower. The adverse
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events appeared similar, although as with all treatment regimes a higher number of
patients terminated treatment early compared with the trials. The long-term outcome
was also similar.
The results from the combination standard IFN and ribavirin treatment analysis were
lower in the Edinburgh cohort compared to the UK cohort. The UK cohort had lower
SVR rates compared with the trials for genotype 1 patients, but similar for non-
genotype 1 patients. These differences may relate to treatment regimes not being
established, in terms of assessment of response and duration of treatment for each
genotype, when the treatment was initially used. This was demonstrated with the
improved SVR rates when at least 6 months of treatment has been given. Adverse
events were lowest in the Edinburgh cohort but this may relate to underreporting.
Dose reduction rates were similar to the trials. Both cohorts demonstrate that SVR is
very durable.
Overall the SVR rates for combination PEG-IFN and ribavirin were lower than the
trials due to the high number of patients being retreated. The SVRs for IFN naive
patients were comparable. Discontinuations were similar to trials but higher than
combination standard IFN and ribavirin. Dose reductions were much higher than
those in the trials. They were most commonly for neutropenia and anaemia and
therefore may necessitate the use of GM-CSF and erythropoietin. This markedly
increases the cost of treatment and probably its cost-effectiveness. The incidence of
low mood appeared higher in the PEG-IFN and ribavirin group compared with
combination standard IFN and ribavirin. There was no evidence to suggest the
durability of the SVR is different with this treatment regime.
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7.3 Utilisation of the database application
A major positive outcome of this thesis has been the creation of a database
application that can be used in any liver unit to collect epidemiological and audit
data. The database is now successfully used in all the liver units in Scotland as part
of an ongoirg project to collect data on all patients with HCV, that have attended
hospital and been assessed. This will culminate in the creation of a National Clinical
HCV database which will provide information for health planners and researchers to
assess and combat the health burden poised by the infection in Scotland.
7.4 Conclusion
Chronic HCV is a significant health problem in Edinburgh with large numbers being
referred for assessment, treatment and management of the complications of cirrhosis.
Treatments are effective, although do have significant adverse effects that affect
compliance. The numbers still requiring treatment in the cohort still remain high
overall. The natural history of the infection and how it is influenced by therapy is
becoming clearer, in particular the influence of alcohol and the age of the patient.
However for further progress to be made, it will require the analysis of larger cohorts
from a variety of settings.
7.5 Suggested future work
7.5.1 Natural History
• Further analysis of the factors that influence presentation to hospital.
• Further follow up over time of the cohorts identified in this thesis to identify
further progression to the end-points.
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• Performing the same survival analysis on patients on the National Clinical
HCV database that has been set up. The larger numbers will allow left-
truncation of the survival analysis to be more accurate.
• Staging of the liver biopsies using a scoring scheme to further analyse
progression of fibrosis prior to cirrhosis.
• Assessing the influence of steatosis on progression to liver cirrhosis by
documenting its presence on biopsies and how this correlates with the
patients BMI and insulin resistence.
• Analysis of the HCV RNA PCR negative cohort.
• Further validation of Hyaluronic acid as a surrogate marker of cirrhosis and
identifying the causes of false positive and negative results.
7.5.2 Epidemiology
• Collection of basic epidemiological data on all patients referred to hospital in
Scotland using the National Clinical HCV database.
• Analysing how the cohort referred to hospital differs from those that have not
in Lothian, by anonymised linkage with the antibody positive database held
by the Health Protection Scotland in Glasgow.
7.5.3 Treatment
• Ongoing audit of the number of patients suitable for treatment, the reasons of
unsuitability, treatment results, treatment adverse events and long-term
outcome.
• Analysis of the reasons for discontinuation treatment and whether this can be
predicted prior to initiation of treatment.
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Long-term outcome of patients that developed permanent complications of
treatment such as thyroid disorders.
Long-term effect of treatment on progression to complications of cirrhosis
and HCC.
Trials to assess efficacy of shorter courses of treatment in genotype 2 or 3
patients in hospital practise.
Auditing GM-CSF and erythropoietin use in reducing dose reductions or
discontinuations.
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To create a Microsoft Access database application, to enable clinicians to manage,
audit practise and collect epidemiological and natural history data on hospital cohorts
of patients with HCV infection.
1.2 Description of database
1.2.1 Sign on
On opening the database the first screen that is displayed is the 'Hepatitis C Database
Sign on' form. The user has to enter their name and password. This functions to
limited entry to the database and it also identifies who is using the database, so that
when a record is changed it is possible to identify who made that change and when.
The user is then taken to the main switchboard.
1.2.2 Main switchboard
This is portal of entry into the database. It allows access to either a form that has all
the patent possible patient fields or just the fields of the minimum dataset of the
Scottish HCV database project. Reports and charts can be accessed based on the
whole population or subgroups within the population, including those concerning
treatment.
1.2.3 Patient Records
1.2.3.1 All patient records form
The 'All patient records' form (Figure 41) shows all the available fields / boxes for
entering the patient's details. The form however, can also display information entered
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on all the patients already entered into the database and allows editing of this
information.
Figure 41 All patient records form.
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Current Follow-up Status: [Unknown
Date of last clinic: |
Date of last follow-up: [
BP Practice \
Number:
Date when the records of this Last operator to update
patient were last updated. records:
j Record: N | 4 11 706T | H | I of 706
Clicking the labelled tabs at the top of the form accesses the main subforms (First
appointment/admission, Clinical data, Blood tests, Biopsies, Treatment,
Radiology, Endoscopy, Other Diagnoses and Outcome).
1.2.3.2 Organising data entry
When a patient is seen for the first time in clinic then the main Patient details. First
appointment/admission, Outcome and previous Blood tests, Biopsies,
Endoscopies or Radiology procedures can be entered.
A new Clinical Data record should only be entered at presentation, at liver biopsy
and if there is a change in the clinical findings. Therefore it is not necessary for each
clinic visit.
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Blood test data such as Bilirubin, Albumin and Prothrombin ratio should be entered
at the time of first diagnosis of cirrhosis or HCC and thereafter at each clinic visit so
that an accurate Childs grade can be calculated for the Current Stage of Disease.
Subsequent procedures or interventions such as treatment episodes and outcomes can
be entered as they occur.
1.2.3.3 Main areas
1.2.3.3.1 Patient details
The Patient details page (Figure 41) includes boxes to record details of the patient
that do not change.
• Surname soundex and Maiden name or Alias soundex: These fields are
automatically calculated using an algorithm pre-programmed into the
application (Mortimer & Salathiel 1995).
• Current Follow up status: This should be updated every time information is
changed on a patient. This can be entered manually or it can be filled in
automatically when entering information into other fields.
• Date of last follow-up: This is the date of the last contact with a patient i.e.
endoscopies, radiology, death, transplantation etc. This can be entered
manually or it can be filled in automatically when entering information into
other fields.
• Date when the records of this patient were last updated: Automatically
updated when data is changed on a patient.
• Last operator to update records: Automatically updated when data is
changed on a patient.
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1.2.3.3.2 First appointment
The First appointment page (Figure 42) includes boxes to record details of the
patient that will usually be available at their first appointment.
Figure 42 First appointment page.
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• BMI: The body mass index is automatically calculated.
1.2.3.3.3 Clinical data
The Clinical data page (Figure 43) includes information on the common symptoms
in patients with HCV. It also records the presence or absence of the signs of HCV
and the signs of liver decompensation.
The Degree of ascites or the Degree of encephalopathy can be record in the drop¬
down lists. If presence of ascites or encephalopathy is recorded for the first time, the
operator will be asked if they want to update either Date of first episode of ascites
or Date of first episode of encephalopathy on the 'Outcome' tab. If this is the first
time a complication of cirrhosis has been present and the patient is not known
previously to be cirrhotic the operator will be asked if they want to fill in the Date of
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first diagnosis of cirrhosis with this date and the Mode of first diagnosis of
cirrhosis as 'Clinical' on the 'Outcome' tab.
Figure 43 Clinical data page.
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The Blood tests page (Figure 44) includes boxes for the most commonly requested
blood tests on a patient with Hepatitis C.
• If the Bilirubin >35, Albumin <35 Prothrombin ratio (PTR) >1.2 and
Platelets <100 then this might suggest that the patient is cirrhotic. This will
prompt the option of automatic filling in of the Date of first diagnosis of
cirrhosis and the Mode of first diagnosis of cirrhosis on the 'Outcome' tab.
• AFP: Alphafetoprotein. If a value of >20 is entered this may suggest the
presence of an HCC. This will prompt the option of automatic filling in of the
Date of first diagnosis of HCC and the Mode of first diagnosis of HCC as
'AFP' on the 'Outcome' tab. If the HCC was later confirmed then this should
be done.
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• ALT chart this will plot the patients ALT over time.
Figure 44 Blood tests page.
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The Liver screen (Figure 45) includes boxes to record all the common liver screen
blood tests except for virology serology.
Figure 45 Liver screen form.
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1.2.3.3.4.2 Virology
The Virology form (Figure 46) includes boxes to record all the common virology
blood tests. The form is divided up into six subforms that can be accessed by clicking
the appropriate tab headings:
Figure 46 Virology form.
HCV serology HCV genotype ] HBV Serology | Infrequent HBV tests | HIV serology j Other HIV tests |
Date
AntHCV: |Not tested 3
Add Record Delete Record
Record: Jil II r mi irfl
1.2.3.3.5 Biopsy data
The Biopsy data page (Figure 47) includes boxes for entering information on
biopsies performed on patients.
Figure 47 Biospy data page.
Patient records
Patient details First appointment/ admission Clinical data Blood tests Biopsies Treatment Radiology bndoscopy *
Date of biopsy: | | Pathology number: ! Years from
infection to biopsy:
Microscopic cirrhosis: |Unknown ^1 Liver sample stored; I* Liver PCR litre: |
Macroscopic cirrhosis; |Unknown j Serum sample stored; 1®
Hepatocellular carcinoma; |Unknown * |
Local Ishak Modified HAI Score
I oc»l HAI Score I Local METAVIR Score I
National Ishak Modified HAI Score i
Add New Record Delete Record
Record: Hj 11 l | H 1 | of 1
Laboratory data at time of biopsy
263
• Microscopic cirrhosis: This field will be updated if you classify the biopsy
as cirrhotic using the scoring system forms.
• The Macroscopic cirrhosis: At laparoscopic procedures or at the time of
surgery or transplantation it may be possible to determine if a liver is cirrhotic
without biopsy. If the patient is recorded as not cirrhotic in the Microscopic
cirrhosis field then the patient will not be classified as cirrhotic whatever is
entered in this field.
• If the patient is recorded as cirrhotic using either of these fields it will prompt
the option of automatic filling in of the Date of first diagnosis of cirrhosis
and the Mode of first diagnosis of cirrhosis.
• Hepatocellular carcinoma: If HCC was seen on biopsy or macroscopically
it can be recorded here and it will prompt the option of automatic filling in of
the Date of first diagnosis of HCC and the Mode of first diagnosis of
HCC.
• There is a choice of scoring systems available. One or more of these can be
chosen depending the scoring system used by clicking on the appropriate
button.
1.2.3.3.6 Treatment
The Treatment page (Figure 48) includes the Treatment data subform on which to
record treatment episodes.
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Figure 48 Treatment page.
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• Type of treatment is descriptive name given to the treatment regime i.e.
"Combined interferon and ribavirin".
• Medications dose and frequency button can be clicked to bring up the
Treatment regime form. This allows each of the drugs that make up the
treatment regime to be entered with its frequency and dose.
• Treatment Adverse effects button can be clicked to record treatment side
effects. The action taken and the outcome can also be recorded.
Below the Treatment data subform there are a number of data boxes and buttons to
collect and display additional treatment related data:
• There are two buttons to help determine the response to treatment. One plots
the ALT from blood samples taken from one month prior to starting the
treatment regime that is currently displayed in the Treatment data subform,
and all subsequent measurements. The other button displays all the HCV
PCR results in chronological order and plots the log 10 quantitative PCR
results.
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• Treatment status is a field that can be used to classify all patients on the
basis of whether they want or have been offered treatment and the results of
this and whether they want further treatment. The options are selected from
the fixed drop down list. If the patient is dead or transplanted then this can be
recorded.
1.2.3.3.7 Radiology
The Radiology page (Figure 49) includes boxes to record radiology procedures.
Figure 49 Radiology page.
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• Cirrhosis: A choice of options is available in the drop-down lists. If present
it will prompt the option of automatic filling in of the Date of first diagnosis
of cirrhosis and the Mode of first diagnosis of cirrhosis.
• Hepatocellular carcinoma: A choice of options is available in the drop¬
down lists. If present it will prompt the option of automatic filling in of the
Date of first diagnosis of HCC and the Mode of first diagnosis of HCC.
• Ascites: If present and this is the first time that ascites has been diagnosed it
will prompt the option of automatic filling in of the Date of first ascites and
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the Date of first diagnosis of cirrhosis and the Mode of first diagnosis of
cirrhosis if appropriate.
1.2.3.3.8 Endoscopy
The Endoscopy page (Figure 50) includes boxes to record endoscopic procedures.
Figure 50 Endoscopy page.
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• Oesophageal varices drop-down list is to enter the presence or absence of
oesophageal varices and their grade if present. If this the first time that Grade
II varices have been diagnosed, it will prompt the option of automatic filling
in of the Date of first diagnosis of G2 varices, Date of first diagnosis of
cirrhosis and the Mode of first diagnosis of cirrhosis if this is appropriate.
• Bleeding varices: This can be recorded using the drop down list. If this the
first time that bleeding varices have been present, it will prompt the option of
automatic filling in of the Date of first bleeding varices, Date of first




The Outcome page (Figure 51) includes boxes to record the outcome of a patient.
Figure 51 Outcome page.
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The dates of the first diagnosis of cirrhosis and its complications should be recorded
on this form. These are often automatically filled in, as a result of entries elsewhere
in the database. Next to each box is a button that opens a form that allows the entry
of the components of the Childs-Pugh score. This will also be automatically filled in
from the Clinical data and Blood tests records of the same date.
The Type of death box records the death category i.e. Liver-related death, while the
Cause of death box records the exact cause of death.
1.2.3.4 Current stage of disease
Each patient can be staged by their biopsy fibrosis results and / or their clinical state.
This can be displayed clicking the Current stage of disease button (Figure 52) at the
foot of the AH patient records form.
Figure 52 Current Stage of disease button
Sehrat fail name | | » | New patient 1 Current stage ot 1 Clinic summary 1 Return to previous form
Of Select surname | |
Record: 14 I 4 11 702 1 M 1 | of 702
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As the stage of fibrosis depends on the scoring system used for the liver biopsy the
first screen asks the operator to select one that has been used.
The hierarchical categorisation list is: Dead, Alive transplant, Cirrhosis with
complications, Cirrhosis, Liver biopsy stage of fibrosis (depending on scoring system
used), No evidence of cirrhosis but no biopsy, No clinical details and no liver biopsy.
For those patients that are cirrhotic two buttons will be displayed. One opens a screen
that displays the Current Childs-Pugh score. The other displays when the last
surveillance procedure for varices or HCC was carried out and whether any are due
1.2.3.5 Clinic summary sheet
This report (Figure 53) has been designed for use as a clinical summary that can be
attached to a clinic letter following an outpatient appointment. Data cannot be
entered on this sheet, it simply displays the information on the patient entered
previously.
Figure 53 Clinic summary sheet.
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1.3 Reports and charts on patient aroups
The database can provide pre-programmed reports on the data that has been entered.
These can be on the whole population or on different subgroups (Followed up
patients, biopsied patients, biopsied patients with a probable date of infection and
patients with a probable date of infection irrespective of whether they have had a
biopsy). These reports are accessed using switchboard forms (Figure 54).
Figure 54 Whole population switchboard.
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Command buttons can then open the desired reports and charts (Figure 55).
Figure 55 Population demographics.
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Examples of other reports and charts on patient groups in the database include:
• Pie chart of the current stage of disease (Figure 56).
Figure 56 Pie-chart of current stage of disease.
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• Pie charts of the Childs grade at diagnosis of cirrhosis, first complication of
cirrhosis and HCC.
• The number of patients diagnosed with cirrhosis for each year.
• The number of patients presenting with their first complication of cirrhosis
for each year.
• The number of patients presenting with HCC for the first time for each year.
• Patient characteristics at the time of diagnosis of HCV or at the time of
referral. The aim is to identify changes in the characteristics of the population
being diagnosed or referred. There are line graphs (Figure 57) for each key
characteristic (probable source of infection, previous maximum alcohol
intake, HIV serology and age at infection). The years are on the x-axis and
the number of patients on the y-axis.
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Figure 57 Patient characteristics by year of referral.
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1.4 Identifying and trackinq patients underqoina treatment
The treatment switchboard (Figure 58) can be accessed by clicking a command
button on the main switchboard.
Figure 58 Treatment switchboard.
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• Treatment waiting list is those patients that have not started treatment. The
list is ordered according to whether the patient is prioritised and the date they
were placed on the list.
• Patients suitable for trials are all the patients that are on the treatment
waiting list who have had a biopsy in the last year, no previous treatment and
whose last ALT was > 40.
• Table of treatment response rates for each regime (Figure 59). The Sort
results by different variables command button displays the results of a
particular regime sorted by a specific variable such as the presence or absence
of cirrhosis.
Figure 59 Table of Treatment response rates.
3 0e Edt tfew Insert Format Records Tables Ioob Importing / Exporting MaintaiQance ytfndow Database (jelp *• _ 15 X
273
• Chart of the treatment status of patients that are currently followed up:
This displays a pie chart of the Treatment status of patients that are
undergoing continuing follow-up (Figure 60).
Figure 60 Treatment status pie chart.
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These are the possible categories:
PCR negative, no previous treatment, Mild/Early disease therefore not offered,
Medical contraindication therefore not offered, Psychiatric contraindication therefore
not offered, Liver decompensation therefore not offered, Ongoing IDU therefore not
offered, Chaotic lifestyle therefore not offered, Lack of funding for treatment,
Treatment offered but refused by patient, Awaiting start of treatment, Currently on
treatment, PCR negative Sustained responder, Treatment failure who wants further
treatment, Treatment failure who doesn't want further treatment, Unknown.
At the foot of the form there is a drop down list of categories. The details of the
patients in a particular category can be displayed using this command button.
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1.5 Surveillance for the complications of cirrhosis
All patients that have continued follow-up that are identified as cirrhotic should
undergo surveillance for the treatable complications of cirrhosis. The surveillance
protocols used in the Royal infirmary and therefore the database are:
• Endoscopy to diagnose varices every 2 years in those with no previous
varices or 6 monthly in those with previous varices.
• USS or CT scans every 6 months.
• Alpha-fetoprotein every 6 months.
For an individual patient, information on recent surveillance procedures can be
accessed by clicking on the Current stage of disease button at the bottom of All
patient records form. If the stage of disease is cirrhosis or a complication of
cirrhosis then a Surveillance button will be visible that can be clicked (Figure 61).
Figure 61 Surveillance forms for an individual patient.
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A list of patients that have surveillance procedures are overdue, is available in the
followed-up patient's Reports and charts section of the database.
1.6 Audit trail
There are two methods used to identify when data has been changed in the database
and by whom.
• Whenever a patient record is changed the name of the operator and date that
the whole record was last change is updated in the field boxes on the Patient
details page of the A11 patient records form (Figure 41).
• Whenever data in a field in a record is added or changed, an entry is added to
the 'AuditTraif field in the table the field originates from. This entry details
the name of the operator who made the change, the date it occurred and the
old value. Therefore if a field is changed in error, it is possible to correct it
retrospectively and inform the person who made the error of their mistake.
1.7 Help available to users of the database
Hovering the mouse pointer over a box or button can access an explanation of what
should be entered into a field box.
An HTML help file has also been created for the database. It gives full explanations
of all the forms and data entry boxes in the database. It utilises hyperlinks to allow
easy navigation from topic to topic.
To display the help topic for a particular form, the form in question needs be opened.
Help on the menu bar at the top of the screen can then be clicked. The drop-down list
includes the item Hepatitis C database help. If this is clicked, the topic will be
displayed.
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A user manual for the database has also been created. It is 75 pages long and fully
indexed. Screen shots of the database forms are used to illustrate the manual.
1.8 Consent from patients for their data to be held on the
database
The final report of the Confidentiality and Security Advisory Group for Scotland
(CSAGS) has provided useful guidance on the issues of consent. The two areas of
particular relevance were concerning data collection relating to direct NHS Scotland
Patient Care (applicable to the local databases, which provide an electronic patient
record) and data collected for Multiple uses including disease registries,
epidemiology and national databanks (applicable to a National HCV database). They
concluded that "implied consent" for data to be collected in these settings would be
acceptable, provided that "patients are clearly informed about such uses of their data,
that data controllers use only the data needed for the task and that they have strict
and monitored code of confidentiality. The right to opt-out must be integral to this
although patients must be aware of the implications of this and any operational
impediments in agreeing to such requests." They recommend that the information
provided can be in two forms: (a) generic information leaflet on how NHS Scotland
uses patient identifiable information, (b) A patient information leaflet detailing the
specifics of the project concerned.
Therefore all patients that are under ongoing follow up at the Royal Infirmary are
supplied with a version of the generic leaflet and a patient information sheet about
the aims of the project, what information will be collected and how it will be used.
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This explicitly states how to opt out. A time limit of four weeks for this opt out is
also set, so that it is possible to determine who has or has not opted out.
This approach is taken because in practical and logistical terms it would be
impossible to undertake this sort of epidemiological study, if written consent was
required from all those in the target population.
The strategy to address the consent issues of with those subjects that are no longer
attending follow-up (defined as those not attending the hospital for over one year and
not attending their last scheduled appointment, or those discharged from hospital
review) or those that have died, is different. The main concern about this group is
that by trying to contact these persons to supply information about the project, by its
very nature discloses that the person has Hepatitis C infection. Therefore, if the letter
were to be opened by anyone other than the addressee, patient confidentiality would
be broken. Therefore the information on the subjects defined above, has been
collected as previously described and held on the local database. However, no patient
identifiable information except the Master Index (see below) is associated with their
data and therefore it is "acceptable anonymised". This process therefore does not
compromise the patient's right to confidentiality, and complies with the CSAGS's
recommendations on consent when data is "acceptable anonymised".
For those patients that opt out a master index reference for them is created. As this
Master Index is "acceptably anonymised" and contains no clinical information, we
feel it does not require patient consent. The data contained within the Master Index
enables a description of those that participated and those that did not to be made in
very basic terms. This gives information on whether our cohort is biased or
unrepresentative in this respect.
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1.9 Anonymisation
Anonymisation is undertaken by creating a Master Index reference of each patient.
The constitutive parts are first name initial, 4 digit Soundex code (Mortimer &
Salathiel 1995) of surname, Sex of patient, Date of birth, Postcode sector. For
example a Sandra Bird, date of birth 18/05/1962, living in postal district EH03 would
be coded as: [S] [B][6][3][0] [f] [1][8] [0][5] [1][9][6][2] [E][H][0][3], A 4 digit
Soundex code of maiden name or other alias surname will also recorded separately as
appropriate for each patient. Health Protection Scotland, formerly known as the
Scottish Centre for Infection and Environmental Health has used this method in
similar projects in the past. It will allow database linkage to their HCV antibody
positive database.
This process of anonymisation has been automated in the database by adding a
command button on the footer of the All patient records form that removes the
patient identifiable data and leaves the constituents of the master index. It is also
possible to search the database using a surname and identify all the patient records
with the soundex of that surname. This allows patients that have been lost to follow
up and therefore anonymised, to be identified if they are re-referred.
1.10 The database structure
The database is based around numerous tables related by the patient reference
number (PatRefNo) assigned to the patient. Each table has various fields depending
on the type of information that is being stored in the table. Figure 62 lists all these
tables and fields.
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